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SUMMARY OF THESIS 
Cancer is a multifactorial disease, with the development of metastases being a 
major cause of morbidity and mortality. Several molecular pathways are thought to be 
involved in the tumourigenesis of colorectal cancer and possibly metastasis. The aim of 
this research was to explore aspects of these pathways and relate genetic changes to 
clinicopathological variables and outcome, with the goal of ascertaining novel genetic 
abnormalities predictive of metastasis. A second cancer, uveal melanoma was also studied 
as a comparison, as these cancers invariably metastasise to the liver, in which abnormalities 
of chromosomes 3 and 8 have already been shown to be predictive of liver metastasis and 
hence a poor prognosis. Fluorescent in situ hybridisation (FISH) analysis of fresh-frozen 
uveal melanomas using alpha-centromeric probes for chromosomes 3 and 8 confirmed a 
significant association between genetic imbalance and the presence of liver metastasis and 
reduced survival. Difficulties were encountered with using FISH for the analysis of 
chromosomal abnormalities in formalin-fixed paraffin-embedded samples of colorectal 
cancers and their liver metastases. Therefore, comparative genomic hybridisation (CGH) 
was utilised for the genome-wide analysis for regions of chromosomal amplification and 
loss. The technique was partially successful; however problems were encountered in 
obtaining analysable target metaphase slides, this was partly overcome by the manufacture 
of target slides in-house. The analysis of microsatellite instability (MSI) using polymerase 
chain reaction (PCR) was more successful with the presence of MSI being associated with 
the presence of solitary metastases, but interestingly not with an improved prognosis. 
Finally, the collection of a single paired fresh-frozen sample of a colorectal cancer and its 
metastasis enabled all the techniques to be applied, thus showing that prospective 
collection and analysis is not only feasible but would allow the clinical significance of 
genetic abnormalities to be assessed more accurately. 
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One in three people will develop a cancer during his or her lifetime, with one in four 
dying as a consequence of the disease (Cancer Research Campaign, 1999). Worldwide, 
cancer is the third most common cause of death, after death from infectious diseases and 
diseases of the circulatory system (Franks, 1997). 
1.1 NEOPLASIA 
Neoplasia literally means "new growth," and the new growth is termed a neoplasm. 
The term neoplasm is used interchangeably with the term "tumour," which was 
originally applied to the swelling caused by inflammation and cancer is the common 
term for all malignant tumours. It should be noted that the term neoplasia reflects both 
benign and malignant tumours the only absolute criterion is the ability of malignant 
tumours to invade surrounding tissue and to colonise distant sites (metastasis), (Cotran 
et aI., 1989). The best available definition of a neoplasm is one that was suggested by 
Sir Rupert Willis (1952), 
"A neoplasm is an abnormal mass of tissue. the growth of which exceeds and is 
uncoordinated with that of the normal tissues, and which persists in the same excessive 
manner after the cessation of the stimulus which has evoked the change." 
Analysing this definition in functional terms, it becomes clear that there are at least 
four types of disturbance of cell behaviour inherent within it: 
1) A disturbance in cell proliferation. 
2) A disturbance in cell differentiation. 
3) A disturbance in the relationship between cells and their surrounding structure. 
4) A disturbance in normal programmed cell death (apoptosis). 
There is no single cause for malignancy, but the influence of a number of 
environmental and genetic events playa part in the malignant transformation. Evolution 
through natural selection is a concept that applies to many biological systems (Darwin, 
1859). It can also be applied to cancer development, where a multi-step process involves 
the selection of a number of somatic mutations and therefore clones of cells (Nowell, 
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1976; Vogelstein and Kinzler, 1993; Klein, 1998). A number of reports also reveal a 
distinctive pattern of genetic alterations in different tumours, implying that the 
carcinogenic process may proceed through a variety of genetic pathways (Shackney and 
Shankey, 1997). The extent to which different alleles are favoured in the selection 
process is totally dependant on the surrounding milieu, with different genes and 
phenotypes being selected for, by environmental variations (Breivik and Gaudemack, 
1999). There are many types of malignant tumours occurring in man, which are causally 
related to environmental factors. Such factors may be chemical, physical or viral. The 
genetic influence in malignant transfonnation is by the interplay of so-called cancer 
genes. A cancer gene is any gene sequence contributing directly to neoplastic change. 
1.2 CANCER GENETICS 
There appears to be four groups of genes, at present, that are thought to contribute to 
neoplastic change and tumour progression by constitutive activation, mutation or 
deletion. These are oncogenes, tumour suppressor genes, DNA repair genes and 
apoptotic genes 
However, as with most biological systems, there is some functional overlapping 
among these categories. 
1.2.1 Oncogepes 
Oncogenes in general have a positive effect on tumour development and tend to be 
highly conserved "household" genes involved in a variety of cell signalling pathways, 
coding for growth factors, growth factor receptors or signal transduction proteins. 
Others code for transcription factors that when activated as a result of mutations, 
retroviral insertions, chromosomal translocations or gene amplifications, result in cell 
growth and division. Examples of oncogene activation include, c-myc, which becomes 
activated when an immunoglobulin locus is inserted next to it, resulting in Burkitt's 
lymphoma (Teich, 1997) and the fonnation of the Philadelphia chromosome, which 
results in the fonnation of a new protein the product of the fusion of BCR and c-abl 
genes as a result of chromosomal translocation in chronic myeloid leukaemia (Rowle, 
1973). 
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1.2.2 Tumour Suppressor Genes 
Tumour suppressor genes conversely tend to negatively regulate cell growth and 
whose absence can lead to tumourigenesis. It has been known for sometime that the 
fusion of normal cells to malignant cells, results in the suppression of the malignant 
phenotype, as long as the chromosome complement derived from the normal parent is 
maintained (Klein, 1987). Further information was derived from studies of 
retinoblastoma, a malignant tumour of the eye. There are two clinical forms of 
retinoblastoma, one of which is sporadic (always unifocal and unilateral) and the other 
hereditary (often multifocal and/or bilateral). Knudson (1971) proposed that the 
development of any retinoblastoma was the consequence of two mutations within a 
retinoblast, the "two-hit" hypothesis. One of these mutations was inherited while the 
other was acquired spontaneously during the child's development. Comings (1973) 
proposed that the Knudson's two genetic targets could be the two alleles of a single 
gene, whose product negatively regulated cellular growth. Thus, a germ line mutation in 
one retinoblastoma (RB) allele was followed by a somatic loss of the remaining gene, as 
a result of chromosome loss, mutation, deletion or mitotic crossing over, resulting in 
tumour formation (Cavenee, 1983). Other examples of tumour suppressor genes include: 
p53;pJ6 andpJ5, cyclin dependant kinase inhibitor genes; Von Hippel-Lindau disease 
gene (VHL) and E-cadherin gene, although many more exist (Klein, 1998; Kok et aI., 
1997). 
1.2.3 DNA Repair and Apoptotic Genes 
A number of genes exist which act either to repair DNA or are involved in 
programmed cell death (apoptosis). There are those that directly repair DNA, such as 
those involved in nucleotide excision repair (NER) and DNA mismatch repair (MMR), 
(e.g. hMSH, hMLH), but also those that act as cell checkpoint genes, thus allowing DNA 
to be repaired prior to progression through the cell cycle (e.g. hBUBJ, p53), (Janin, 
2000). 
Genes which influence apoptosis include p53, bel-2 and v-abl. The protein product of 
bel-2 acts by interacting with the protein products of BAX, BAD and several other genes, 
which act in concert to either accelerate or inhibit apoptosis (White, 1996). 
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The onset of cancer is generally initiated by mutations in normal (wild-type) cellular 
genes. These mutations develop as a result of uncorrected errors in DNA replication e.g. 
after exposure to physical or chemical carcinogens. The gene function can either be 
activated or inactivated by these mutations. These mutations may arise as a result of 
several mechanisms. the process being termed "genetic instability" (Lengauer et aI., 
1998) 
1.3 GENETIC INSTABILITY 
It is generally accepted that cancers arise as a result of mutations in genes that control 
cell genesis and cell apoptosis (Lengauer et aI., 1998). Mutations in these genes may 
arise as a result of alterations in chromosome number, chromosome translocations, 
subtle sequence changes or gene amplifications. 
1.3.1 Alteratiops ip Chromosome Nymber 
Alteration in chromosome number involves losses and gains of whole chromosomes 
(aneuploidy). For example, the complete loss of chromosome 3 in uveal melanomas is 
associated with liver metastasis (Prescher et aI, 1990; Sisley et aI., 1990). Cytogenetic 
studies have shown that the majority of cancers have lost or gained chromosomes, so 
called "chromosomal instability" (CIN), (Reichman et aI., (1981). However, these 
cytogenetic studies may actually underestimate the true extent of such changes, and the 
loss of heterozygosity (LOH), where either the paternal or maternal allele is lost, is 
commonplace in the majority of tumours (Kinzler and Vogelstein, 2002). Even in 
instances where the chromosomes themselves appear to be unaffected, the true genetic 
status may vary as the loss of one allele is often accompanied by the duplication of the 
remaining allele, thus leaving a cell with a normal karyotype but an abnormal allelotype 
(Vogelstein et aI., 1989). 
Genes that when altered that could lead to eIN include those involved in: 
chromosome condensation; sister chromatid adhesion; kinetochore structure and 
function; centrosome/microtubule function and dynamics; and cell "checkpoint" genes 
which monitor progression of the cell through the cell cycle (Lengauer et aI., 1998). One 
type of checkpoint, the "DNA-damage checkpoint", prevents cells with DNA damage 
from entering mitosis. DNA damage could have arisen as a result of: base mismatches 
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by DNA polymerase; exogenous mutagens (such as ultraviolet light); endogenous 
mutagens (such as oxygen free radicals); or from incomplete repair. Chromosomes 
containing damaged DNA could segregate abnormally because sister chromatids may 
still be connected to each other by abnormal DNA-DNA or DNA-protein links 
(Lengauer et aI., 1998). Several genes have been implicated in DNA-damage checkpoint 
control, including ataxia telangectasia mutated (ATM), the ATM-related gene (ATR), 
BRCA J and BRCA 2 genes, and p53 (Lane, 1998). A second checkpoint effectively 
targets cell division itself, the "spindle checkpoint," ensuring that chromatids do not 
separate until they have aligned along the mitotic spindle. A disruption at this 
checkpoint could lead to daughter cells receiving an abnormal complement of 
chromosomes (Cahill, 1998). Potential spindle checkpoint genes mutated in colorectal 
cancer include hBUBJ (Cahill, 1998). Another cause of aneuploidy, involves abnormal 
numbers of centrosomes and although abnormal numbers of centrosomes have been 
detected in breast, lung, prostate, colon and brain cancers, specific genes responsible for 
centrosome formation have not yet been found (Doxsey, 1998). 
1.3.2 Chromosome Translocatiops/RearraPlemepts 
These alterations can be seen on cytogenetic analysis as fusions of different 
chromosomes or of normally non-contiguous segments of a single chromosome. This 
can have the result of fusing two genes together, thus leading to the activation of a 
normally quiescent gene or the inactivation of an active gene. In addition, the loss of 
large proportions of chromosomal material can also occur during the complicated 
rearrangements that take place during translocation. These deletions can often be seen as 
loss of heterozygosity at the molecular level. 
Two patterns of chromosome translocation are seen in human cancers, the complex 
type and the simple type. The complex type involves many random translocations not 
only between tumours, but also between individual cells and can also result in the gain 
and loss of chromosome material. The simple type is characterised by a distinctive 
rearrangement of chromosome segments, and is found in certain lymphomas and rare 
sarcomas (Le Beau and Rowley, 1986), and also in chronic myeloid leukaemia with the 
Philadelphia chromosome, where the c-ab/ gene on chromosome 9 is joined to the BCR 
gene on chromosome 22 (Rowle, 1973). 
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1.3.3 Subtle SegueDce CbaDges 
These involve either base substitutions, or the insertion or deletion of nucleotides 
resulting in either translational errors or the premature cessation of protein synthesis. 
For example, missense mutations in the K-ras gene occur in over 50% of colorectal 
cancers (Fearon et aI., 1993). There are three separate mechanisms involved in the repair 
mismatched bases, one involves the detection and replacement of mismatched bases by 
DNA polymerase and the others are nucleotide excision repair and DNA mismatch 
repair. As yet no consistent pattern of defects of DNA polymerase has been seen in 
tumours (Lengauer et aI., 1998). 
Nucleotide excision repair (NER) is primarily involved in repairing damage caused 
by exogenous mutagens. Defects in NER are notably seen in patients with xeroderma 
pigmentosum, who develop skin tumours in response to exposure to ultraviolet light 
(Cleaver, 1968). 
The mechanism of DNA mismatch repair involves the correction of mismatched 
and/or unmatched bases, which arise after DNA replication, or occasionally secondary 
to mutagens (Jircny, 1998). Defects in DNA mismatch repair enzymes usually results in 
the non-correction of mismatched bases, particularly in long base repeating tracts known 
as micro satellites, thus the genetic instability produced is also termed "microsatellite 
instability" (MSI), (Jircny, 1998). 
1.3.4 GeDe Amplifications 
These are seen as homogenously stained regions or double minutes on cytogenetic 
analyses, and usually represent multiple copies of growth promoting genes (Lengauer et 
aI., 1998). Gene amplifications tend to occur in late stage cancers and tend to affect a 
few specific genes, notably, genes that may be important in the metabolism or 
inactivation of certain chemotherapeutic agents. The mechanism of gene amplification is 
largely unknown, although inactivation of p53 may play an important role (Yin et aI., 
1992). Examples of specific gene amplifications include, the amplification ofN-myc 
that is seen in approximately 30% of advanced neuroblastomas (Seeger et aI., 1985) and 
that of HER21neu gene in breast cancers, which is also thought to have prognostic 
significance (Pegram et aI., 1998). 
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Mutations in genes do not necessarily imply a tumourigenic state, as these mutations 
may initiate apoptosis or a selective growth advantage may not be induced. For 
mutations to produce a tumourigenic state, the mutation must either initiate growth and 
clonal expansion at a rate greater than its surrounding normal cells, or apoptosis is not 
induced until the cell has replicated several generations more than its normal 
counterparts. 
1.4 OYERYIEW OF CANCER TUMOURIGENESIS 
In summary, several key events may need to occur in order for a neoplasm to arise: 
genetic instability; activation of oncogenes; inactivation of tumour suppressor genes; 
defects in DNA repair mechanisms; functional loss of cell cycle checkpoint control; 
mutational or regulatory changes in genes that protect cells against apoptosis. However, 
as with any biological system, there are exceptions; leukaemias and lymphomas may 
require a smaller number of changes than solid tumours, whereas retinoblastoma 
appears to only require two mutational losses (Lengauer et aI., 1998). 
Unfortunately, for many patients the primary tumour is not the prime cause of death, 
the development of metastases poses the major cause of morbidity and mortality in 
patients with cancer, with symptoms including cachexia, anorexia, apathy and pain as a 
result of bone or liver metastases. 
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1.5 METASTASIS 
Metastasis describes the spread and growth of a tumour from its original (primary) 
site to a distant (secondary) site via the blood stream (haematogenous metastasis), the 
lymph vessels (lymphatic metastasis) or transcoelomic (through the pleural or peritoneal 
spaces). There are several steps in the metastatic process: invasion into adjacent 
structures; intravasation into blood or lymphatic vessels; arrest of the liberated cancer 
cells at a receptive site; extravasation out of the vessel and into the surrounding tissues 
and for growth to occur angiogenesis must take place (neovascularisation) to supply the 
growing tumour with nutrients (figure 1.1). 
Figure 1.1 Diagrammatic representation of the metastatic cascade (adapted from 
Fidler, (1990)) . 
Malignant 
transformation ~ • 
Angiogenesis 
Invasion and ~ 
Intravasation 
~ Embolisation 
in circulation 
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 capillary beds 
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vessel wall 
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At each of these steps the cancer cell must have the ability to complete each step of 
the metastatic cascade. The cancer cell does not necessarily have to be very efficient in 
completing each step but must be able to do so eventually, in order to proceed to the 
next step. Therefore, inefficiency can be expressed as the death of large numbers of 
cancer cells entering each step of the metastatic cascade, or inefficiency may manifest as 
the length of time required completing one or another of the metastatic process, and so 
may explain why some tumours metastasise more readily than other tumours (Weiss, 
1990). 
1.5.1 Invasion 
There appears to be two processes involved in the penetration of tissues by cancer. 
Firstly, the proliferation of cancer cells causes them to expand along the pathways of 
least resistance and secondly, the active locomotion of cancer cells through the tissues, 
which involves attachment of the cancer cell to the basement membrane, degradation of 
the connective tissue, and finally migration (Liotta et ai., 1991). 
The degradation of the basement membrane involves the release of enzymes e.g. the 
metalloproteinases, a family of metal-dependant endopeptidases (Stetler-Stevenson, 
1990) which include enzymes with degradative activity for interstitial collagen, type IV 
collagen, type V collagen, gelatin and proteoglycans, as well as the release of certain 
enzyme inhibitors, such as tissue inhibitor ofmetalloproteinases (TIMPs) which can 
inhibit interstitial collagenase, stromelysin and type IV collagenase (Khokha et aI., 
1989). This is because maintenance of the normal basement membrane is a continuous 
process of degradation and synthesis. Therefore, a reduction in the synthesis of 
connective tissue by normal cells could also result in cancer cell invasion (Adams et ai., 
1982). Studies by Segain et al. (1996), suggest that the expression of gelatinase by 
fibroblasts is induced to a greater extent by cell lines derived from the primary tumour 
as compared to metastases, suggesting that the primary tumour not only induces 
degradation of the surrounding connective tissue to aid metastasis but the expression of 
gelatinase by the surrounding fibroblasts is then switched off once the tumour cells have 
reached their metastatic site and thus enabling adhesion; or, a specific subclone of cells 
induce gelatinase in the primary tumour which enable the release of a metastatic 
subclone of cells. The expansion of the tumour itself could also cause pressure atrophy 
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of the surrounding tissue, thus allowing the spread of cancer cells (Gabbert et aI., 1987). 
Neutrophils are known to play an important role the inflammatory response, releasing 
proteolytic enzymes and generating oxygen free radicals, thus providing another 
mechanism in which to facilitate the spread of cancer cells (Glaves, 1983). 
In the case of colorectal cancers, metastatic efficiency appears to be greater in cells 
cultured from the deep part (serosal surface) of the tumour as compared to cells cultured 
from the superficial part (mucosal surface) of the tumour (Jass et aI., 1989; Danova et 
aI., 1995; Inomata et aI., 1998). This could be explained by differing phenotypes 
(subclones) between the superficial and deep parts of the tumour (Kim et aI., 1991) or, 
the fact that intravasation and spread is facilitated by a rich lymphatic and vascular 
system, which is, absent superficial to the muscularis mucosa (Fenoglio et aI., 1973). 
Talbot et al. (1980), showed that invasion of the thick walled extramural veins located 
on the serosal surface of the bowel, was associated with a poorer prognosis and the 
frequent development of liver metastases. 
1,5.2lptmasatiop 
This usually involves the active migration of cancer cells into the lumen of lymphatic 
and blood vessels, in a similar manner to leukocytes (de Bruyn and Cho, 1982). 
Migration may be facilitated by certain motility aiding factors, such as MRP 1, which 
appears to be highly expressed in primary tumours as compared to its metastases (Cajot 
et al., 1997). Another method could be tumour erosion into lumen of these vessels as a 
consequence of pressure necrosis (Ouichi et aI., 1996). 
1.5.3 Arrest of Capcer Cells 
During haematogenous metastasis, cancer cells become arrested in the 
microvasculature of many organs. The majority of cancer cells will arrest in the first 
microvasculature system they encounter, which in the case of colorectal cancers, this 
could be the liver, via the portal system. Studies have shown that the site for major 
cancer cell death is in these microvasculature systems (Weiss, 1990). Cell death within 
the microvasculature system is biphasic, the majority of cells being destroyed within 5 
minutes of entering the system and then the remaining survivors over a variable length 
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of time. The rapid phase of post intravasation cancer cell death may occur as a result of 
..... ,.."' ... " ... :"',,1 n+mf]M'n/lp~'W1ItPA11roJMlmi+~r)'rp<n·,/lmw·9lnt1n.w.:.qt'lNl'Vl'rtfflnl~}1h''l'lt>:.trmm 
and Dimitrov, 1986). The slow phase of post intravasation cancer cell death involves 
destruction by the host defence system (Weiss et aI., 1989). However, Chambers et ai. 
(2000), using in vivo video-microscopy studied the outcome of fluorescently labelled 
cancer cells in the microcirculation of a variety of murine tissues and found that rather 
than being destroyed, the vast majority of cancer cells survived arrest and deformation, 
and then went on to extravasate into the tissue. 
Arrest of cancer cells at certain sites is probably enhanced by the expression of cell 
surface receptors, which enhance the arrest of the cancer cell and allow the cells to 
survive the host defences once they have arrested. For example, cell adhesion molecules 
such as ganglioside GM2, oligosaccharides (sialylle structures, (Ono et aI., 1996; Sato 
et aI., 1997; Yamada et aI., 1997», ~ I integrins, bcI-2 (Skopelitou et aI., 1996), EGF-R 
(Parker et aI, 1998), CEA (carcinoma embryonic antigen), (Kim et aI., 1997) and CD44 
(Guo et aI, 1994) may enhance colorectal cancer cell arrest and survival within the liver 
(Singh et aI., 1997). 
1.5.4 Extmasatjon 
There appears to be two different extravasation mechanisms, the first involves the 
active migration of cancer cells in a similar way to leukocytes and the other, follows 
intravascular growth, when after the tumour reaches a certain size it bursts through and 
out of the vessel (Crissman et aI., 1985). Movement of tumour cells into the liver could 
be further aided by the fact that the liver sinusoids are heavily fenestrated and so 
allowing an easier passage of metastatic colon cancer cells (Fukumura et al., 1997). The 
intravascular growth of the tumour itself may induce an inflammatory reaction, which 
may weaken the vessels adventitial tissues and thus aid extravasation (Weiss et aI., 
1989). As stated previously, Chambers et al. (2000) propose that the rate-limiting step is 
not arrest and extravasation but post-extravasation events, suggesting that nearly all 
cancer cells, be they highly metastatic or not, can arrest, deform and extravasate into the 
surrounding tissue, but only cells with the genotype and phenotype to divide and 
continue to grow, can survive in these tissue beds. 
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1.5.5 NeoyascularjzatioQ 
The growth of tumour emboli beyond 0.1-0.2cm3 requires the growth of blood 
vessels into the tumour, as the nutritional requirements of the cells will not be satisfied 
by the diffusion of nutrients alone (Carlsson et aI., 1979). Work by Folkman (1989) has 
established that angiogenesis is necessary for both primary and metastatic tumour 
growth, indicating the higher the vascularity of the primary tumour, greater is the chance 
of distal metastases. In both uveal melanoma and colorectal cancer, increased vessel 
density has been associated with the development of metastases (Folberg et aI., 1993; 
Rummelt et aI., 1995; Takahashi et aI., 1995). The secretion of angiogenic factors, such 
as VEGF appears to aid angiogenesis (Brown et al., 1993; Tokunaga et aI., 1998), but 
the process of angiogenesis is also controlled by anti-angiogenic factors, such as 
angiostatin and the modulation of these various factors may provide a suitable point of 
action for anti-metastatic therapy (Warren et aI., 1995; Cherrington et aI., 2000). 
1.6 0YERYIEW OF METASTASIS 
It has long been observed that certain tumours show an organ-specific pattern of 
metastasis. Breast cancers preferentially metastasise to the bone, liver, brain and lung 
and the incidence of liver metastases from primary cutaneous melanoma and ocular 
melanoma is greater than metastases to any other single organ, even though these 
tumours do not directly drain into the liver (Pickren et aI., 1982). In 1889, Stephen Paget 
proposed the "seed and soil" hypothesis of metastasis, stating, "when a plant goes to 
seed, its seeds are carried in all directions; but they can only live and grow if they fall on 
congenial soil." This is most probably due to specific cancer cell ("seed")-target organ 
("soil") interactions allowing and facilitating invasion, intravasation, arrest, 
extravasation, neovascularisation and growth at a distant site (Fidler and Hart, 1982; 
Fidler, 1990, 1995; Radinsky, 1995; Radinsky and Ellis, 1996). Ewing 40 years later 
challenged Paget's "seed and soil" hypothesis, claiming that metastasis occurred solely 
as a result of the arrest of the majority cancer cells in the first microvasculature system 
they come across, which in the case of colorectal cancer would be the microcirculation 
of the liver. However, studies by Sugarbaker (1981), concluded that common regional 
metastases could be attributed to anatomic or mechanical considerations, such as 
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efferent venous circulation or lymphatic drainage to regional lymph nodes, but that 
distal organ colonisation by metastatic tumour cells from numerous types of cancers 
established their own patterns of site specificity. It is interesting to note that cells from 
hepatic metastases show different karyotypes and phenotypes when compared to lymph 
node metastases even from the same patient, suggesting that site-specific interactions 
relevant to the selection of various clones from the same cancer (Fidler and Kripke, 
1977; Gregoire et aI., 1993; Singh et aI., 1997; Nicolson and Moustafa, 1998). 
It is known that intra-tumoural heterogeneity exists with different subclones of cells, 
each with a slightly different phenotype and possibly genotype (Fidler and Hart, 1982; 
Kim et aI., 1991; Danova et aI., 1995; Katsura et ai, 1996). Nowell proposed a genetic 
theory of tumour evolution in 1976, where there is sequential selection of variant 
subclones being undertaken by either genetic changes within the metastatic cascade or 
by local host defence systems, mechanical and/or biological (figure 1.2). Tollenaar et al. 
(1997) provided evidence that clonal divergence seemed to take place during the 
transition from adenoma to carcinoma, where several different phenotypes were seen, 
but only one would be required to produce metastases. The outcome of metastasis is 
also dependant on the cell interacting with the local microenvironment in order to avoid 
the host immune response, vascularise and hence grow (Radinsky, 1995; Fidler 1995; 
Singh et aI., 1997). The newly formed metastasis may then progress to metastasise itself 
(Fidler, 1990). 
Variations in metastatic potential is not necessarily dependant on increased 
aneuploidy (Frankfurt et aI., 1984; Jass et aI., 1989; Lind et aI., 1992), but requires only 
that genes which aid metastasis are switched on and that those genes which suppress 
metastasis (at any stage in the metastatic cascade) are switched off (Schirmacher, 1985; 
Klein and Klein, 1985). 
It is unlikely that there is a single metastatic gene, but the interactions of multiple 
metastasis-related genes occur. Studies have shown that when cells derived from 
metastases were injected into nude mice, they were more likely to produce metastases 
than those cells derived from the primary tumour (Morikawa et aI., 1988; Adachi et ai, 
1999). 
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Figure 1.2 Diagrammatic representation of tumour progression: Waves of clonal divergence adapted from Nicolson and 
MOllstafa, (1998). 
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1.6.1 Metastatic Gepes 
Cancer metastasis is a highly complex process and as such is unlikely to be 
controlled by a single gene. It is more plausible that a number of genes may be either 
activated or inactivated (Sobel, 1990). These genetic changes may occur permanently or 
transiently within the genome (Radinsky and Ellis, 1996). Several different approaches 
have been taken in the search for genes involved in metastasis. One approach uses 
techniques to identify genes that are differentially expressed in cells with different 
metastatic properties. Differential ("plus-minus") screening of cDNA libraries 
constructed from metastatic and non-metastatic cells of the same tumour type, relying 
on the premise that the metastatic phenotype is associated with a change in the 
transcription of various genes (Dong et aI., 1995; Cajot et aI., 1997). Subtractive 
hybridisation, involves the physical removal of sequences of mRNA which are common 
to both populations of metastatic and non-metastatic cells, thus isolating mRNA which 
is different in the two populations (Lee et ai., 1996). A third technique involves the use 
of reverse transcription and the polymerase chain reaction to compare cDNA from 
paired metastatic and non-metastatic cells in a search for either genetic loss (putative 
tumour suppressor gene) or over-expression (putative oncogene) in cells with different 
metastatic potentials (Fidler and Radinsky, 1996). A second approach relies on the 
isolating of genes that encode for proteins of known functions involved in one or more 
steps of the metastatic cascade (Fidler and Radinsky, 1996). Thirdly, the karyotypic 
analysis of metastasising and non-metastasising cells from the same tumour can identify 
regions of chromosomal gains, which may predict the site of a putative oncogene, 
whereas regions of chromosomal loss may predict for a putative tumour suppressor gene 
(Mertens et ai., 1997). Karyotypic analysis involves the preparation of metaphase 
spreads from short term cultures of the tumour under investigation and provides a basis 
from which techniques such as fluorescence in situ hybridisation (FISH) can be used. 
Another technique which allows for the examination of the entire genome is 
comparative genomic hybridisation (CGH), (Kallioniemi et al., 1992). 
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1,7 COLORECTAL CANCER 
Colorectal cancer is the third leading cause of cancer deaths worldwide every year, 
after lung cancer and stomach cancer (Cancer Research Campaign, 1999). In the United 
Kingdom colorectal cancer was the second commonest cause of death due to cancer 
accounting for nearly 16,000 deaths in both men and women in 1994, with a reported 
incidence of approximately 29,000 (Office for National Statistics, 2000). 
1.7,1 Aetiology 
It is now generally accepted that most colorectal cancers arise from the progression 
from an adenoma to a carcinoma (Muto et aI., 1975). There are numerous aetiological 
factors, environmental and genetic, all interacting to initiate and promote the formation 
of an adenoma into a cancer (Wilmink, 1997). 
1.7,1.1 Environmental Factors 
A number of investigators have proposed that a diet high in fat (especially saturated 
fats), protein, calories, red meat and alcohol, and low in fibre, dietary fruit and 
vegetables, calcium, folate and other micro-nutrients are associated with an increased 
incidence of colorectal cancer (Haenszel and Kurihara, 1968; McKeown-Eyssen and 
Bright-See, 1985; Armstrong and Doll, 1975; Jacobs 1988; Vargas and Alberts, 1993). 
Several studies have shown a positive association between alcohol intake and colorectal 
cancer, possibly by stimulating mucosal cell proliferation and by activating pro-
carcinogens (Boutron and Faivre, 1993; Kune and Vitetta, 1992). Interestingly, aspirin is 
thought to have a protective effect against the development of colorectal cancer (Thun et 
aI., 1991; Smalley et aI., 1999) however, not all epidemiological studies have 
substantiated this claim (Gann et aI., 1993). 
Smoking has also been linked with the genesis and development of adenomas, with 
data directly linking the duration and the amount of smoking to the size of adenomas 
(Giovannucci et aI., 1994a, 1994b; Giovannucci and Martinez, 1996). 
The presence of inflammatory bowel disease is also thought to playa role in the 
development of colorectal cancer with patients with ulcerative colitis having an 
increased risk, especially if they were young and have extensive disease at diagnosis 
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(Ekbom et aI., 1990a). The risk in Crohns disease although initially less certain (Glotzer, 
1985), also appears to be associated with an increased risk of colorectal cancer, 
particularly if there is extensive colonic involvement (Ekbom et aI., 1990b). 
1.7.1.2 Genetic Factors 
Genetic factors were thought to play an important role after several cancer families 
were found. Studies divided these familial colorectal cancers into two groups, those 
characterised by the presence of multiple colorectal polyps (polyposis) and those 
without polyposis, hereditary non-polyposis colorectal cancer (HNPCC). 
There are several types of polyposis syndromes, which include; familial adenomatous 
polyposis coli (F AP), Peutz-Jeghers syndrome, Cronkkite-Canada syndrome and 
hyperplastic polyposis. F AP is an autosomal dominant inherited disorder, in which 
individuals are affected with hundred to thousands of adenomatous polyps, although 
only one to two ever become malignant. The average age of diagnosis of polyposis is 27 
years of age, with the median age of cancer in these patients at 39 years. The incidence 
of F AP in the United States is I in 5000 to 10,000 although only 1 % of all colon cancers 
occur in these patients because of the practise of prophylactic colectomy. A variant of 
F AP is Gardner syndrome, a rare autosomal dominant disease, where as well as the 
colonic manifestations there are also soft tissue tumours, osteomas, dental abnormalities 
and congenital hypertrophy of the retinal pigment epithelium (Gardner, 1951; Gardner 
and Plenk 1952; Gardner 1962). Another variant is Turcot's syndrome, a rare autosomal 
recessive disease, which is characterised by the presence of CNS tumours as well as a 
predisposition to colorectal cancer. 
HNPCC also displays an autosomal dominant inheritance pattern and is characterised 
by the early onset of colorectal cancers, which are predominantly right-sided and with 
multiple primary sites (synchronous and metachronous). There is also a predisposition 
to developing carcinoma of the ovary, endometrium, stomach, small bowel, ureters and 
renal pelvis (Lynch and Smyrk, 1996). The syndrome is diagnosed according to the 
Amsterdam criteria, where at least three relatives have had colorectal cancer, affecting 
two or more generations, one a first degree relative of the other two and diagnosed 
before the age of 50 years, all in the absence of F AP (Vasen et aI., 1991). HNPCC 
accounts for around 2-3% of all colorectal malignancies and of which there are two 
subtypes described; the Lynch I and Lynch II syndromes. Lynch syndrome I, or site-
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specific colorectal cancer is characterised by an early age of onset, on average 45 years 
and a predilection to proximal colon cancers (70%). In Lynch syndrome II or cancer 
family syndrome, frequent carcinomas in other organs occur in addition to this (Lynch et 
aI., 1985, 1993). 
The majority of colorectal cancer cases are sporadic with only 3-5% occurring in 
those with well-characterised inherited diseases. However, studies have shown that 
relatives of those with colorectal cancer have a higher than average lifetime risk of 
colorectal cancer. Therefore, a person may have a genetic predisposition to colorectal 
cancer, but environmental factors may initiate and/or promote tumourigenesis. Primary 
prevention therefore involves the identification of genetic and environmental factors that 
are involved in the aetiology of colorectal cancers. 
1.7.2 Clipical Coune 
Approximately 60-70%% of all colorectal cancers are located within the rectum, 
recto-sigmoid or sigmoid colon, 5% within the descending colon, 12% within the 
transverse colon and 22% within the ascending colon (Mortensen et aI., 1992). Clinical 
symptoms depend on the site of the tumour. Left sided tumours tend to present with 
prominent features of disturbance of bowel function such as malaena, diarrhoea and 
constipation, whereas, right-sided tumours tend to present with non-specific symptoms 
of weakness, weight loss and unexplained anaemia (Forrest et aI., 1991). All colorectal 
tumours spread by direct extension into adjacent structures and also by metastasis via 
the lymphatic and blood vessels. Sites of metastatic spread include the regional lymph 
nodes, liver, lung, bones and occasionally the brain (Dayal and DeLellis, 1989). 
Diagnosis relies on a careful history and examination, proctoscopy and 
sigmoidoscopy, faecal occult blood tests followed by either a colonoscopy or a double 
contrast barium enema. If the cancer is particularly large and especially if it is a rectal 
cancer, other imaging techniques may be used such as magnetic resonance imaging 
(MRI), computed tomography (CT) and/or transrectal ultrasonography, in order to 
assess the size of the tumour and to see if it is invading adjacent structures (Mortensen 
et aI., 1992). 
Useful blood tests include the measurement of CEA, which is raised in 19-40% of 
patients with early tumours and almost 100% of patients with large metastatic tumours 
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and has also proven to be a useful indicator of recurrence. However, raised levels of 
CEA may also be produced by cancers of the lung, breast, ovary, urinary bladder and 
prostate, and also in a variety of non-neoplastic disorders, such as alcoholic cirrhosis, 
pancreatitis and ulcerative colitis (Haier et aI., 2000). 
1.7.3 Treatmept 
The treatment options considered for a patient with colorectal cancer is dependant on 
the patient's clinical state and any co-morbid disease, the site of the tumour and the 
clinical stage of the disease as outlined in appendix I. Essentially, the treatment offered 
to a patient, must be in the best interests of the patient with due consideration of any 
morbidity or mortality as a result of the therapy. 
1.7.3.1 Surgery 
Surgery is the only curative treatment option for colorectal cancer. The cancer and 
involved bowel is excised together with the regional lymph nodes (which usually lie 
adjacent to the major blood vessels). The length of bowel resected is dependent on the 
site of the cancer and the blood supply to that part of the bowel (figure 1.3). If there are 
multiple tumours within the colon, a total colectomy may be performed, with the small 
bowel being anastomosed to the rectum. If tumours are also present in the rectum, a pan-
proctocolectomy is performed to excise the entire large bowel. This may be required for 
patients with F AP. For small polyps, a colonoscopic polypectomy may be all that is 
required, as long as the stalk of the polyp is clear of malignant invasion (Bond, 1993; 
Winawer et al., 1993; Byers et aI., 1997). 
Local recurrence rates for colorectal cancer are dependant on a number of factors 
including tumour involvement of either the circumferential or resection margins and on 
surgical technique, this is more so in the case of rectal cancer, where recurrence rates 
vary from 4-40%, depending on the operating surgeon. For rectal cancers, the technique 
of total mesorectal excision (where there is meticulous dissection outside the mesorectal 
fascia, with conservation of the nerve supply to the bladder and genital organs), offers 
the lowest local recurrence rates (Heald et aI., 1998). 
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Figure 1.3 The various surgical resections that can be performed for colorectal 
cancer (adapted from Mortensen et aI., 1992). 
Right hemicolectomy Left hemicolectomy 
Sigmoid colectomy Abdomino-perineal resection 
1.7.3.2 Chemotherapy 
Chemotherapy may be given either pre-operatively (known as neo-adjuvant 
chemotherapy) or post-operatively (adjuvant chemotherapy). Currently, adjuvant 
chemotherapy is only offered to patients with stage III (Dukes C) colorectal cancers, 
comprising of a combination of 5-fluorouracil (5-FU) with either levamisole or 
leucovorin (National Institutes of Health, 1990; Wolmark et aI., 1993). Adjuvant 
chemotherapy has also been given via the hepatic portal vein in an attempt to reduce the 
occurrence of liver metastases, however a randomised trial by the Swiss Group for 
Clinical Cancer Research revealed no survival differences between systemic 5-FU 
versus hepatic portal vein infusion (Laffer et al. , 1998). The use of adjuvant 
chemotherapy in patients with stage II (Dukes B) cancers remains controversial, but a 
recent large meta-analysis study claimed a survival advantage of 2% when surgery alone 
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was compared with surgery plus 5-FU/leucovorin (International Multicentre Pooled 
Analysis of B2 Colon Cancer Trials (IMP ACTB2), 1999). 
In stage IV (Dukes D) cancers, distant metastases are already present and 
chemotherapy has been administered either systemically or via a hepatic artery infusion 
in an attempt to be curative, however, there have been no consistent improvement in 
survival. Chemotherapy with 5-FU has been used palliatively, given either as a 
continuous infusion or in bolus doses (Moertel, 1994). Newer agents such as Irinotecan 
(CPT-II), a topoisomerase-I inhibitor and Tomudex, a specific thymidylate synthase 
inhibitor have recently been licensed for use in patients with metastatic disease, who 
have either not previously received chemotherapy or are refactory to 5-FU therapy 
(Rothenberg et aI., 1996; Conti et al., 1996; Cunningham, 1998; Von Hoff, 1998). 
Chemotherapy is not without side-effects, such as nausea, vomiting, diarrhoea, 
mucositis, neutropaenia, hair loss and malaise but, chemotherapy has demonstrated 
improved survival and quality of life when compared to supportive care alone 
(Scheithauer et aI., 1993). 
1.7.3.3 Radiotherapy 
Short-term radiotherapy (over five days) has yielded excellent results in terms of 
reducing local recurrent rates after surgery for small rectal cancers, while long-term 
radiotherapy has primarily been used to down size large rectal tumours (Marijnen and 
van de Velde, 2001). However, its main role has been in palliating recurrent tumours 
(Forrest et at, 1991). Some studies have shown that either neo-adjuvant or adjuvant 
radiotherapy reduces the incidence of local recurrence by up to 50%, though some 
researchers claim that radiotherapy may be compensating for imperfect surgery (Willett 
et aI., 1993; Schild et al., 1997). Radiotherapy is not without its side-effects, which 
include erythema to the skin, small bowel radiation enteritis, small bowel obstruction 
and perforation. The growing trend is for radiotherapy to be used for large tumours only. 
1.7.3.4 Biologic Therapy 
Newer treatment modalities are currently being developed such as immunotherapy 
and radio-immunotherapy. The use of monoclonal mouse antibodies to colorectal cancer 
(such as MOAB 17-1 A, which is an antibody directed to an epithelial cell surface 
glycoprotein present on normal and malignant cells), has been used successfully in the 
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laboratory setting and clinical trials are currently on-going (Colacchio, 1997; 
Riethrnuller et al., 1998; Pazdur et al., 1999). Radio-immunotherapy with radioactive 
iodine bound to anti-CEA monoclonal antibody and autologous tumour vaccines may 
also provide clinicians with other options in their armaments (Benson, 1996). 
1.7.4 Histopathology 
A single layer of epithelial cells lines the colon and rectal surfaces. These arise from 
4-6 stem cells, which are situated at the base of crypts. These stem cells give rise to a 
population of absorptive cells, mucus secreting goblet cells or neuroepithelial cells. 
These cells then migrate from the base of the crypts towards the apex, differentiating en 
route, where at the apex the cells slough off with the passage of faeces. This journey 
takes 3-6 days (Lipkin et al., 1963). 
Nonnally, the rate of genesis of these cells equals that of cell loss at the luminal 
surface. If however, the rate of genesis exceeds that of loss, then a tumour arises. This 
early tumour usually appears as a small elevated button or as a small polypoid mass. 
These epithelial tumours tend to produce polyps. These polyps can be divided into non-
neoplastic or neoplastic depending on whether they have malignant potential, however 
there is some overlap between the two. 
Generally, non-neoplastic polyps include: hyperplastic polyps, which histologically 
are composed of well fonned glands and crypts lined by well differentiated epithelial 
cells, and as stated have no malignant potential, but a small proportion of these with 
adenomatous foci may undergo neoplastic transfonnation; hamartomatous polyps, 
which represent developmental malfonnations resulting in lesions, which consist of 
essentially nonnal mucosal components but which are arranged abnonnally, malignant 
degeneration is extremely rare but can occur; inflammatory polyps, which occur in 
patients with long standing inflammatory bowel disease, predominantly in ulcerative 
colitis and rarely Crohns disease and lymphoid polyps, which occur as a result of 
mucosal protrusions secondary to reactive hyperplasia of the mucosal and submucosal 
lymphoid tissues (Dayal and DeLellis, 1989). 
Neoplastic polyps include a group of adenomas, which can be divided histologically 
into tubular, tubulo-villous and villous adenomas. They are differentiated on the basis of 
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the majority tissue present, whether it is tubular or composed of finger like papillae 
(villous type). 
There is a definite increase in the risk of cancer from tubular to tubulo-villous to 
villous type adenomas (Day and Morson, 1978). Increasing malignant potential also 
relates to the size of the polyp, and increases from 1 % if it is less than 1 cm in diameter 
to 10% ifit is between 1-2cm in diameter, and finally up to 45% ifit is greater than 2cm 
in diameter (Muto et aI., 1975; Day and Morson, 1978). Carcinoma in situ, i.e. without 
invasion of the underlying fibrovascular core or submucosa, of the colon is present in 
about 10% of villous adenomas, with frank invasive carcinoma in an additional 25-40% 
(Coutsoftides et aI., 1979). As the tumour increases in size it eventually extends to 
encircle the lumen, which can take up to one to two years. The deeper layers are invaded 
slowly, and so for a long time the tumour tends to remain superficial. 
Ninety-five per-cents of all colorectal carcinomas are adenocarcinomas, many of 
which produce mucin. Commonly this mucin is secreted within the gland lumen or 
within the interstitium of the gut wall. This secretion of mucin is thought to aid the 
extension of the cancer by dissecting the gut wall layers and thus leading to a poorer 
prognosis (Bresalier et al., 1998). 
1.7.5 Proposis 
Various factors influence survival after surgery, but the most important factors which 
determine prognosis are the stage (the extent of spread), tumour-free surgical margins, 
lack of lymphatic/blood vessel invasion and the grade (the level of differentiation) of the 
cancer (Hobday and Erlichman, 2001). 
Currently the most reliable indicator of prognosis is the stage of the disease. Staging 
can only be performed once the cancer has been excised and analysed by a pathologist. 
The characteristics that form the basis of the staging system are the degree of 
penetration of the tumour through the bowel wall, the presence or absence of lymph 
node metastases and the presence or absence of distant metastases, such as liver or lung 
metastases (figure 1.4). There are three widely used staging classifications, the Dukes, 
the Astor-Coller modified Dukes staging and the TNM classification (American Joint 
Committee on Cancer, 1997), (see appendix II). 
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Figure 1.4 Pathological staging of colorectal cancer (adapted from Dayal and 
DeLellis, 1989). 
Stage 1 - TI or T2, NO, MO 
(Dukes A) 
Stage III - Any T, N 1-3, MO 
(Dukes C) 
Stage II - T3 or T4, NO, MO 
(Dukes B) 
Stage IV - Any T, any N, Ml 
(Dukes D) 
Generally, the 5-year survival rates, when corrected for age is between 70-90% for 
Dukes' A and B cancers, 30-40% for Dukes' C cancers and less than 20% for those with 
distant metastases. The development of complications, particularly perforation or 
obstruction, adversely affects survival (Mortensen et aI. , 1992). However, if all patients 
including those with inoperable cancers are taken into account, the five-year survival 
rate is between 35-49%, which is particularly disheartening in view of the potential for 
cure, if the disease is diagnosed early (Dayal and DeLellis, 1989). 
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1.8 GENETICS OF COLORECTAL CANCER 
The clonal nature of cancer is that it is derived from a single cell. That cell has a 
growth advantage over its adjacent cells. as a result of a mutation in its genetic make-up. 
With successive cycles of cell division. further mutations occur. conferring further 
growth advantages for individual cells and also conferring abilities that enable them to 
metastasise and grow at distant sites (Nowell. 1976). 
The clonal nature of cancer as proposed by Nowell (1976) was examined in 
colorectal cancers by Vogelstein et al. (1987). They looked at the X chromosome in 
these cancers. A female has two X chromosomes. one derived from her mother and the 
other from her father. In any given cell only one of the X chromosome is active i.e. 
either the maternal or paternal X chromosome. When looking at normal colonic mucosa. 
inactivation of either chromosome is distributed equally throughout the population. 
however. in the case of benign or malignant tumours. there was a monoclonal pattern of 
X inactivation. This was consistent with other cytogenetic studies performed on many 
carcinomas (Martin et aI .• 1979; Reichmann et al.. 1981) and adenomas (Mitelman et 
a1.. 1974; Reichmann et a1.. 1985). 
It is generally accepted that there is a step-wise progression from adenoma to 
carcinoma, involving the accumulation of a number of genetic mutations. There appears 
to be two pathways in colorectal cancer tumourigenesis, the first involves gains and 
losses of chromosome segments (chromosomal instability), accounting for 
approximately 90% of all colorectal cancers and the other involving mutations of DNA 
mismatch repair genes (micro satellite instability), (Vogelstein et aI., 1988; Aaltonen et 
aI., 1993; Peltomaki et al., 1993; Ionov et aI., 1993; Thibodeau 1993). However, there 
may be a third pathway with alterations in the level of DNA methylation resulting in 
genomic instability (Jones and Gonzalgo, 1997; Breivik and Gaudernack, 1999). 
1.8.1 Chromosomal Instability Pathway of Colorectal Cancer Tumourigenesis 
The chromosomal instability pathway as proposed by Vogelstein et al. (1988), 
involves the sequential accumulation of several mutations: the loss or mutation of the 
APe gene on chromosome 5q; mutation ofK-ras; the loss of Dee on chromosome 18q 
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and the loss or mutation of p53 (figure 1.5). It also appears that accumulation. rather 
than the order of genetic mutations is important (Fearon and Vogel stein. 1990). 
Figure 1.5 The chromosomal instability pathway of colorectal cancer 
tumourigenesis (adapted from Fearon and Vogelstein. 1990). 
APC K-ras DCC/SMAD p53 
Nonnal Dysplasia Early Intennediate Late Carcinoma 
epithelium adenoma adenoma adenoma 
1.8.1.1 Chromosome 5g: The APe gene 
? 
Metastasis 
Chromosome 5q losses were reported to occur in 20-50% of colorectal cancers. but 
also of interest is the fact that loss of chromosome 5q sequences occurred not only in 
large cancers but also in small benign colorectal tumours. suggesting that the 
inactivation of this tumour suppressor gene occurred as an early event (Vogel stein et aI.. 
1988). Another line of evidence came from the examination of patients with familial 
adenomatous polyposis coli (F AP). where loss of 5q was visible on cytogenetic analysis 
(Herrera et al .• 1986). 
The area of alteration was a small region on chromosome 5q 21 (Bodmer et aI.. 1987; 
Leppert et al .• 1987). Four genes were mapped to this region MCC. TB2 (DP 1). SRP 19 
and APC (Joslyn et al .• 1991). The adenomatous polyposis coli (APC) gene is found to 
be mutated in the germ line of F AP patients and in some sporadic cancers (Nishisho et 
aI.. 1991). Most mutations occur in the central region of the APC gene. called the 
mutation cluster region (MCR). and usually result in COOH-terminally truncated 
proteins. Mutations in the first or last thirds of the APC gene are associated with a 
milder form of polyposis. termed attenuated polyposis (AAPC). which is associated with 
fewer polyps and a later time of onset (Spirio et aI.. 1993). Conversely. mutations in the 
central mutation cluster region are associated with a more severe phenotype. with 
thousands of polyps. an earlier age of onset and extra-colonic manifestations such as 
osteomas and retinal lesions (Polakis. 1995). The majority of mutations (60%) occur in 
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the mutation cluster region, which only accounts for 10% of the entire coding region. 
Almost all the mutations, of which there are 737 mutations recorded so far, are either 
nonsense mutations (30%) or frame-shift mutations (68%), resulting in a truncation of 
the APe protein (De Vries et aI., 1996; Beroud and Soussi, 1996). Approximately 80% 
of patients with FAP have been shown to have mutations of the APC gene. To 
determine the cause of F AP in the remaining 20%, Laken et al., (1999) used monoallelic 
mutation analysis (MAMA) to determine independently the status of each of the two 
APC alleles. They found that there was reduced expression from one of the two alleles 
suggesting that complete loss of both alleles is not necessarily required and that there 
may be an additional gene involved in F AP patients, such as APCL located on 19p 13.3 
which is a homolog of APC (Nakagawa et aI., 1998; van Es et aI., 1999). 
The importance of the APC gene in tumourigenesis comes from evidence collected 
from chimeric mice which produce a truncated APe protein and who develop on 
average 30-50 intestinal tumours by the age of 90 days, and are known as Min (multiple 
intestinal neoplasia) mice (Moser et aI., 1990). Homozygous mice for the mutation at 
the APC allele invariably die in utero, while those heterozygous for the mutation 
develop polyps from the third week onwards. Analysis of these polyps by Oshima et aI., 
(1995), showed that these polyps consisted of a microadenoma surrounded by normal 
intestinal epithelium. The analysis of the dissected microadenoma revealed loss of the 
wild-type allele with preservation of the mutant allele. Dietrich et aI., (1993) also found 
that a gene located on chromosome 4, was able to modify the number of polyps formed 
and was named Mom-l (modifier of Min-I). Halberg et al., (2000) also found that the 
combination of APC and p53 mutations in Min mice leads not only to an increased 
number of polyps but also to an increased malignant potential of these polyps. 
The wild-type APC is thought to be primarily involved in apoptosis (Morin et aI., 
1996). Immunohistochemical analysis indicates that the APe protein is located on the 
basolateral membrane and levels increase as the cell migrates from the base of the crypt 
upwards (Miyashiro et al., 1995). The APe protein is also thought to play an integral 
part in the intra- and inter-cellular signalling pathway and has several functional 
domains, some of which act as binding and degradation sites for ~-catenin. Beta-catenin 
is also involved in cell-to-cell adhesion, and plays an important role in the activation of 
E-cadherin (Rubinfeld et al., 1993). With the ability of the APe protein to bind to ~­
catenin, it may also inhibit the ~-cateninffCF regulated transcription of certain genes 
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such as c-myc (Morin et aI., 1997; He et aI., 1998). Another function of the wild-type 
APC protein is its involvement in chromosome segregation by binding to, and 
promoting the assembly of microtubules (Munemitso et aI., 1994; Smith et aI., 1994). 
1.8.1.2 The Ras Oncogene 
The first ras genes were identified as the transforming components of the Kirsten and 
Harvey rat sarcoma virus genomes. Later, other ras genes were found. Three very 
closely related proteins in the Ras family, H-Ras, K-Ras, and N-Ras were found to be 
the primary regulators of cell growth and are frequently mutationally activated in 
tumours, although K-Ras appears to be involved in malignancy much more frequently 
than either H-Ras or N-Ras (Bos et al., 1987; Forrester et aI., 1987; Bishop, 1991). 
The activated Ras protein hydrolyses GTP to GDP, and so may be involved in the 
transduction of signals (Roussel, 1998). It is also thought to act on the cytosolic 
serine/threonine protein kinase, Raf, where the activated Raf kinase phosphorylates 
another enzyme MAP (mitogen activating protein) kinase, which in turn acts on several 
target proteins some of which are involved in gene regulation. However, the RaflMAP 
kinase pathway is not the only pathway in altering gene expression and there are 
probably others (Neer, 1995; Pawson, 1995). 
Recently, the gene responsible for neurofibromatosis type 1 (NFl) was found to have 
GAP activity (Martin et aI., 1990). GAP's are negative regulators of ras and so if the 
healthy allele of NFl is lost, ras cannot be switched off (Haubruck and McCormick, 
1991). In 50% of colon cancers there is no ras gene mutation but in a few there was a 
mutation of NFl (Li et al., 1992). 
1.8.1.3 Chromosome 18g: The Dee and SMAD genes 
While 17p is the most common region of allelic loss in colorectal cancer, 
chromosome arm 18q is the site of the second most common region, lost in 
approximately 70% of cases (Vogelstein et aI., 1988). There are several tumour 
suppressor genes located on 18q. The first to be described was that for the Dee (deleted 
in colon cancers) gene located on chromosome 18q21.3 (Fearon et aI., 1990). The 
protein sequence of DCC is very similar to that of neural cell adhesion molecules that 
are involved in cell-to-cell adhesion (Cho et al., 1994). Loss of Dee may allow 
increased motility of the cells and thereby enhancing metastasis (Fearon et aI., 1990; 
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Goi et aI., 1998). Studies by Jen et aI., (1994) and later by Shibata et aI., (1996) found 
that colorectal cancers with either a loss of DCC gene or a loss of DCC expression had a 
worse prognosis in terms of liver metastasis, as compared to cancers which expressed 
DCC. However, Gotley et aI., (1996) found no cases of complete loss of DCC 
expression in either the primary or metastatic colorectal cancer. 
Interestingly, approximately 90% of pancreatic carcinomas also show allelic loss at 
18q. Hahn et aI., (1996) reported the identification of a putative tumour suppressor gene 
on chromosome 18q21.1, which was termed DPC4 (for homozygously deleted in 
pancreatic carcinoma, locus 4). The gene DPC4 coded for a protein which was very 
similar to the Drosophila Mad ('mothers against decapentaplegic') protein and the 
Caenorhabditis elegans Sma protein, both of which were implicated in signal 
transduction by members of the IGF-~ family, in these organisms (Sekelsky et aI., 1995; 
Hoodless et aI., 1996). Derynck et aI., (1996) proposed a revised nomenclature 
incorporating the Sma and Mad roots to form SMAD. DPC4 was designated as 
SMAD4. Subsequently other SMAD proteins were found to exist, all sharing a certain 
degree of homology. These were termed SMAD1, SMAD2, SMAD3 and SMAD5 
encoded for by genes situated on chromosomes 4q28, 18q21.1 (approximately 3Mb 
proximal to SMAD4), 15q21-22 and 5q31 respectively (Riggins et aI., 1996; Eppert et 
aI., 1996; Nakao et aI., 1997). All are involved in the signal transduction of the 
transforming growth factor-beta (TGF-~) family of cytokines, which also include 
activins, inhibins, bone morphogenetic proteins and Mullerian-inhibiting substance (Zhu 
et aI., 1998). Members of the TGF-~ family exert a wide range of biologic effects 
including regulation of cell growth, differentiation, matrix production and apoptosis. 
TGF-~ suppresses growth in normal cells, however, the action ofTGF-~ is further 
complicated because it can also increase the growth and metastatic potential of colon 
cancer cells (Huang et aI., 1995). They also play an important role in mouse 
embryogenesis, determining tissue differentiation and body plan (Waldrip et aI., 1998). 
Zhu et al., (1998) reported that disruption of the SMAD3 gene in mice resulted in the 
mice developing large colorectal neoplasms, which metastasised to the lymph nodes. 
Bruno et aI., (1998) showed that SMAD5 played a vital role in the signalling pathway by 
which TGF-~ inhibits the proliferation of human haematopoietic progenitor cells. 
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1.8.1.4 The MCC gene 
The MCC (mutated in colon cancer) gene was identified on 5q 21 several months 
before the APC gene (Kinzler et aI., 1991; Lindgren et aI., 1992). Although there were 
several reported incidence of mutation in 6% of sporadic colorectal cancers, there were 
no mutations seen in 90 F AP kindreds (Nishisho et aI., 1991). Therefore, the role of the 
MCC gene in colorectal cancer tumourigenesis appears to be limited. 
1.8.1.5 Chromosome 17pI3.1: The p53 gene 
Certain DNA viruses can induce tumour formation. In particular, the SV40 DNA 
virus causes tumour formation through the activity of a protein called large T antigen. In 
order to understand the mechanism by which large T antigen induces oncogenesis, 
attempts were made to detect the host cell protein to which large T antigen binds. 
Immunoprecipitation of large T antigen from cells infected by SV 40 revealed a host cell 
protein of 53 kDa (known as p53) in addition to large T antigen itself (Lane and 
Crawford, 1979). 
The p53 gene was originally thought to be a proto-oncogene, partly because of its 
increased expression on tumours and because it was apparently able to transform rat 
embryo fibroblasts in collaboration with ras oncogenes (Eliyahu et aI., 1984). However, 
subsequent studies in colorectal cancers indicated that the wild-type p53 gene was a 
tumour suppressor gene and not a proto-oncogene. The studies in colorectal tumours 
consistently showed losses of 17p (Baker et aI., 1990). The common region of deletion 
was mapped to 17p 13.1 (lsobe et aI., 1986). 
Drawing on Knudson's "two-hit" hypothesis, it was hypothesised that loss of 17p 
13.1 removed one copy of the suppressor gene, while the remaining copy was mutant. 
The majority of somatic mutations of the p53 gene were single base substitutions (point 
mutations) resulting in a replacement of one of the amino acids (missense mutation). 
There are several sites at which mutations can occur, so called "hot spots" and this 
normally causes a loss of function (Nigro et aI., 1989; Malkin et aI., 1990; Hollstein et 
aI., 1991). Normal p53 protein exists as a tetramer and binds to specific DNA sequences 
and thus regulates the transcription of genes (Kern et ai., 1991). One of the genes that 
p53 protein regulates is the p21 gene (WAF llCIP 1) (EI-Deiry et aI., 1993), which codes 
for a protein that inhibits cyclin-dependant kinases, which control entry into the cell 
cycle (Waldman et aI., 1995). This is not the only pathway that controls cell cycle and 
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there are several others where p53 protein acts to control genes involved in cell 
proliferation, by either acting to induce apoptosis or arresting the cell in the G 1 phase, 
which may optimise the time available for DNA repair within the cell (Clarke et aI., 
1993). The interaction between certain DNA tumour virus proteins, such as the EIB 
protein of adenoviruses and the E6 protein of papilloma viruses can also result in the 
inactivation of many of the functions of the p53 protein, hence mimicking the effects of 
a mutation in the gene (Oliner et aI., 1992). 
Germline mutations in the p53 gene are responsible for the Li-Fraumeni cancer 
syndrome, characterised by an increased risk of early breast cancer, childhood sarcomas 
and other neoplasms. Carriers of a mutated p53 gene also have an increased risk of 
developing early cancers, with the likelihood of a cancer developing, increasing to 
nearly 90% by the time they are 65 years old (Malkin et aI., 1990). Interestingly, p53 is 
not required for the normal development of the embryo in mice, but these mice are more 
susceptible to tumour formation (Donehower et aI., 1992). Also worthy of note, is that 
cancers without functional p53 protein are resistant to DNA damaging chemotherapeutic 
agents, as the cell continues to divide and does not undergo apoptosis, such as Wilm's 
tumour and B-CLL. Tumours that have low proportions of p53 mutations such as 
testicular tumours are more sensitive to DNA damaging chemotherapeutic agents. 
It is notable that the genes identified in colorectal tumours affect almost all the 
cellular compartments; APC in the cytoplasm, ras at the cell membrane and p53 within 
the nucleus, and that they also have similar sites of action, such as on TGF-p. 
Suggesting that normal cells have evolved several levels of cellular protection and that 
many of these protective mechanisms must be disassembled before a cancer can develop 
(Kinzler and Vogel stein, 1998). Even when malignancy does occur, the subclones 
continue to evolve, developing varying degrees of metastatic capability, together with 
radiation and drug resistance (Nowell, 1976). It must be noted that not all tumours have 
abnormalities of p53 or APC and not all have ras mutations, it can therefore be assumed 
that there are also other pathways involved in colorectal tumourigenesis (Kinzler and 
Vogelstein, 1998). 
- 33 -
1,8,2 Microsatellite Instability Patbway of Coloredal Cancer Tumouriaennis 
Microsatellites are short tandemly repeated base sequences that occur randomly 
throughout the genome and may be of varying sizes both between cells and individuals 
(Bocker et aI., 1997). A microsatellite sequence is defined as two or more bases, which 
are repeated e.g. CACAo Microsatellites may be either monomorphic and show no 
variation between individuals or polymorphic, showing a variety of sizes. Very 
occasionally, the length of a microsatellite changes between one cell and its offspring 
after cell division, which has been ascribed to a slippage by DNA polymerase during 
DNA replication (Frayling, 1999). Slippage is where one DNA strand rides over its 
complementary partner and is more likely to happen in regions of repetitive sequences 
probably because DNA polymerase is less able to process through these regions (Strand 
et aI., 1993). When this alteration is found somatically in tumour cells, as compared to 
normal tissue cells, it is termed replication error. Thus, tumour cells showing changes in 
microsatellite lengths are termed replication error positive (RER+). Genes involved in 
the detection and repair of these replication errors are termed DNA mismatch repair 
genes. Mutations in these DNA mismatch repair genes lead to microsatellite instability 
(MSI), thus the terms replication error positive and microsatellite instability can been 
used interchangeably. The presence of MSI has been further categorised into MSI-H 
(when MSI is present in more than 30% of micro satellites examined) and MSI-L «30% 
of microsatellites examined), (Boland et aI., 1998). This generalised genomic instability 
may affect cancer-related genes and result in tumour formation (Aaltonen et aI., 1993; 
Peltomald et aI., 1993; Thibodeau 1993; Ionov et aI., 2000; Janin, 2000). Genes that 
could possibly be inactivated due to frame-shift mutations include those with long 
microsatellite tracts such as TGFp receptor II gene (where TGFp is known to inhibit 
growth and induce apoptosis), the BAX gene (which also induces apoptosis) and the 
APe gene (Janin, 2000). 
Microsatellite instability has been found in up to 90% of tumours of the hereditary 
non-polyposis colorectal cancer (HNPCC) syndrome (Aaltonen et aI., 1993) and in 
nearly 20% of sporadic colorectal cancers (Thibodeau et al., 1993; Aaltonen et aI., 1993; 
Kim et aI., 1994; RUschoff et aI., 1995). The incidence of HNPCC is around 2-3% of all 
colorectal malignancies (Evans et al., 1997) and are characterised by early onset of 
colorectal cancer (usually before the age of 50 years), location of tumours in the right 
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side of the colon, and an increased risk of developing tumours in other organs such as 
the uterus, stomach, bladder, small intestine and ovary (Marra and Boland, 1995). Sites 
where there is a rapid turnover of cells and where cells are sloughed off as a result of 
nonnal physiological processes (Peltomaki and de la Chapelle, 1997). Janin (2000), 
proposes that the loss of the remaining wild-type allele of an MMR gene in RER+ 
cancer prone individuals occurs many times in a number of cells at sites where there is a 
continuous proliferation of cells, the ensuing genetic instability then leads to the 
accumulation of numerous mutations in a number of genes, which can then either lead 
to carcinogenesis or early senescence and apoptosis. The mutated cells, which have 
escaped apoptosis and have not been sloughed off, could then continue to mutate at an 
explosive rate, fonning the so-called "aggressive polyp". This hypothesis could explain 
why several cases of advanced cancers have occurred in patients less than three years 
after nonnal colonoscopic screening (assuming these polyps were not missed at the 
initial screening). However, the small bowel also has a rapid turnover rate of mucosal 
cells and yet the risk of small bowel tumours is only 1 % compared to the risk of 
colorectal cancers in hereditary non-polyposis cancer syndrome, which is close to 80% 
(Aarnio et al., 1995). This may be explained by the differing luminal environments at 
the two sites, where differences in water and potential carcinogen contents could affect 
the selection of these mutated cells (Janin, 2000). The effect of environment could also 
explain why the majority of endometrial cancers, in HNPCC kindreds, occur in pre-
menopausal women as compared to post menopausal women as the hormone dependant 
endometrium proliferation, leads to an increased risk (Aarnio et aI., 1995). Conversely, 
the absence of childhood tumours could be explained by a more efficient induction of 
apoptosis in young stem cells, which may become less efficient with increasing age 
(Jan in, 2000). 
The microsatellite instability found in colorectal cancers is very similar to that found 
in yeast, where mutations in DNA mismatch repair (MMR) genes cause a 100-700 fold 
increase in microsatellite instability. The first human MMR gene MSH2 (MutS 
homologue 2) was so called because of its close similarity to the MMR homologue, 
MutS. The second major locus found to be mutated in HNPCC was identified as MLH J 
(MutL Homologue 1). Other MMR genes have also been identified: PMSJ and PMS2, 
so called because mutations in these genes cause aberrations in the post-meiotic 
segregation of chromosomes (Baker et aI., 1995), and GTBPIMSH6 (G:T mismatch 
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binding protein). The human homologue of these yeast genes, are represented by 
hMSH2, hMLHI, hPMSI and hPMS2 which are located on chromosomes 2, 3, 2 and 7 
respectively (Nicolaides et aI., 1994; Papadopoulos et aI., 1994). Liu et at., (1996) found 
that the majority (90%) of micro satellite instability found in HNPCC patients was 
associated with mutations of MSH2 and MLH 1, a very small percentage are associated 
with mutations of PMSJ and PMS2 and none with mutations ofGTBPIMSH6. Although 
no mutations of GTBPIMSH6 were found in colorectal cancers from patients with 
HNPCC, endometrial cancers showing microsatellite instability from HNPCC kindred 
do show mutations in GTBPIMSH6 (Wijnen et aI., 1999). Another DNA mismatch 
repair gene, MSH3 (MutS homologue 3), located on chromosome 5q, although not 
directly implicated in HNPCC, has been found to be mutated in some colorectal cancers 
from HNPCC patients (Akiyama et aI., 1997). 
The tumours that develop with microsatellite instability are usually situated in the 
right side of the colon, have a near diploid chromosomal constitution and are thought to 
be less aggressive in terms of growth, rate of relapse or recurrence, and metastases as 
compared to the tumours associated with loss of heterozygosity for genes (Lothe et aI., 
1993; Thibodeau et al., 1993; Bubb et aI., 1996; Myrhoj et aI., 1997). These tumours are 
also less likely to have loss of heterozygosity on 5q, 17p and 18q (Thibodeau et aI., 
1993; Kim et aI., 1994). 
DeWeese et aI., (1998) reported that mouse embryonic stem cells from mice carrying 
mutations in either one or both alleles for MSH2, displayed an increased survival 
following protracted exposures to low level ionising radiation as compared to wild-type 
embryonic stem cells. The increased survival was attributed to a failure to execute 
apoptosis efficiently, when a defect in DNA mismatch repair was present. There is also 
preliminary evidence that the presence of MSI might also confer increased resistance to 
the cytotoxic effects of alkylating agents of the types used in cancer chemotherapy (Fink 
et aI., 1996; Carethers et al., 1999). 
1.8.3 Methylatjou as a Pathway for Coloreetal Capcer Tuwouduucsjs 
Primordial germ cells and embryonic stem cells can progress through the cell cycle 
and divide without any detectable levels of DNA methylation (Lei et aI., 1996). 
However, once differentiation begins, DNA methylation is essential for the cell's 
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viability (Baylin et aI., 1998; Okano et al., 1999) and appears to play an important role 
in stabilising the active (euchromatic) and inactive (heterochromatic) DNA regions 
(Bird, 1992). 
It is known that in colorectal cancer cells there is generalised hypomethylation of the 
genome. In normal cells, about 80% of the 51_CO_3 1 dinucleotides are methylated and it 
is thought that methylation plays a role in gene expression and chromosome 
condensation (Bird, 1992). In mammalian cells, DNA methylation occurs at the 5-
position of cytosine within the CpG dinucleotide with approximately 70% of all CpG 
dinucleotides being methylated. The distribution of these CpO dinucleotides is not 
random within the genome, but appears to be concentrated in small genomic regions 
called "CpG islands," and which appear to reside within or near the promoter regions of 
various genes, where methylation apparently impairs the ability of transactivating 
factors to bind and initiate gene expression (Goel et aI., 2001). Conversely, the same 
mechanism has been found to silence tumour suppressor genes in a variety of tumours 
(Herman et aI., 1998). This distinct pathway, involving transcriptional silencing in 
selected genes in cancer has been termed CpG island methylator phenotype (CIMP), and 
is distinct from age-related methylation which has been observed in gene promoters as a 
function of age (Toyota et aI., 1999). 
The majority of tumour cells have less methylation than normal cells but, in 
conjunction with this generalised hypomethylation is a region specific gain of 
methylation within the CpO islands, which is associated with an increase in activity of 
the DNA methyltransferases (Baylin et aI., 1991; Laird and Jaenisch, 1994; Jones, 
1996). Genes which can become silenced by CpG island hypermethylation, include; the 
retinoblastoma gene, the Von Hippel-Lindau gene, the E-cadherin gene and the cyclin 
dependant kinase inhibitor genes, p 16 and p 15 (Baylin et aI., 1998). Thus, alterations in 
the level of methylation in genes can either activate normally silenced genes or silence 
normally active genes (Baylin et aI., 1998; Robertson and Wolffe, 2000). 
A correlation between micro satellite instability and aberrant DNA methylation has 
also been recently highlighted, with a strong association between CpO island 
methylation and MSI being reported in sporadic colorectal cancers (Ahuja et aI., 1997; 
Viegl et al., 1998; Miyakura et aI., 2001; Hawkins et al., 2002). Yamamoto et ai. (2002), 
analysed both hereditary (from HNPCC patients) and sporadic colorectal cancers for 
aberrant DNA methylation, and stated that 53% of the sporadic colorectal cancers with 
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high-level microsatellite instability (MSI-H) also exhibited CpG island methylation 
whereas only 23% of the HNPCC tumours did so. Concluding that the differential 
methylation within these CpG islands, may be associated with divergent developmental 
pathways in hereditary and sporadic colorectal cancers, despite both exhibiting similar 
MSI-H phenotypes. 
1.8.4 A Genetic Model for Coloredal Cancer Tumourigenesis 
Thus, the process of colorectal tumour evolution is probably the interaction of several 
mechanisms; chromosomal instability, microsatellite instability, methylation and 
probably others, as yet not described (figure 1.6). 
Figure 1.6 A genetic model for coloredal cancer tumourigenesis. 
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1.9 COLORECTAL CANCER METASTASIS 
Colorectal cancers can metastasise to a variety of organs. Sites of metastatic spread 
include the regional lymph nodes, liver, lung, bones and occasionally the brain (Weiss et 
ai., 1986). Liver metastases are present in 15-25% of patients at the time of diagnosis of 
colorectal cancer and another 20% of patients will develop liver metastases following 
resection of the primary tumour (Ballantyne and Quin, 1993; Fong et aI., 1996). The 
median survival time of patients with liver metastases from colorectal cancer, and 
receiving no treatment for these metastases, is less than 1 year (Ballantyne and Quin, 
1993). Thus, metastases represent a significant cause of morbidity and mortality in 
patients with colorectal cancer. 
1.9.1 Diagnosis of Liver Metastases 
In the case of colorectal cancer, prospective studies indicate that serial serum 
carcinoma embryonic antigen (CEA) assays are the most effective screening method for 
the detection of subsequent metastases, with 85-90% of patients with liver metastases 
having an elevated CEA (Kemeny et ai., 1982). Investigations prior to any therapy 
include a detailed history and examination, CT scan of the chest, abdomen and pelvis 
and regional imaging of the liver with magnetic resonance imaging (MRI) and possibly 
angiography (Fong et al., 1996). 
J .9.2 Treatment or Metastases 
Several modalities exist for the treatment of liver metastases; liver resection surgery, 
systemic chemotherapy, hepatic artery chemotherapy of the liver, cryoablation, 
microwave coagulation therapy, radiation therapy, chemo-embolisation, ethanol 
injection and laser photocoagulation (reviewed in Geoghegan and Scheele, 1999; 
Shibata et ai., 2000). Although all of these therapeutic methods may offer some 
palliative benefit, none of them provides satisfactory effectiveness in the control of liver 
metastases as compared to liver resection performed in selected patients. Thus, liver 
resection remains the treatment of choice, if feasible (Shibata et aI., 2000). 
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1.9.2.1 Chemotherapy and De-arterialisation 
Chemotherapy may be administered either systemically or regionally directly to the 
liver. Recently, the National Institute for Clinical Excellence, (2002), published 
recommendations on the use of chemotherapy in patients with colorectal cancer 
metastases confined to the liver, when shrinkage of the metastases might permit 
potentially curative surgery, recommending 5-fluorouracil (5-FU)/folinic acid and 
oxaliplatin as first line combination therapy and irinotecan as second line monotherapy. 
However, multidrug resistance is found in virtually all colorectal cancers and appears to 
be an inherent property of colonic mucosa cells (Fong et aI., 1996). The exact 
mechanism of 5-FU inactivation is not completely understood, but future trials of 
chemotherapeutic agents may incorporate biologic studies of cancer cells in the hope of 
identifying cancer cells resistant to 5-FU and so direct therapy using other 
chemotherapeutic agents (Leichman et aI., 1995). 
As the liver metastasis grows it begins to derive most of its blood supply from the 
hepatic artery as compared to the hepatic portal veins, whilst the normal hepatocytes 
derive their blood supply mostly from the portal circulation (Breedis and Young, 1954). 
Thus, hepatic artery chemotherapy would preferentially target the growing liver 
metastases. However, hepatic artery chemotherapy is not without significant 
complications and as yet has not been shown to improve survival as compared to 
systemic chemotherapy (reviewed in Geoghegan and Scheele, 1999). Similarly, 
occlusion of the hepatic artery should have a greater effect on the tumour than the 
normal liver. Three main approaches have been employed; embolisation, hepatic artery 
ligation and intermittent occlusion of the hepatic artery using an implanted intra-arterial 
balloon (the use of intermittent occlusion is an attempt to prevent the development of a 
collateral circulation from the portal vein circulation). Only a few studies have been 
undertaken investigating the usefulness of de-arterialisation, all with inconclusive 
results (reviewed in Fong et aI., 1996). 
1.9.2.2 Cryoablative and Mi~rowave Coagulation Therapy 
Rapid freeze/thaw of tissues results in cellular crystal formation and is associated 
with significant cellular damage and cell death. This cytotoxic effect is the basis of 
cryoablative therapy of liver metastases (Hass and Taylor, 1948). It appears to be a safe 
and effective procedure in experienced centres, however, complications can arise such 
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as; intra-operative hypothennia, cardiac dysrhythmias, cracking of the ice ball resulting 
in catastrophic haemorrhage, pleural effusions, liver abscesses, bilomaslbile fistulae, 
myoglobinuria resulting in acute renal failure, cryoshock (a phenomenon similar to 
septic shock, but without any evidence of infection) and death (Seifert et aI., 1998). Its 
efficacy as a curative treatment has yet to be established. 
Microwave coagulation therapy was first developed in the late seventies, primarily 
for use in liver surgery as a method of cutting and coagulating the bleeding surface 
simultaneously (Shibata et aI., 2000). Its use in the treatment of colorectal cancer liver 
metastases is only recent and its efficacy has yet to be established. However, it has been 
used successfully in the treatment of hepatocellular carcinoma (Hamazoe et aI., 1995). 
Shibata et aI., (2000) reported a prospective study comparing microwave coagulation 
therapy with liver resection surgery and found similar survival rates in both groups, 
concluding that microwave coagulation therapy was equally effective in the treatment of 
multiple metastases and also associated with less blood loss. Further prospective large-
scale studies will need to be undertaken to verify their results. 
1.9.2.3 Surgery 
Surgical resection however, remains the treatment of choice for liver metastases and 
as yet remains the only modality that offers any chance of a cure (Fong et aI., 1996; 
Harmon et al., 1999). 
Several surgical liver resections are possible as well as isolated segmentectomy 
(Blumgart, 1994), but curative resection is dependant on the complete removal of the 
tumour with clear margins of at least 1 cm (Shirabe et aI., 1997; Cady et aI., 1998). 
A number of factors are involved in influencing prognosis in patients undergoing a 
liver resection. Age, gender, primary tumour grade and primary tumour location are not 
major factors. Factors associated with a poor prognosis includes; symptomatic clinical 
presentation, extensive disease affecting more than 50% of the liver, the presence of 
four or more metastases, metastases greater than Scm in diameter, the presence of 
satellite metastatic lesions, regional lymph node metastases, the presence of portal vein 
invasion, hepatic vein invasion, the presence of tumour in the resection margins 
indicating that residual tumour may be present and interestingly the absence of a fibrous 
pseudocapsule on histological examination (Ballantyne and Quin, 1993; Ambiru et aI., 
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1999; Nagashima et aI., 1999; Yamamoto et aI., 1999; Okano et at, 2000; Rodgers and 
McCall, 2000). 
Liver resection in selected patients is associated with a 30-40%, five-year survival 
and a 20% long-term disease free survival, with an associated mortality of less than 5% 
in experienced centres. The majority of deaths arise from either, peri-operative 
haemorrhage, infection or liver failure (Fong et aI., 1996; Harmon et aI., 1999). Major 
complications include bile leak and biliary fistula (3-8%), peri-hepatic abscesses (2-
10%), pneumonia (5-22%), significant haemorrhage (1-3%) and liver failure (3-8%) 
(Schlag et aI., 1990; Doci et aI., 1991; Scheele et aI., 1991; Ballantyne and Quin 1993; 
Harmon et aI., 1999). 
In patients in whom liver resection surgery is not performed, the duration of survival 
is closely related to the extent of liver involvement, where the one-year survival is 60% 
in patients with a solitary liver metastasis but is less than 10% in patients with 
widespread liver disease (Wood et aI., 1976). There are several retrospective case-
controlled studies comparing hepatic resection with no resection, five-year survival in 
the resectional group was approximately 25% but was less than 5% in the non-
resectional group (Wilson and Adson, 1976; Scheele et at, 1991). 
Most patients surviving after liver resection surgery die of recurrent disease, 
indicating that microscopic disease is present at the time of the surgery, the most 
common sites for recurrence being the liver and lungs (Ekberg et aI., 1987). At present 
the use of adjuvant chemotherapy after liver resection surgery for colorectal cancer 
metastases remains unproven, but since the liver is the prime site of recurrence, hepatic 
artery chemotherapy may provide a useful modality (Koea and Kemeny, 2000). 
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1.10 UVEAL MELANOMA 
Melanoma of the uveal tract (iris, ciliary body and choroid) is the commonest 
malignancy of the eye, with 5-7 cases per million population each year in the USA. 
Uveal melanomas can be divided into two sub-types, anterior affecting the iris and 
posterior affecting the ciliary body and choroids, with the most common subtype being 
the posterior melanoma, which affects 80% of all patients (Char, 1997). Uveal 
melanomas are rare in childhood, with the median age at diagnosis for posterior 
melanomas being 55 years (Egan et aI., 1988), whilst for iris melanomas the average age 
of presentation being in the mid forties (Rennie, 1991). 
1.10.1 Aetiology 
There are a number of risk factors associated with the development of uveal 
melanomas, which include pre-existing ocular naevi, ocular melanocytosis, primary 
acquired melanosis, eye colour, skin colour, cutaneous naevi, ultra-violet light and 
genetic factors, but as yet no definitive causative factor has been found (Egan et aI., 
1988; Seddon et al., 1990). 
Familial occurrences of uveal melanoma appear to be rare, however in a survey of 
kindreds with a first degree relative also affected with uveal melanoma, it was shown 
that these cases were unlikely to be due to coincidence, suggesting that a genetic 
predisposition to uveal melanoma was present in these families (Singh et aI., 1996). 
Some cases of uveal melanoma may indeed be related to systemic hereditary cancers, 
with some evidence to suggest a link between uveal melanoma and, breast and ovarian 
cancers (Sinilnikova et al., 1999). Certain pre-neoplastic syndromes have also been 
associated with the predisposition to uveal melanoma. Familial atypical multiple mole 
and melanoma syndrome (FAMM-M), also known as dysplastic naevus syndrome is an 
autosomal dominant inherited syndrome, characterised by the presence of large numbers 
of irregular and multi-coloured naevi and a hereditary susceptibility to cutaneous 
melanoma and possibly uveal melanoma (Singh et aI., 1995). Congenital ocular 
melanocytosis is a disorder characterised by melanocytic hyper-pigmentation and which 
is associated with melanomas of the uveal tract, optic nerve, skin and the central 
nervous system (Kanski 1999). 
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1.10.2 Clinical Course 
The majority of uveal melanomas occur in the choroid, followed by tumours in the 
ciliary body, with tumours occurring in the iris the least common. Melanomas of the iris 
are relatively slow growing and rarely metastasise, with a 5-year survival of 
approximately 95%. Iris melanomas are generally detected at an early stage and are 
usually small. Posterior melanomas tend to be more malignant, are usually detected later 
and metastasise more frequently than iris melanomas, presenting with either blurred 
vision in the case of ciliary body melanomas or with symptoms similar to that of retinal 
detachment (flashing lights or visual shadows), in the case of choroidal melanomas 
(Rennie, 1991). 
Diagnostic investigations include slit lamp biomicroscopy, ultrasonography, 
indocyanine green angiography, CT and/or MRI and fine needle aspiration biopsy in 
selected cases. A general medical examination is essential in order to either exclude a 
metastasis to the choroids (most frequently from the lung or breast, but occasionally 
from the kidneys or gastrointestinal tract), and to detect any metastatic spread to either 
the lungs or the liver (Kanski, 1999). 
1.10.3 Treatment 
Iris melanomas can generally be managed conservatively, with careful observation 
and serial photography for small asymptomatic tumours, but surgical intervention may 
be required for large tumours or those that are growing rapidly and have become 
symptomatic (Geisse and Robertson, 1985). Surgical options include broad iridectomy 
for small tumours, iridocyclectomy for tumours invading the corneo-conjunctival angle 
or enucleation for large diffusely growing tumours (Kanski, 1999). 
The management of posterior melanomas is more complex, with treatment being 
individualised for each patient taking into consideration the size and location of the 
tumour, together with the state of the unaffected eye and the general fitness of the 
patient. However, there is still no general consensus as to the management of these 
melanomas and a number of treatment options are available. A major clinical trial, The 
Collaborative Ocular Melanoma Study (COMS) is in progress in order to address this 
question. Treatment options include, careful and frequent observation of asymptomatic 
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small tumours (Barr et aI., 1978; Thomas et aI., 1979), local irradiation with either 
cobalt-60 or iodine-125 plaques (Shields et aI., 1982; Packer et aI., 1992), proton beam 
(Seddon et aI., 1986; Gragoudas et aI., 1988) or helium ions (Char et aI., 1990) and 
enucleation with or without external-beam irradiation (Fine et aI., 1989). 
1.10.4 Prognosis 
A number of factors influence prognosis. The most important are size, location, cell 
type, extra-ocular extension and cytogenetic abnormalities (Gragoudas et aI., 1991; 
White et aI., 1998). The selection of treatment modality depends on the location 
(whether iris, ciliary body or choroid), size, any co-morbid conditions that the patient 
suffers from and whether any extra-ocular invasion or metastases have occurred 
(Gragoudas et al., 1991). 
The size of the tumour is determined by its elevationlheight and basal diameter. 
Small tumours are 2-3mm or less in elevation, medium-sized tumours range from 2-
3mm up to 10mm in elevation and have a basal diameter of up to 16mm and large 
tumours have a basal diameter of more than 16mm with an elevation greater than 
10mm, where large tumours are associated with a poorer prognosis (McLean et aI., 
1982; Sato et aI., 1997). 
Uveal melanomas can be further classified according to the major cell type present 
within the tumour. These are the spindle cell variety (types A and B) and non-spindle 
cell variety (epithelioid melanomas, mixed cell type melanomas and necrotic 
melanoma). Patients with tumours composing of spindle cells have a better prognosis 
than those with non-spindle cells (Jensen, 1982). 
The major determinant for prognosis as in the case of colorectal cancers is the extent 
of local spread and the development of metastases (Rennie, 1991). 
- 45-
1.11 GENETICS OF UVEAL MELANOMA 
Uveal melanomas unlike most solid tumours are amenable to karyotypic studies and 
also seem to have relatively simple chromosomal abnormalities (Horsman and White, 
1993; Wiltshire et aI., 1993). Early reports suggested that abnormalities of chromosomes 
I, 6, 3 and 8 (in particular isochromosome 8q) were associated with posterior 
melanomas (Horsman et aI., 1990; Prescher et aI., 1990, 1992; Sisley et aI., 1990, 1992; 
Horsthemke et aI., 1992; Dahlenfors et al 1993; Horsman and White, 1993; Gordon et 
aI., 1994; Singh et aI., 1994; Speicher et aI., 1994; Ghazvini et aI., 1996; Becher et aI., 
1997). Later studies confirmed these early findings and also associated monosomy 3 and 
increase in 8q with tumours of the ciliary body, which are also associated with a poorer 
prognosis (Prescher et aI., 1996; Sisley et aI., 1997; White et aI., 1998). It was initially 
postulated that monosomy 3 was the primary event with gains of chromosome 8q as a 
secondary event in the development of uveal melanomas (Prescher et aI., 1994). 
However, it has been shown that both monosomy 3 and gain of 8q are independent 
indicators of poor prognosis, with additional copies of 8q being directly related to 
reduced survival (Sisley et aI., 1997). 
Numerous tumour suppressor genes are thought to be located on chromosome 3, with 
deletions of chromosome 3 being a frequent finding in a number of malignant tumours, 
such as lung, renal and cervical cancer (Kok et aI., 1997). Loss of heterozygosity of 
chromosome 3 in uveal melanomas can also occur through the loss of one copy of 
chromosome 3 followed by the duplication of the remaining copy, thus resulting in a 
functional monosomy, termed isodisomy, and so on cytogenetic analysis appears to be 
normal with two copies of chromosome 3, but by molecular analysis there appears to be 
only one copy (White et aI., 1998). Similarly, gain of 8q also appears to be a consistent 
finding in a number of malignant tumours, notably breast, endometrial and ovarian 
cancers, with the amplification of the c-myc oncogene appearing to playa major role in 
tumourigenesis (Fejzo et aI., 1998). 
There are as yet no prospective studies analysing chromosomal abnormalities of 3 
and 8 with long-term follow-up, but there have been several retrospective studies 
relating the presence of monosomy 3 and gains of 8q to a worse prognosis (Prescher et 
aI., 1996; Sisley et aI., 1997; White et aI., 1998). 
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1.12 UVEAL MELANOMA METASTASIS 
The major routes of spread for uveal melanomas are by local invasion and metastatic 
spread via the blood stream (haematogenous metastasis). The uveal tract is extremely 
vascular but has no lymphatic system and so when regional lymph nodes are involved 
(pre-auricular, sub-mandibular and cervical nodes), it is usually as a result of sub-
conjunctival extension of the primary tumour. Uveal melanomas invariably metastasise 
to the liver, accounting for 70-90% of all metastatic cases, with other sites including the 
skin (24%), presenting as subcutaneous nodules, the lungs (7%) and the vertebrae (7%) 
(Kath et aI., 1993; Luyten, 1996; Char, 1997). 
The majority of patients show no evidence of metastases at the time of presentation 
of the primary tumour (Gragoudas et aI., 1991), with the incidence of metastases 
peaking usually at 2-4 years after primary enucleation (Diener-West et aI., 1992), but 
may present many years after the primary has been excised (Shields et aI., 1985). 
Therefore, it is likely that metastases have already been established, as micro-
metastases, prior to the detection of the primary tumour (Wang et aI., 1993). As a 
consequence, by the time liver metastases present clinically, resectional surgery is not 
possible as the metastases tend to be multiple, and present within both lobes of the liver 
(Salmon et aI., 1998; Pyrhonen, 1998), thus, liver metastatic tissue from uveal 
melanomas is rarely available for study. Consequently, prognosis is generally poor, with 
a 5-year tumour-related mortality of between 16-53% (McClean et aI., 1982; Diener-
West et aI., 1992; Kath et aI., 1993). Most studies have reported a recurrence rate of 
approximately 20-30% within 5 years following treatment (Pach et aI., 1986; Gamel et 
aI., 1992). 
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1.13 AIMS OF THE STUDY 
Liver metastases pose significant morbidity and mortality to patients with colorectal 
cancer, occurring either synchronously or several years after the primary tumour has 
been resected, and as yet no specific histopathological or genetic factor is available to 
predict the development of metastases. The principle aim of the study was to identify 
either a single or set of genetic abnormalities which could predict the development of 
liver metastases. 
At the commencement of the study no protocol was in place for the collection and 
storage of fresh-frozen specimens of primary colorectal cancers and their liver 
metastases, and as such multi-centre ethical approval was sought and obtained prior to 
establishing collection, storage and analysis of tumour specimens. Since this would take 
time to institute, and the prospective collection of uveal melanomas had already been 
established for several years, the decision was taken to commence analysis of archival 
formalin-fixed paraffin-embedded colorectal cancer and their liver metastases and 
simultaneously that of the fresh-frozen uveal melanoma samples, prior to the analysis of 
fresh specimens of colorectal cancers and their liver metastases. 
Abnormalities of chromosomes 3 and 8 are known to be associated with liver 
metastasis in the case of uveal melanomas and as such would provide a starting point for 
our study into the genetic changes involved in the development of liver metastases from 
primary colorectal cancers and uveal melanomas. Thus, the study was divided into three 
main phases, which were as follows: 
1. The analysis of abnormalities in copy numbers of chromosomes 3 and 8 in primary 
colorectal cancers and uveal melanomas with their paired liver metastases, using 
fluorescent in situ hybridisation (FISH), in order to establish the clinical significance 
of changes in copy numbers of chromosomes 3 and 8 with liver metastasis and to 
assess the feasibility and efficacy of FISH to predict prognosis. 
2. The analysis of gross genomic changes in primary colorectal cancers and uveal 
melanomas compared with their liver metastases using comparative genomic 
hybridisation (CGH), in an attempt to elucidate any specific chromosomal 
abnormalities associated with liver metastasis. 
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3. As microsatellite instability appears to play an important role in a group of colorectal 
cancers, the third study was to assess the presence of microsatellite instability in 
primary colorectal cancers and uveal melanomas to the presence or absence of liver 
metastases. 
As the outlined investigations were too extensive for the duration of the study, some 
of the study was divided between a colleague who was investigating uveal melanomas 
(Mr Neil Cross) and myself; this is outlined more clearly in figure 1.7. Unfortunately, no 
liver metastases were available from uveal melanomas for analysis, as clinically patients 
with liver metastases from uveal melanomas tend to present late and with metastases 
present in both lobes of the liver, thus precluding curative resection. The Department of 
Ophthalmology and Orthoptics had already established the collection of fresh uveal 
melanoma tissue with storage at -80°C, whereas no such system of collection and 
storage had been established for colorectal cancers or their liver metastases, thus parts of 
the study was reliant on formalin-fixed paraffin-embedded tissue specimens. 
Figure 1.7 Diagrammatic representation of the studies undertaken, with the 
techniques used and the archival tissue available for analysis. 
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CHAPTER 2 
2.1 MATERIALS 
2.1.1 General LaboratoO' Equipment and Reagents 
Chemicals 
All chemicals were purchased from BDH Laboratory Suppliers or Sigma-Aldrich Co 
Ltd. unless stated otherwise, and all were at least of analar grade. 
Water 
Deionised water for preparing aqueous solutions and rinsing equipment was obtained 
from either, a Purite Select Analyst HP system or Permulab HQ filter system. 
Glassware 
Disposable glass Pasteur pipettes were purchased from John Poulton Ltd. Low iron 
'Superfrost' slides were purchased from BDH Laboratory Suppliers. Coplin jars were 
obtained from general glassware supplies. 
Plastics and disposable laboratory equipment 
Sterile serological pipettes (10ml), 12ml centrifuge tubes. O.5ml and 2ml 
microcentrifuge tubes (eppendorf tubes) were purchased from Sarstedt Ltd. Abgene 
Thermo-Fast 96 low profile plates were purchased from Advanced Biotechnologies Ltd. 
Sterile disposable scalpels were purchased from Swann Morton Ltd. Disposable plastic 
syringes (lml and 10ml) and sterile needles (Microlance 3) were purchased from Becton 
Dickinson Ltd., the accompanying filters (Acrodisc O.8J.1110.2J.11) were purchased from 
Pall Gelman Sciences. Petri dishes (lOOx15mm) and 20ml universals were purchased 
from Bibby Sterilin Ltd. Disposable gloves were purchased from Ansell Medical. 
Blotting paper for use in slide preparation was bought from Raymond Lamb Ltd. 
Heating equipment 
Grant water baths were purchased from Scientific Laboratory Supplies Ltd., while the 
heating block was a Dri-block DB.2A purchased from Techne Ltd. 
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Automatic pipettes and tips 
Gilson Pipetmans (20/J.I, 200/J.I and 1000/J.I) were purchased from Anachem Ltd., the 
accompanying tips were provided by Sarstedt, and sterilised by autoclaving at 15p.s.i. 
and 120°C for 15 minutes. 
Centrifugation 
Cells obtained from tumour disaggregation were pelleted at 1000rpm for 10mins unless 
stated otherwise in a Megafuge I.OR purchased from Deraeus Sepatech. For all other 
techniques a microcentaur MSE purchased from Scientific Laboratory Supplies Ltd. was 
used. 
Storage 
Reagents were either stored at 4°C in an Electrolux fridge or at -20°C in a LabCold 
0020 freezer purchased from Scientific Laboratory Supplies Ltd. Fresh frozen tissue 
samples were stored in a BioStor liquid nitrogen container purchased from Statebourne 
Cryogenics. 
General Equipment 
A water-jacketed CO2 incubator from Sanyo Gallenkamp was used. Sartorius Basic 
weighing scales were purchased from Sartorius Ltd. A Stuart Scientific mini orbital 
shaker and test-tube rotator was purchased from Scientific Laboratory Supplies Ltd. 
Adjustment of pH of prepared solutions was carried out on a 3020 pH meter from 
Jenway. The vortex rotamixer was from Hook and Tucker Instruments Ltd. Both the 
fume safety cabinet and microbiological safety cabinet were purchased from Walker 
Safety Cabinets Ltd. A Speed Vac Concentrator connected to a Vacuubrand diaphragm 
vacuum pump were purchased from Savant Instruments Inc. and Vacuubrand GMBH + 
Co. respectively. DNA spectrometry was conducted on a Lambda Bio UVNIS 
spectrophotometer purchased from Perkin-Elmer Ltd. Finally, the microscope for 
analysis of slide preparations was an Olympus CK2. 
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2.1.2 Biological Samples 
Fresh uveal melanoma tumour specimens were obtained following surgical procedures 
carried out at the Royal Hallamshire Hospital in Sheffield. Ethical approval was 
obtained for specimen collection. The majority of patients were treated by enucleation, 
with tumour material being removed immediately after the globe had been opened and 
then embedded in optimal cutting temperature (OCT) compound and subsequently 
stored at -20°C. 
All liver metastatic tissue was obtained from the Royal Hallamshire Hospital, while 
primary colorectal cancer tissue was obtained either from the Royal Hallamshire 
Hospital, Barnsley District General Hospital, Chesterfield Royal Hospital, Doncaster 
Royal Infirmary or Rotherham District General Hospital. Ethical approval for specimen 
collection was obtained from each individual NHS Trust Local Research and Ethics 
Committee. Tissue specimens obtained were either paraffin-embedded or were collected 
from theatre and stored in liquid nitrogen until required. 
All tissue samples were coded and stored in a secured area. 
2.1.3 Reagents used in Cell Culture and Cell Hanesting 
Cell culture medium 
All short-term cell cultures were grown in modified RPMI 1640 medium with L-
glutamine, purchased from GibcoBRL. Standard RPMI 1640 medium (500ml) was 
modified with the addition of 10% fetal calf serum purchased from Helena Biosciences, 
50000 IV of penicillin-streptomycin purchased from GibcoBRL, 250VG of fungi zone 
also purchased from GibcoBRL and 45% d-glucose. 
Phosphate buffered saline solution with EDT A (PBSe) 
PBS tablets were purchased from Oxoid. Prepare by dissolving 1 tablet in lOOmis of 
deionised water followed by the addition of 0.2g EDT A. Sterilize in an autoclave. 
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Trypsin 1 :20 
Trypsin 1 :20 is produced by the dilution of trypsin 1 :250 with PBSe. 
2.1.4 Reagents used for Chromosome Banding 
Sorensen's buffer 
Dissolve 9.47g of disodium hydrogen orthophosphate (Na2HP04) with 9.08g of 
potassium dihydrogen orthophosphate (KH2P04) in one litre of deionised water. 
Gurr's buffer 
Buffer tablets pH6.8 were purchased from BDH. Prepare by dissolving 1 tablet in 
lOOmis of deionised water and store at room temperature. 
Leishman's staining solution 
Prepare the Leishman stain working solution by diluting the Leishman stain stock 
solution (purchased from BDH) with Gurr's buffer to a ratio of 1 :4. 
2.1.5 Reagents used in Fresh-Frozen Tumour Disaggregation 
Hypotonic solution (O.075M Kel) 
Dissolve 5.5875g of potassium chloride (KCI) into 1 litre of deionised water and 
sterilize by autoclaving. Store at 4°C and pre-warm in an incubator at 37°C prior to use. 
Fixative 
Fixative is freshly prepared, by adding methanol to glacial acetic acid in a ratio of 3: 1. 
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2.1.6 Equipment and Reagents used in Fluorescent In Situ Hybridisation (FISH) 
RNase 
RNase A was purchased from Boehringer Mannheim. Stock solution was prepared by 
dissolving Rnase with lSmM of sodium chloride (NaCI) into 20mglml of 10mM Tris-
HCI (pH 7.S) then stored at -20°C, in aliquots of 100J-l1 until required. 
Pepsin solution 
Pepsin stock 10% (lOOJ-lglml) was purchased from Sigma-Aldrich. Add 2SJ-l1 of 10% 
pepsin stock solution (100J-lglml) to 100ml of pre-warmed O.OlM HCI solution. Pepsin 
stock solution was stored at -20°C until required. 
Phosphate buffered saline (PBS) solution 
PBS tablets were purchased from Oxoid. Dissolve 1 tablet per lOOmis of deionised 
water and sterilise in an autoclave. 
Magnesium chloride solution (MgCh) 
AIM solution of magnesium chloride is prepared by making up to SOOml, by adding 
10 1.6Sg of MgCh.6H20 to de ionised water. The resulting solution is then sterilised by 
autoclaving. 
PBS - magnesium chloride solution (PBS-MgCh) 
Add SOml of the 1 M magnesium chloride solution to 9S0ml PBS, mix thoroughly and 
store at room temperature. 
Alpha satellite centromeric probes 
Initially, both probes were purchased from Cambio, the chromosome 8 probe was 
directly labelled with FITC, whereas the probe for chromosome 3 was conjugated with 
biotin and indirectly labelled with avidin-Texas Red. The probes purchased from 
Appligene-Oncor were indirectly labelled. The chromosome 8 probe being conjugated 
with biotin and the chromosome 3 probe with digoxigenin, thus indirectly labelled with 
avidin-FITC and anti-digoxigenin rhodamine respectively. 
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Denaturation solution 
Add 35ml formamide, 5ml20xSSC and 10mi deionised water into a Coplin jar, mix 
thoroughly and adjust the pH to 7.0. 
FISH hybridisation buffer 
A 10)11 hybridisation buffer solution consists of 5)11 of formamide, 2)11 of 50% dextran 
sulphate (which had been prepared with deionised water and autoclaved), 2)11 of 
deionised water and 1)11 of20xSSC. 
Rubber solution 
This is a polyurethane adhesive purchased from Phillips. 
Tween 20 
10% Tween 20 was purchased from Pierce. 
20xSSC 
Add 175.3g of sodium chloride (NaCl) to 88.2g oftri sodium citrate (Na3C6Hs072H20) 
and make up to 800ml with deionised water. Adjust to pH 7.0 and make up to 1 litre 
with deionised water before being autoclaved. 
2xSSC 
Add 50ml of20xSSC to 450ml of deionised water and adjust to pH 7.0. 
Stringency wash 
Add SOml formamide, 10ml 20xSSC and 40ml deionised water into a Coplin jar, mix 
thoroughly and adjust pH to 7.0. 
SSCT 
This consisted of 100mi of20xSSC, 2.5ml of 10% Tween 20 and mixed with 397.5ml 
of deionised water. 
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SSCTM 
Add 10ml of SSCT through a 0.45J.lm filter to 0.5g of dried semi-skimmed milk powder 
(MarveI™). The resulting solution is vortexed and then mixed on a test-tube rotator for 5 
minutes. 
Detection reagents 
Texas red conjugated to avidin was obtained from Vector for use with the Cambio 
chromosome 3 probe. Indirect Labelling Solution containing avidin-FITC and anti-
digoxigenin rhodamine was purchased from Appligene-Oncor for use with their 
chromosome 8 and 3 probes. 
Slide mountant 
Antifade (PBS/Glycerol) was purchased from Citifluor. Counterstain contained 2J.lI of 
OAPI stock solution added to 1 ml of anti fade. 
FISH analysis 
FISH preparations were analysed using a Cohu high performance CCO camera attached 
to a fluorescent microscope. Images of FISH results were captured and manipulated 
using a PSI Powergene programme running on a Power PC 8500/180 computer from 
Apple Macintosh. 
2.1.7 Reagepts used (or DNA Extractiop 
Proteinase K 
Proteinase K (fungal) 100mg (>20 Units/mg) was purchased from Life Technologies. 
Stock solution was prepared by dissolving proteinase K in 10mM Tris HCI (pH 7.5), 
20mM Calcium chloride and 50% glycerol. Then stored in aliquots of 50J..lI at -20°C, 
until required. 
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Digestion buffer 
Prepare by dissolving 60.57g Tris (pH 8.5), 0.372g EDTA and 5m110% Tween into 
1000ml deionised water to prepare a 50mM Tris (pH 8.5), 1 mM EDT A, 0.5% Tween 20 
stock solution. 
QIAamp@ DNA Extraction Kit 
The DNA extraction kit was purchased from Qiagen Ltd. The kit contained QIAamp® 
spin columns, 2ml collection tubes, AL buffer (lysis buffer), ATL buffer (wash buffer), 
AWl buffer (wash buffer), AW2 buffer (wash buffer), AE buffer (elution buffer) and 
proteinase K enzyme solution. 
TE buffer 
Add 8g ofTris HCL and 2g EDT A into 500ml of deionised water and mix thoroughly, 
adjust pH to 7.4. 
2.1.8 Reagepts used ip DNA Labelljpg 
Two methods for DNA labelling were employed. One was nick translation, reagents for 
which were purchased from Vysis UK, Ltd., the other was Ulysis® labelling purchased 
from Kreatech diagnostics. The QIAquickTM PCR purification and QIAquick™ 
nucleotide removal kits, used in the purification of ULS® labelled DNA probes, were 
purchased from Qiagen Ltd. The kits were supplied with PB buffer (binding buffer for 
use in the QIAquickTM PCR purification kit), PN buffer (binding buffer for use in the 
QIAquick™ nucleotide removal kit), PE buffer (wash buffer containing ethanol) and EB 
buffer (elution buffer-l OmM Tris-CI, pH 8.5). 
2.1.9 Equipmept apd Reagepts used for Comparative Gepomic Oybridisatjop 
(eGO) 
All reagents, normal metaphase target slides and control DNA used for CGH were 
purchased from Vysis UK, Ltd. 
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20xSSC, pH5.3 
Add 66g of20xSSC to 200ml deionised water and mix thoroughly. Make up to a final 
volume of 250m I and adjust pH to 5.3. 
Denaturation solution 
Add 49ml formamide, 7ml20xSSC (pH 5.3) and 14ml deionised water into a Coplin jar 
and mix thoroughly. Adjust the pH to 7.4. 
O.4xSSC/O.3% NP-40 Stringency wash solution 
Add 20ml of20xSSC to 950ml of deionised water and mix thoroughly. Add 3ml ofNP-
40 and using a magnetic stirrer mix thoroughly until the NP-40 is completely dissolved. 
Adjust the ph to 7.4. Aliquot out 50ml into clean 50ml centrifuge tubes and store at 
ambient temperature. Discard these aliquots after six months or if the solution appears 
cloudy. 
2xSSC/O.l % NP-40 Stringency wash solution 
Add 100ml of20xSSC to 850ml of deionised water and mix thoroughly. Add Iml of 
NP-40 and using a magnetic stirrer mix thoroughly until the NP-40 is completely 
dissolved. Adjust the ph to 7.4. Aliquot out 50ml into clean 50ml centrifuge tubes and 
store at ambient temperature. Discard these aliquots after six months or if the solution 
appears cloudy. 
Test and Control DNA 
Test and control DNA were labelled using either nick translation or ULS direct labelling 
methods. 
CGH analysis 
CGH slides were analysed using a Cohu high performance CCD camera attached to a 
fluorescent microscope. Images of CGH results were captured and manipulated using a 
MacProbe programme running on a Power PC 8500/180 computer from Apple 
Macintosh. 
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2.1.10 Equipment and Realents used (or Polymerase Chain ReactiOn (PCR> 
Primers 
Infra-red dye (lRD) labelled and unlabelled primers were purchased from MWG-
Biotech (UK) Ltd. (For details of primer sequence and annealing temperatures see 
appendix III). 
Taq polymerase 
Taq polymerase together with the nuclease free water, ammonium buffer, magnesium 
and dNTP master mix were purchased from Bioline Ltd. 
PCR thermo cyclers 
PCR thermo cyclers used included the Primus 96 Plus thermo cycler purchased from 
MWG Biotech (UK) Ltd. and the Biometra UNO-Thermoblock purchased from 
Scientific Laboratory Supplies Ltd. 
2.1.11 Equipment and Realen's used (or Alarose and Polyacrylamide Gel 
Electrophoresis 
All reagents were purchased from either BDH Laboratory Suppliers or Sigma-Aldrich 
Co Ltd. A Bio Rad 1000/500 power supply was used for all electrophoresis procedures. 
A Bio Rad Protean II xi Cell tank was used for polyacrylamide gel electrophoresis and a 
Bio Rad Mini Sub DNA Cell was used for agarose gel electrophoresis. All Bio Rad 
equipment was purchased from Life Science Research. Gels stained with ethidium 
bromide were visualised on a UV transilluminator purchased from UVP Inc. and images 
were captured using a Kodak DC290 Zoom digital camera connected to an Apple iMac 
computer running Kodak Scientific Imaging Systems 1 D software purchased from 
Anachem Ltd. 
PCR loading buffer 
Add 0.25g of bromophenol blue to a 40% glycerol solution and mix thoroughly. 
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10xTBE buffer 
Add 121g ofTris HCL, 61g of boric acid and 7.4g of EDT A into 800ml of de ionised 
water, mix thoroughly, adjust pH to 8.0 and make up to a final volume of I litre. 
20% Ammonium persulphate solution (20%, APS) 
Add 4g of ammonium persulphate to 20ml of deionised water, mix thoroughly and store 
at 4°C. 
Polyacrylamide gel solution 
A 20ml polyacrylamide gel solution was prepared according the concentration of gel 
required (table 2.1). The 20% APS and TEMED (N, N, N', N',-
tetramethylethylenediamine) were added just prior to the gel being poured. 
Table 2.1 Volumes of the various constituents used to prepare a specific 
concentration of polyacrylamide gel. 
6% 8% 10% 
Deionised Water 30ml 28ml 26ml 
40% 29: I Polyacrylamide 6ml 8ml 10mi 
10xTBE 4ml 4ml 4ml 
20%APS 200J.lI 200J.lI 200J.lI 
TEMED 20J.lI 20J.lI 20J.lI 
2.1.12 Reagents used for Ethidium Bromide Staining and Silver Staining 
All reagents were purchased from either BDH Laboratory Suppliers or Sigma-Aldrich 
Co Ltd. Ethidium bromide is a potent carcinogen and all precautions must be used in 
handling and disposing of this compound. 
Solution 1 (Initial fix solution) 
A solution of SOml 100% ethanol, Sml glacial acetic acid and 44Sml deionised water. 
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Solution 2 (Silver nitrate solution) 
Dissolve 0.5g silver nitrate into 500ml deionised water. 
Solution 3 (Developer) 
Dissolve 1.5ml formaldehyde and 2.25g sodium hydroxide into 500ml deionised water. 
Solution 4 (Final fix/stop solution) 
Dissolve 7.5g sodium carbonate into 500ml deionised water. 
2.1.13 Equipment and Reagents used (or LOngRanger Gel Electrophoresis 
All reagents were purchased from either BDH Laboratory Suppliers or Sigma-Aldrich 
Co Ltd., with the exception of 50% LongRanger Gel Solution which was purchased 
from BioWhittaker Molecular Applications Inc., urea from United States Biological and 
Chill-out 14 liquid wax from MJ Research Inc. Electrophoresis was performed on a 
LiCor 4200 LongRead IR automated sequencer (Li-Cor Technologies), with the 
products visualised using the LiCor ImagIR software on a PC computer, purchased from 
MWG-Biotech (UK) Ltd. 
Stop solution 
Prepare a solution of95% (v/v) formamide with 10mM EDT A, 0.4% basic fuchsin and 
adjust pH to 9.0. 
LongRanger gel solution 
A 25cm LongRanger gel was prepared by mixing 4ml of 50% LongRanger Gel Solution 
with 1 0.5g urea, 2.5ml of 10xTBE buffer, 250111 DMSO and make up to 25ml with 
deionised water. Add 25111 TEMED and 175111 of fresh APS just prior to pouring the 
gel. 
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2.2 METHODS 
2.2.1 Cell Culture Protocols 
2.2.1.1 Producing a Short-Term Cell Culture 
I. All the steps are performed in a sterile safety cabinet. 
2. Transfer the tumour tissue into a Petri dish. Discard any fat, muscle, fibrous or 
necrotic tissue. 
3. Add a small amount of PBS and fragment the tumour tissue manually using two 
scalpels. Try and squeeze cells loose from the clumps of tissue. Tilt the Petri dish to 
allow the larger fragments to settle and harvest the cell suspension into a sterile 
plastic centrifuge tube. 
4. Centrifuge the harvested cell suspension at 1000rpm for 10 minutes. 
5. Remove the supernatant and add 5ml of cell culture medium (RPMI 1640) gently 
and re-suspend the pelleted cells. 
6. Divide this sample into three and aliquot out into sterile T25 culture flasks. 
2.2.1.2 Cell Culture Passage 
1. Assess the culture flasks to ensure that the cell culture layer is 60-80% confluent. 
2. Remove the media. Note that some cells that are actively dividing will detach from 
the flask bottom. To assess whether these cells in suspension are viable or not, 
perform a tryphan blue test. 
3. Add 5ml of trypsin 1:20 to the flask and gently agitate the flask and incubate for 15 
minutes at 37°C. 
4. Assess the flask to ensure that the cells have lifted off the bottom of the flask and are 
in suspension. The flask may need to be tapped to dislodge the cells completely. If 
the cells are still adhering to the flask bottom, incubate for a further 10 minutes and 
re-assess. 
5. Once the majority of the cells are in suspension, aliquot a small volume into a sterile 
flask and add IOml of fresh medium. Other aliquots may be cryopreserved in 20% 
DMSOIRPMI 1640 medium. 
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2.2.1.3 Tryphan Blue Test for Cell Viability 
1. Remove the cell/medium suspension and transfer to a clean centrifuge tube. 
2. Centrifuge the cell suspension at 1000rpm for 10 minutes. 
3. Remove the supernatant except for O.S-lml remaining above the cell pellet and 
gently re-suspend the pelleted cells in the remaining medium. 
4. Transfer SOJlI of the suspended cells into a clean microcentrifuge tube and add SOJlI 
of tryphan blue. 
S. Pipette out 10JlI of the cell/tryphan blue suspension onto a clean haemocytometer 
and examine under a microscope. 
6. Dead cells will be stained dark blue, whilst living cells will not be stained. 
2.2.1.4 Slide Washing 
1. Place 20ml of Decon 90 detergent into a 21 beaker, and dilute with IS00ml of hot tap 
water. 
2. Place as many slides as required into this solution and cover with aluminium foil. 
Leave the slides to soak overnight. 
3. Rinse the slides thoroughly with hot tap water on each side for approximately 10 
seconds. And then rinse with cold tap water and finally deionised water. 
4. Store the washed slides in a covered beaker of deionised water at 4°C. 
2.2.1.5 Preparation of Metaphase Chromosome Spreads 
1. Assess the culture flasks to ensure that the cell culture layer is 60-80% confluent so 
that the cells will be still dividing and to ensure a good yield of cells. 
2. Add 0.1 ml of colcemid (final concentration 10Jlglml) to 10ml of media and incubate 
for 3-4 hours at 37°C. 
3. Remove the media and any non-adherent cells and transfer to a clean plastic 
centrifuge tube. 
4. Add Sml of trypsin 1 :20 to the flask and gently agitate the flask and incubate for 15 
minutes at 37°C. 
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S. Assess the flask to ensure that the cells have lifted off the bottom of the flask and are 
in suspension. The flask may need to be tapped to dislodge the cells completely. If 
the cells are still adhering to the flask bottom, incubate for a further 10 minutes and 
re-assess. Once the majority of the cells are in suspension, transfer them into the 
clean tube containing the initial sample. 
6. Centrifuge the cells at 1000rpm for 10 minutes. 
7. Remove the supernatant, except for O.S-I ml remaining above the cell pellet. Gently 
re-suspend the pelleted cells in the remaining medium and carefully add Sml of pre-
warmed (37°C) hypotonic solution, drop-by-drop, with gentle agitation. (Hypotonic 
treatment causes a swelling of the cells, thus causing the cell membrane to burst 
when the cells are dropped onto a microscope slide to prepare metaphase spread). 
The optimal time of hypotonic solution treatment varies for different cell types and 
must be determined empirically. 
8. Incubate for 15 minutes at 37°C. 
9. Centrifuge the cells at 1000rpm for 10 minutes. 
10. Remove the supernatant, except for O.S-Iml remaining above the cell pellet. Gently 
re-suspend the pelleted cells in the remaining medium and carefully add Sml of 
freshly prepared fixative, drop-by-drop, with gentle agitation. 
11. Repeat steps 9 and 10 two to three times. 
12. After the last centrifugation, re-suspend the cells in a small volume of fixative and 
drop a drop of the suspension onto a cold, wet, clean microscope slide. The height 
from which the drop is dropped is determined empirically. Then add a drop of 
fixative onto the cell spot to facilitate further spreading. The quality of the 
metaphase spreading is dependent on a number of factors, including humidity, 
airflow and cell concentration. 
13. After the required number of slides have been prepared, add Sml of fixative to the 
cells gently and store at -20°C. 
2.2.1.6 Leishman '8 Stain Banding 
1. Age the prepared metaphase spread slides for one week at room temperature. 
2. Place a slide on a rack over the sink and cover with trypsin solution 1 :20 for 10-20 
seconds. 
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3. Wash the slide with Sorenson's buffer for 10-20 seconds and then quickly drain. 
4. Cover the slide with Leishman's stain working solution and leave for 30-90 seconds 
and then quickly drain and wash with Gurr's buffer. The optimal time for staining 
will need to be determined empirically. 
5. Carefully blot-dry the slides and examine without mounting. 
2,2,2 Tumour Cell DisaggregatiQn Protocols 
2.2,2.1 Disaggregation of Tumour Cells from Formalin-Fixed Paraffin-Embedded 
Tissue 
1. Cut a 50J.ID1 section from each block of paraffin-embedded tumour specimen using a 
cryostat machine. 
2. Remove excess paraffin wax using a scalpel. Then transfer the tumour sample to a 
polyurethane test tube and place in a water bath at 70°C for -20 minutes, in order to 
melt the wax. 
3. Once the wax has completely melted, add 5ml of xylene into the tube, and leave in a 
water bath at 70°C for 10mins. Gently vortex the tube midway through the wash to 
aid removal of the wax. Centrifuge the tube at 1000rpm for 10 minutes and carefully 
pipette off the supernatant. 
4. Add 5ml of 100% ethanol into the tube and gently vortex. The tumour sample is 
then left in suspension for 10 minutes at room temperature. Centrifuge the tube at 
1000rpm for 10 minutes and carefully pipette off the supernatant, so as not to disturb 
the pelleted tissue. This procedure is repeated at ethanol concentrations of 95%, 70% 
and 50%. 
5. Add 10ml of deionised water into the tube and gently vortex. The tumour material is 
then left in suspension for 10 minutes at room temperature. Centrifuge the tube at 
1000rpm for 10 minutes and carefully pipette off the supernatant, so as not to disturb 
the pelleted tissue. 
6. The tumour sample is then digested with Iml of protease at 37°C. The aim of which 
was to release single tumour cells into suspension, allowing these cells to be more 
accessible for FISH. The tumour sample is digested until a fine suspension is 
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produced. During the digestion process gently vortex the tumour sample every five 
minutes. (The length of time required for digestion is partially dependent on the 
individual tumour; however, most tumours were digested for approximately 
30mins). Following the digestion process, remove any large clumps of undigested 
tumour material centrifuge at 1000rpm for 10 minutes. Then carefully pipette off the 
supernatant except for 0.5-1ml remaining above the cell pellet. 
7. Gently re-suspend the pelleted cells in the remaining supernatant and carefully add 
5ml of freshly prepared fixative, drop-by-drop, with gentle agitation. Then 
centrifuge the tube at 1000rpm for 10 minutes and carefully pipette off the 
supernatant except for 0.5-1ml remaining above the cell pellet. Repeat this fixation 
step twice. 
8. Finally, re-suspend the disaggregated tumour cells in 5ml of fixative and store at -
20°C until required. 
2.2.2.2 Disaggregation of Tumour Cells from Fresh-Frozen Tissue 
I. Retrieve fresh-frozen tumour samples out of frozen storage and place in a Petri dish. 
2. If the sample has been stored in optimal cutting temperature (OCT) compound, 
remove excess OCT from around the sample and add a small amount of deionised 
water, in order to dissolve out the remaining OCT. 
3. Using a scalpel blade, mince the tumour as finely as possible in order to release 
individual intact tumour cells. Use two scalpels in a sweeping action rather than a 
cutting action, so as to reduce the amount of damage to the individual cells. 
4. Transfer the suspension containing the released tumour cells into a clean centrifuge 
tube using a pipette. Rinse the Petri dish with deionised water, to ensure that the 
maximum numbers of disaggregated cells are collected. Then centrifuge at 1000rpm 
for 10 minutes and carefully pipette off the supernatant. 
5. Re-suspend the pelleted tumour cells with 3ml of hypotonic solution with gentle 
agitation, so as to cause the cells to swell and incubate at 37°C for 15mins. 
Following the incubation, centrifuge the tube at 1000rpm for 10 minutes and 
carefully pipette off the supernatant except for 0.5-1ml remaining above the cell 
pellet. (Initially, the cells were digested with protease at this stage; however, this 
was found to destroy the cells. Consequently this step was abandoned). 
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6. Gently re-suspend the pelleted cells in the remaining supernatant and add 5ml of 
PBS. Then carefully add Sml of freshly prepared fixative, drop-by-drop, with gentle 
agitation. Centrifuge the tube at 1000rpm for 10 minutes and carefully pipette off the 
supernatant except for O.S-lml remaining above the cell pellet. Repeat this fixation 
step twice. 
7. Finally, re-suspend the disaggregated tumour cells in 5ml of fixative and store at 
-20°C until required. 
2.2.3 Slide Preparatjop for FISH 
1. Centrifuge the tumour cell suspension at 1000rpm for 10 minutes. Remove the 
supernatant, except for 0.5-1 ml remaining above the cell pellet. 
2. Gently re-suspend the pelleted cells in the remaining supernatant and carefully add 
5ml of freshly prepared fixative, drop-by-drop, with gentle agitation. 
3. Allow any large particles of tumour to settle to the bottom of the tube, before 3-4 
drops of the re-suspended cells are dropped onto the centre of a cooled washed slide, 
from a height of about 1 em. The ends of the slide are then blotted dry with blotting 
paper. 
4. Air-dry the slide slightly until the surface appears frosted. At this point, a further 1-2 
drops of the re-suspended cell suspension is dropped onto the cell spot, if required. 
5. Finally, a drop of fixative is dropped onto the cell spot, causing the cells to spread 
out into a single layer. 
6. Air-dry the slides completely, and store in slide holders for 1 week prior to 
Fluorescent In Situ Hybridisation. 
2.2.4 Fluorescent In Sjtu Hybridjsatjop 
Day 1 
Preparation of Solutions 
1. Freshly prepare denaturation solution (consisting of 35ml formamide, 5ml20xSSC 
and 10ml deionised water and adjusted to pH7) and pre-warm to 70°C in a water 
bath placed in a fume cupboard. 
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2. Prepare the working solution for pepsin digestion (consisting ofO.Sml of INHCl in 
49.Sml of deionised H20) and pre-warm to 37°C in a water bath. 
Pre treatment with RNase 
1. The RNase working solution is made by adding SOIlI of RNase stock to IOml of 
2xSSC in a universal container and mixing. 
2. Pipette 120111 of the RNase solution onto each 22x50mm cover slip. Each slide is the 
carefully touched on top of each cover slip and incubated in a humid chamber at 
37°C for 1 hour. 
3. Remove the cover slips by tapping the slides vertically. Then immerse the slides into 
a Coplin jar containing 2xSSC at room temperature, and agitate on a shaker for 5 
minutes. Repeat this wash twice. 
Pepsin Digestion 
1. During the third wash in 2xSSC, add 25 III of pepsin stock into the working solution 
prepared at the beginning of the procedure. 
2. Immerse the slides into the pepsin solution for between 10-15 minutes depending on 
the cells under investigation. Tumour cells are generally digested for 10-15 minutes; 
whereas the blood spreads (positive controls) require only IOminutes. 
3. Then wash the slides in PBS at room temperature on the shaker for 5 minutes. The 
wash is repeated once. Following this, the slides undergo a wash in PBS-MgCh 
(50ml MgCh in 950ml PBS) at room temperature on the shaker for 5 minutes. 
Fixation 
1. Freshly prepare the fixative solution by adding I.35ml of formaldehyde to 50ml of 
PBS-MgCh. 
2. Immerse the slides into the fixative solution at room temperature for 10 minutes and 
place the Coplin jar in a fume cupboard. 
3. Immediately following fixation, wash the slides in PBS at room temperature on a 
shaker for 5 minutes. 
4. Then dehydrate the slides through an ethanol series (70%, 95% and 100%) at room 
temperature for 3 minutes each. 
5. Allow the slides to air-dry at room temperature. 
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Probe Preparation 
I. The probes are prepared while the slides are in the fixative solution. 
2. Prepare a master mix in a microcentrifuge tube. For each slide add 3111 of salmon 
sperm, 61lJ of 100% ethanol and O.5IlJ and I.OIlI of chromosome 3 and 8 centromeric 
probes. Microfuge the microcentrifuge tube at 13000rpm for 3 minutes. 
3. Then pJace the microcentrifuge tube onto a heating block at 80°C, in order to 
remove all traces of ethanol, which could seriously affect hybridisation. This usually 
takes approximately 12-15 minutes. 
4. Once dry, add IOIlI of hybrid is at ion mix for each slide into microcentrifuge tube 
containing the master mix. Denature the probes by placing the microcentrifuge tube 
onto the heating block at 80°C for 8 minutes. 
5. Then place the microcentrifuge tube immediately onto ice so as to prevent re-
annealing of the DNA probes. 
Slide Denaturation 
I. Place the slides momentarily onto a heating block at 80°C to warm. 
2. Then rapidly immerse the slides into the denaturation solution, which had been 
prepared at the beginning of the procedure. Leave the slides to stand for exactly 2 
minutes. 
3. Having been denatured, the slides are then swiftly transferred into an ice-cold 
(-20°C) ethanol series (70%,95% and 100%) for 3 minutes each, before being left to 
air-dry at room temperature. 
Loading the Probes 
1. Pulse-microfuge the probe mixture immediately prior to use. 
2. Pipette lOf.1l of the probe mixture onto a 22x22mm cover slip. Touch each slide on 
top of each cover slip and seal with rubber solution. It is important to ensure that the 
position of the probe mix on the slides coincide with that of the greatest 
concentration of cells. 
3. Incubate in a humid chamber at 37°C for 24 hours. 
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Day 2 
Post-Hybridisation Stringency Washes 
I. Freshly prepare a stringency solution (containing SOml formamide, 10ml 20xSSC 
and 40ml deionised water and adjusted to pH 7.0) and warm to 42°C in a water bath, 
in a fume cupboard. 
2. Remove the slides from the humid chamber and remove the cover slips by removing 
the rubber sealant and tapping the slides vertically. Then place the slides into the 
stringency solution for S minutes. Repeat this wash once. 
3. Then immerse the slides into 2xSSC (adjusted to pH 7.0), also at 42°C, for S 
minutes. Repeat this wash once. 
Detection 
I. Wash the slides in SSCT for 3mins. 
2. Prepare SSCTM and transfer I ml to a microcentrifuge tube. Microfuge at 13000rpm 
for 2 minutes and pipette 120~1 of the supernatant onto the centre of a 22xSOmm 
cover slip. Touch each slide on top of each cover slip and incubate in a humid 
chamber at room temperature for 10 minutes. 
3. Remove the cover slips by tapping the slides vertically, and then immerse the slides 
in SSCT for 3 minutes. 
4. Pipette 30~1 of the detection solution onto the centre ofa 22xSOmm cover slip. 
Touch each slide on top of each cover slip and incubate in a humid chamber at 37°C 
for 20 minutes. 
5. Remove the cover slips by tapping the slides vertically and immerse the slides in 
SSeT at room temperature for 3 minutes, in the dark. Repeat this wash twice. 
6. Then immerse the slides in PBS for 5 minutes, in the dark. Repeat this wash once. 
7. Dehydrate the slides through an ethanol series (70%, 95% and 100%) at room 
temperature for 3 minutes each, in the dark. The slides are then left to air-dry, in the 
dark. 
8. The counterstain is produced by adding 2~1 ofDAPI to Iml of anti fade in a 
microcentrifuge, which is then vortexed and pulsed in a microfuge. 
9. Pipette 25)..1.1 of the counterstain onto the centre ofa 22x50mm cover slip. Touch 
each slide on top of each cover slip, care being taken to avoid the introduction of air 
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bubbles, and allow the counterstain to spread right across the area of hybridisation. 
Use nail varnish to seal the edges of the cover slip. 
10. Use lightproof slide boxes to hold the completed slides and store at 4°C until 
required for viewing. 
2.2.5 DNA Extraction Protocols 
2.2.5.1 DNA ExtractiOn usin& PbenoljCbloroform for Formalin-Fjxed Paraffin-
Embedded Tissue for use in CGO 
De-waxing of Paramn-Embedded Tissue 
Slide preparation 
Prepare twelve 51lm sections from the paraffin-embedded tissue. The first and last slides 
are stained with haematoxylin and eosin (H&E), to ensure that there is no abrupt change 
in the tumour cell population throughout the sectioned tumour specimen. The remaining 
slides are left unstained and the tumour cell population microdissected using the H&E 
stained slide as a guide. 
The various protocols utilised for the de-waxing of the microdissected paraffin-
embedded tissue are discussed more fully in chapter 4.2.1 Optimisation of DNA 
Extraction from Formalin-Fixed Paraffin-Embedded Tumour Samples. 
Tissue Digestion 
I. Place the microdissected tissue sample into a 2ml microcentrifuge tube and add 
600111 of digestion buffer and 30,...1 of proteinase K and incubate on a rotator at 55°C 
for 24 hours. 
2. Centrifuge at 13000rpm for 10 minutes at room temperature. 
3. Place on a heating block and boil for 10 minutes in order to de-activate the 
proteinase K. 
4. Centrifuge again at 13000rpm for 10 minutes at room temperature. 
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DNA Purification using Phenol:Chloroform 
1. Add an equal volume of phenol:chloroform to the de-waxed and digested DNA 
solution sample in a polypropylene tube with a plastic cap. (Ensure that the phenol 
has been equilibrated to ph 7.8-8.0, otherwise the DNA will partition into the 
organic phase). 
2. Mix the contents of the tube until an emulsion forms. 
3. Centrifuge at 13000rpm for 10 minutes at room temperature. 
4. Remove the aqueous layer (top clear layer, which contains the DNA) avoiding the 
white interface layer (which contains protein) and place into a fresh tube. 
5. Repeat steps I through to 4 until no white interface layer is present. 
6. Add an equal volume of cold (-20°C) chloroform (to remove any phenol) and repeat 
steps 2 through 4. 
7. Add an equal volume of cold (-20°C) 100% ethanol and precipitate the DNA by 
centrifuging at 13000rpm for 30 minutes. 
8. Carefully remove the supernatant, ensuring not to disturb the pellet and then vacuum 
dry at ambient temperature, so as to remove all traces of ethanol. 
9. Finally, resuspend the DNA pellet in either 1O-20~1 of deionised water (if the DNA 
is to be used immediately) or 1O-20,.d ofTE buffer (pH 7.4) and store at _20DC. 
2.2.5.2 DNA Extraction using the OIAamp@ DNA Mini Kit for Formalin-Fixed 
Paraffin-Embedded Tissue for use in CGH 
I. Microdissect 8-10 unstained 51lm sections and place in a 2ml microcentrifuge tube. 
2. Add 1200~1 xylene and vortex vigorously for at least 30 seconds. 
3. Centrifuge at 13000rpm for 5 minutes at room temperature. 
4. Carefully remove the supernatant, without disturbing the tissue pellet. 
5. Add 1200111 of 100% ethanol and gently vortex. 
6. Centrifuge at 13000rpm for 5 minutes at room temperature. 
7. Carefully remove the supernatant, without disturbing the tissue pellet. 
8. Repeat steps 5-7 once more. 
9. Place the microcentrifuge tube onto a heating block set at 37°C, with the lid off for 
between 10-20 minutes, until all the ethanol has evaporated. 
10. Re-suspend the tissue pellet in 180~1 of Buffer A TL. 
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11. Add 20, . .tl of proteinase K, gently vortex and incubate at 56°C until the tissue has 
been completely digested. Vortex occasionally during incubation to disperse the 
sample. (The tissue digestion usually takes 24 hours but the addition of a further 
20, . .tl of proteinase K after 24 hours and incubation for a further 24 hours will 
improve DNA yields). 
12. Briefly centrifuge and add 200J.ll of Buffer AL. Gently vortex the microcentrifuge 
tube and place on a heating block set at 70°C for 10 minutes. (A white precipitate 
may form during this step, but it will dissolve during the incubation). 
13. Add 200J.ll of 100% ethanol and gently vortex for 15 seconds. Briefly centrifuge to 
remove drops from the inside of the lid. 
14. Transfer the contents of the microcentrifuge tube into a QIAamp spin column 
without wetting the rim. Close the cap and centrifuge at 8000rpm for 2 minutes. 
Place the spin column in a clean 2ml collection tube and discard the tube containing 
the filtrate. (Ensure that all of the solution has passed through the membrane of the 
spin column, ifit has not, then centrifuge at 13000rpm for a further 2 minutes). 
15. Carefully open the lid and add 500J.lI of Buffer AWl without wetting the rim. Close 
the cap and centrifuge at 8000rpm for 2 minutes. Place the spin column in a clean 
2ml collection tube and discard the tube containing the filtrate. 
16. Carefully open the lid and add 500J.lI of Buffer A W2 without wetting the rim. Close 
the cap and centrifuge at I3000rpm for 5 minutes. Place the spin column in a clean 
2ml collection tube and discard the tube containing the filtrate. 
17. Place the spin column in a clean 2ml collection tube and centrifuge again at 
13000rpm for 5 minutes, to ensure that there is no carry over of any Buffer A W2. 
18. Place the spin column in a clean 2ml collection tube and discard the tube containing 
the filtrate. Carefully open the lid and add 50J.ll of Buffer AE. Close the lid and 
incubate at room temperature for at least 30 minutes. Centrifuge at I3000rpm for 5 
minutes and transfer the filtrate to a clean 0.5 ml centrifuge tube. 
19. Store the eluted DNA at -20°C until required. Determine the DNA yield using a 
spectrophotometer. 
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2.2.5.3 DNA Extraction using the OIAamp@ DNA Mini Kit for Fresh Frozen Tissue 
for use in CGH 
1. Retrieve the tissue sample from storage and place in a Petri dish. 
2. Finely mince approximately 25mg of the tissue into small pieces and place in a 2ml 
microcentrifuge tube. 
3. Add 180,...,1 of Buffer ATL and gently vortex. 
4. Follow steps 11-19 as for the DNA Extraction Protocol for Paraffin-Embedded 
Tissue (QIAamp@ DNA Mini Kit). 
2.2.5.4 DNA Extraction of Formalin-Fixed Paraffin-Embedded Tissue for use in 
Slide Preparation 
Two S,...,m sections are required. One is stained with H&E the other with 0.01 % aqueous 
toludine blue. The H&E stained slide is used as a guide when dissecting the toludine 
blue stained slide. Wet the toludine blue slide before microdissection with digestion 
buffer, so that the microdissected cells are not blown away. 
Tissue Digestion 
I. Pipette 200,...,1 of digestion buffer into a microcentrifuge tube (100,...,1 for small 
samples). 
2. Place the microdissected material into the microcentrifuge tube. 
3. Add 10,...,1 (5,...,1 for small samples) proteinase K. 
4. Incubate at 55°C overnight (after 1.5 to 3 hours, give the bottom of the tube a "flick" 
to re-suspend any settled material; do not vortex. 
5. Centrifuge at 13000rpm for 10 minutes at room temperature. 
6. Place on a heating block and boil for 10 minutes in order to de-activate the 
proteinase K. 
7. Centrifuge again at 13000rpm for 10 minutes at room temperature. 
8. Store at -200C. 
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2.2.6 DNA Labelling Protocols for Comparative Genomic Hybridisation 
2.2.6.1 Nick Translation Labelling of DNA 
Nick translation is a process of incorporating a fluorochrome label to the test DNA. The 
process fragments large pieces of DNA into smaller pieces tagged at the 3' - end with 
either Spectrum Green or Spectrum Red dUTP, depending on which fluorochrome is 
used to label the control DNA. Test DNA would be labelled with Spectrum Green 
dUTP, when the control DNA is labelled with Spectrum Red dUTP, and vice-versa. 
1. Place a clean 0.5ml microcentrifuge tube on ice and allow to cool. 
2. The following constituents are added into the microcentrifuge tube in this order: 
(17.5 - x)JlI nuclease free water 
XJ.11 for 1 Jl.g extracted genomic test DNA 
2.SJlI 0.2mM Spectrum Green or Spectrum Red dUTP 
5Jl.I 0.1 mM dTTP 
10Jl.I dNTP mix 
SJl.I lOx nick translation buffer 
10Jl.I nick translation enzyme 
50Jl.I total volume 
x = volume of extracted test DNA in solution which is equal to 1 Jl.g of test DNA 
3. Vortex the microcentrifuge tube briefly and incubate at 15°C for 2-4hrs. 
4. The reaction is stopped by heating the microcentrifuge tube on a heating block to 
70°C for 10minutes. 
5. Then either place the microcentrifuge tube on ice or store at -20°C until required. 
Determining Nick Translated DNA Probe Size 
Determining the probe size is essential, in order to ensure that the genomic test DNA 
has been effectively nick translated to the desired size of - 600-2000 bp. If the probe 
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size is either too large or too small then the hybridisation will either appear too dim or 
appear granular. The probe size is determined using 1% agarose gel electrophoresis with 
ethidium bromide staining. 
2.2.6.2 Ulysis@ ULS Labelling of DNA 
1. Add 2, . .tl of either rhodamine-ULS® or dGreen- ULS® to Illg of the test DNA to 
label it with rhodamine or dGreen respectively into a 0.5ml microcentrifuge tube. 
2. Adjust the volume with labelling solution to 20111 and vortex. 
3. Incubate at 65°C on a heating block for 15 minutes. 
4. Briefly centrifuge the tube to remove droplets from the lid. 
5. Purify the labelled DNA using QIAquickTM PCR purification Kit spin columns. 
2.2.6.2.1 QIAguick peR Purification/Nucleotide Removal Protocol 
1. Add IOOIlI of PB buffer to 20111 of the Ulysis labelled DNA and vortex briefly and 
pulse microcentrifuge. (Originally, the QIAquick nucleotide removal protocol was 
employed to purify the labelled DNA, which involved the addition of either 100111 or 
200111 ofPN buffer to 20111 of the Ulysis labelled DNA. However, it was found that 
more efficient CGH hybridisations were obtained using the PCR purification 
protocol). 
2. Transfer the solution into a QIAquick spin column and centrifuge at 13000rpm for 1 
minute. 
3. Discard the filtrate and add 750111 ofPE buffer into the spin column. Centrifuge at 
13000rpm for I minute and discard the filtrate. Repeat the centrifugation at 
13000rpm for a further 1 minute and ensure that the membrane in the spin column 
appears dry. 
4. Place the spin column into a clean 2ml microcentrifuge tube and place 30111 of EB 
buffer onto the membrane of the spin column. 
5. Leave at room temperature for at least 30 minutes and the centrifuge at 13000rpm 
for 5 minutes. Transfer the eluted filtrate into a clean 0.5ml microcentrifuge tube. 
6. Store the eluted labelled DNA at -20°C until required. 
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2.2.7 Comparative Gepomjc Hybridjsatjop 
Day 1 
Preparation of Denaturation solution 
1. Freshly prepare the denaturation solution (containing 49ml formamide, 7ml 20xSSC 
and 14ml deionised water and adjusted to pH 7.0) and heat in a water bath to 
73± 1°C, in a fume cupboard. 
Preparing the Probe Mix 
1. Combine the following in a 1.5ml microcentrifuge tube: 
10J.11 (200ng) labelled test DNA 
IJ.11 (100ng) labelled total genomic reference DNA 
1OJ.11 (10J.1g) Human Cot-l DNA 
2. Add 2.11l1 (0.1 volume) of 3M sodium acetate to the mixture followed by 52.51l1 
(2.5 volumes) of 100% ethanol, in order to precipitate the DNA. The sodium acetate 
acts as a carrier. Then place the microcentrifuge tube in a -70°C freezer for 15-30 
minutes. 
3. Microfuge the microcentrifuge tube at 12,000rpm for 30 minutes in order to pellet 
the DNA. 
4. Carefully remove the supernatant so as not to disturb the pellet and then vacuum dry 
in a vacuum centrifuge at room temperature so as to remove all traces of ethanol. 
5. Re-suspend the dried DNA pellet in 3111 of purified water and 7111 of CGH 
hybridisation buffer. 
6. Then denature the DNA mixture by heating in a water bath at 73°C for exactly 5 
minutes. 
Hybridising the Probe DNA to the Target Metaphase 
1. Mark the hybridisation areas on the target metaphase slides using a diamond tipped 
scribe. 
2. Then immerse the slides in the denaturation solution for exactly 5 minutes. 
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3. Having been denatured, dehydrate the slides at room temperature in an ethanol series 
(70%, 85% and 100%) for 1 minute each, before being left to air-dry at room 
temperature. 
4. Apply 1O1l1 of the denatured DNA mixture to the marked hybridisation area. 
5. Then apply a cover slip immediately to each hybridisation area and seal with rubber 
solution. 
6. Incubate the slides in a humid chamber at 37°C for between 48-72 hours. 
Day 3 
Preparation of Solutions 
1. Prepare a fresh stringency wash solution (containing 0.4xSSC/O.3% NP-40 and 
adjusted to pH 7.0-7.5) was and heat to 74±1 °C in a water bath placed in a fume 
cupboard. 
2. Freshly prepare a second stringency wash solution (containing 2xSSC/O.l % NP-40 
and adjusted to pH 7.0-7.5) and place at room temperature in a fume cupboard. 
Post-Hybridisation Stringency Washes 
I. Remove the slides from the humid chamber and remove the cover slips by removing 
the rubber sealant and tapping vertically. Immerse the slides into the 0.4xSSC/0.3% 
NP-40 stringency solution, agitate gently for 1-3 seconds and then allow to stand in 
the stringency solution for 2 minutes. 
2. Remove the slides and immediately immerse them into the 2xSSC/O.I % NP-40 
stringency solution, agitate gently for 1-3 seconds and allow to stand for 1 minute. 
3. Then allow the slides were to air-dry in darkness. 
Detection and Visualising the Hybridisation 
1. Once the slides are dry apply IOll1 of DAPI II counterstain to each hybridisation area 
and apply a cover slip. Use nail varnish to seal edges of the cover slip. The slides 
can then be stored in lightproof slide boxes at 4°C, until required for viewing. 
2. Visualise the hybridisation using a CCD camera and image enhancement software, 
with appropriate filters for the fluorochromes and DAPI used. 
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2.2.8 Polymerase Chaip Reactiop 
2.2.8.1 PCR using O.5ml Microcentrifuge tubes and the Biometra UNO-
Thermoblock for use on Agarose or Polyacrylamide Gels 
1. Place all 0.5ml microcentrifuge tubes to be used for the PCR reaction on ice and 
allow to cool. 
2. Add the following constituents into a 2ml microcentrifuge tube, also placed on 
ice, to produce a master mix in this exact order: 
19.1 J..ll nuclease free water 
2.5J..l11 OxN~ buffer Each constituent was multiplied by (n+2) 
0.75,.!l MgCh before being added into the master mix. 
O.5J..ll dNTP mix Where n = number of tumour DNA 
0.5J..ll forward primer (lOOpmol/J..ll) samples and 2 extra volumes to allow for 
0.5J..lI reverse primer (1 OOpmol/J..ll) 
0.15J..lI Taq polymerase 
24J..lI total volume per reaction 
one negative control and any mis-
pipetting 
3. Place an aliquot of 24J..lI from the master mix into each 0.5ml microcentrifuge 
tube. 
4. Pipette IJ..lI of the tumour DNA to be amplified into the microcentrifuge tube. 
5. Add a drop of mineral oil to each microcentrifuge tube to prevent evaporation of 
the PCR reaction mixture during thenno-cycling. 
6. Finally, pulse each microcentrifuge tube briefly in the microfuge and place on 
the PCR block for thenno cycling. All samples underwent an initial denaturation 
step at 94°C for 3 minutes followed by 30 cycles of denaturation at 94°C for 1 
minute, an annealing step at the optimal temperature as shown in appendix III for 
30 seconds and extension at 72°C for 30 seconds, with a final extension step at 
72°C for 5 minutes. 
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2.2.8.2 peR using the Abgene Thermo-Fast 96 Low Profile Plate and the Primus 96 
Plus thermo cycler for use on LongRanger Sequencing Gels 
I. Place a 2ml microcentrifuge tube on ice and allow to cool. 
2. Add the following constituents into the microcentrifuge tube to produce a master 
mix in this exact order: 
7.05JlI nuclease free water 
1 JlI 1 OxNHt buffer 
0.3JlI MgCh 
0.2JlI dNTP mix 
0.15JlI unlabelled forward primer 
(100pmoIlJlI) 
0.15JlI unlabelled reverse primer 
(lOOpmoIlJll) 
0.15JlI Taq polymerase 
9JlI total volume per reaction 
Each constituent was multiplied by (n+2) 
before being added into the master mix. 
Where n = number of tumour DNA 
samples and 2 extra volumes to allow for 
one negative control and any mis-
pipetting 
3. To the final master mix add 3JlI of the IRD labelled forward primer. 
4. Place an aliquot of 9JlI from the master mix into each well of the 96 well plate. 
5. Pipette IJlI of the tumour DNA to be amplified into the well. 
6. Add a drop of Chill-out 14 liquid wax (purchased from MJ Research Inc.) into each 
well to prevent evaporation of the PCR reaction mixture during thermo-cycling. 
7. Place the 96-well plate immediately onto the PCR block for thermo cycling. All 
samples underwent an initial denaturation step at 94°C for 3 minutes followed by 30 
cycles of denaturation at 94°C for I minute, an annealing step at the optimal 
temperature as shown in appendix III for 30 seconds and extension at 72°C for 30 
seconds, with a final extension step at 72°C for 5 minutes. 
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2.2.9 Agarose Gel Electrophoresis 
1. The agarose gel is prepared by mixing 1 g agarose to 100ml 1 xTBE buffer, and 
heating the solution in a microwave until the agarose is in solution. Take care not to 
super heat the solution. 
2. Allow the agarose solution to cool to approximately 45°C and add 2.5J.11 of ethidium 
bromide. 
3. Pour the agarose solution into a mini-gel fitted with combs and allow to set. 
4. Pour TE buffer over the gel so as to cover it completely by approximately lmm. 
5. In a O.5ml microcentrifuge tube, mix 9J.11 of the reaction mixture with IJ.11 ofPCR 
loading buffer and pipette the resultant solution into one of the wells. 
6. Electrophorese the reaction mixture with a lkb DNA marker placed in another well, 
in order to determine the size of the DNA product. 
7. Electrophorese the gel at 10 V fcm until the peR loading buffer is approximately 2-
3cm from the edge of the gel. Visualise the gel with UV light, using all appropriate 
precautions. 
2.2.9.1 Ethjdjum Bromide Staipjpg 
Ethidium bromide is a potent carcinogen and all precautions must be used in handling 
and disposing of this compound. Ethidium bromide may either be incorporated directly 
into a gel or may be added to a volume of electrophoresis buffer placed in a plastic tray 
and the gel immersed into the buffer for a variable period of time so as to stain the 
DNA. This immersion technique may be used to stain either agarose or polyacrylamide 
gels. 
2.2.10 Polyacrylamjde Gel Electrophoresis 
1. Prior to pouring the gel, ensure that the glass plates are perfectly clean by cleaning 
with methanol and wiping dry with tissue paper. 
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2. Place the spacers between the glass plates and clamp the plates onto a casting tray, 
ensuring that there is a tight seal between the glass plates and the casting tray, in 
order to prevent leakage of the polyacrylamide gel solution. 
3. Pour the gel solution quickly in between the glass plate and carefully insert the 
comb, ensuring that no air bubbles are trapped between the comb and gel. 
4. Allow the gel to set for approximately 30 minutes. 
5. Once the gel is set, the comb is carefully removed and the wells washed with IxTBE 
buffer using a syringe, in order to remove any polyacrylamide gel that has not yet 
set. 
6. The gel and glass plates are removed from the casting tray and clamped into the gel 
running tank and the tank filled with 1 xTBE buffer. 
7. Pre-electrophorese the gel at 175 volts for 30 minutes, so as to warm the gel, so that 
the PCR products electrophorese uniformly along the gel. 
8. 5111 ofPCR loading buffer is added to each sample. 
9. Using a Hamilton syringe, load 20111 of each PCR sample into each well, ensuring 
that the syringe is washed out prior to loading the next sample. 
10. The gel is then electrophoresed at 175 volts for approximately 16 hours. 
11. Once the loading dye has reached the end of the gel, the power is switched otT and 
the glass plates and gel removed from the tank. Carefully separate the glass plates 
and slide the gel into a clean plastic tray containing IxTBE buffer. Cut off the top 
right corner of the gel for orientation, prior to silver staining. 
2.2.10.1 Silyer Stainipg 
1. Remove the polyacrylamide gel from the tray containing the 1 xTBE butTer and 
carefully place into a clean plastic tray containing solution 1 (initial fix solution) and 
leave at room temperature for 10 minutes. 
2. Remove the gel and place in a clean tray containing solution 2 (silver nitrate 
solution) for approximately 15 minutes. 
3. Remove the gel and place in a clean tray containing deionised water and rinse once. 
4. Remove the gel and place in a clean tray containing solution 3 (developer) and 
gently shake the tray until the bands appear on the gel and have reached the desired 
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intensity. (Over-development will result in a dark brown background with low 
contrast bands rather than a grey background with sharp bands). 
5. Remove the gel and place in a clean tray containing solution 4 (final fix/stop 
solution) for 5 minutes. 
6. After the final gel fix the gel is removed and sealed in a plastic sleeve. 
2.2.11 LongRanger Gel Electrophoresis 
1. Prior to pouring the gel, ensure that the glass plates are perfectly clean by 
cleaning with methanol and wiping dry with tissue paper. 
2. Place the spacers between the glass plates and clamp the plates onto a casting 
tray, ensuring that there is a tight seal between the glass plates and the casting 
tray, in order to prevent leakage of the polyacrylamide gel solution. 
3. Pour the gel solution quickly in between the glass plate and carefully insert the 
comb, ensuring that no air bubbles are trapped between the comb and gel. 
4. Allow the gel to set for approximately 30 minutes. 
5. Once the gel is set, the comb is carefully removed and the wells washed with 
1 xTBE buffer using a syringe, in order to remove any gel that has not yet set. 
6. The gel and glass plates are removed from the casting tray and clamped into the 
LiCor 4200 LongRead automated sequencer and the tank filled with 1 xTBE 
buffer. 
7. Pre-electrophorese the gel at 800 volts for 20 minutes, so as to warm the gel to 
50°C. 
8. Prior to loading the gel, add 4J.lI of stop solution to each well and denature at 
75°C for 5 minutes. 
9. Using a Hamilton syringe, load IJ.lI of each PCR sample into each well, ensuring 
that the syringe is washed out prior to loading the next sample. 
10. The gel is then electrophoresed at 800 volts. 
11. The PCR products will be visualised automatically with the LiCor Base ImagIR 
software on a PC computer. 
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2.3 LIST OF SUPPLIERS 
Advanced Biotechnologies Ltd. 
Longmead Business Centre. Blenheim Road. Epsom. KT19 9QQ. 
Ansell Medical 
Ansell House. 119 Ewell Road. Surbiton, KT6 6A Y. 
Anachem Ltd. 
Anachem House, Charles Street, Luton, LU2 OEB. 
Appligene-Oncor 
Parc d'Innovation, B.P.72, F-67402, Illkirch, France. 
Becton Dickinson Ltd. 
Between Towns Road, Cowley, Oxford, OX4 3L Y. 
BDH Laboratory Suppliers 
Merck Ltd, Hunter Boulevard, Lutterworth, LE17 4XN. 
Bibby Sterilin Ltd. 
Tilling Drive, Stone, Staffordshire, ST15 OSA. 
Bioline Ltd. 
16 The Edge Business Centre, Humber Road, London, NW2 6EW. 
Bio Whittaker Molecular Applications Inc. 
191 Thomston St, Rockland, Maine, USA. 
Boehringer Mannheim 
Boehringer Mannheim House, Bell Lane, Lewes, BNY 1 LG. 
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Cambio 
34 Millington Road, Cambridge, CB3 9HP. 
Citifluor 
UKC, Chemical Laboratories, Canterbury, CT2 7NH. 
Corning Costar UK Ltd. 
I The Valley Centre, Gordon Rd, High Wycombe, HB 13 6EQ. 
Flowgen 
Novara House, Excelsior Road, Ashby de la Zouch, LE65 ING. 
Gibco Life Technologies Ltd. 
PO Box 35, Trident House, Renfrew Rd, Paisley PA3 4EF. 
Helena Biosciences 
Sunderland Enterprise Park, Sunderland SR5 3XB. 
John Poulton Ltd. 
75-93 Tanner Street, Barking, IG 11 8QD. 
Kreatech Diagnostics 
Vlierweg 20, 1032 LG Amsterdam, The Netherlands. 
LI-COR 
4308 Progressive Avenue, Lincoln, Nebraska, USA. 
Life Science Research 
Bio-Rad House, Mayland Avenue, Hemel Hempstead, HP2 7TD. 
MJ Research Inc. 
590 Lincoln Street, Waltham, Massachusetts, USA. 
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CHAPTER 3 
3.1 INTRODUCTION 
Uveal melanomas are the commonest malignancy of the eye with an annual incidence 
of 5-7 cases per million population (Egan et at., 1988; Jensen, 1982). They account for 
approximately 80% of all non-cutaneous melanomas (Scotto et at., 1976), and are 
classified as either posterior when located in the ciliary body or choroid or anterior when 
located in the iris (Char, 1997). Uveal melanomas invariably metastasise to the liver, 
with the incidence of metastases peaking usually at 2 years after primary enucleation 
(Diener-West et aI., 1992). Thus prognosis is generally poor, with a 5-year tumour-
related mortality of between 16-53% (Diener-West et al., 1992). 
A number of prognostic indicators have been established for uveal melanomas, which 
include: a maximum tumour diameter of greater than 15mm; the presence of epithelioid 
cells; extra-scleral extension; tumour location in the ciliary body (Coleman et at., 1993; 
McLean et at., 1982) and possibly vascular patterns (Folberg et at., 1993; Rummelt et 
at., 1995). More recently, cytogenetic studies have shown that a loss of chromosome 3 is 
a significant prognostic indicator of early relapse and poor survival (Prescher et at., 
1996; Sisley et at., 1997). Several groups have also shown that a gain of chromosome 8, 
principally in the form of an isochromosome 8q, is also associated with a worse 
prognosis (Dahlenfors et at., 1993; Horsman and White, 1993; Horsthemke et at., 1992; 
Prescher et at., 1992, 1996; Singh et at., 1994; Sisley et at., 1990, 1992). Other groups 
have found that the presence of chromosome 6 abnormalities is predictive of a good 
prognosis even when associated with abnormalities of chromosomes 3 and 8 (White et 
al., 1998). 
However, cytogenetic analysis requires the short-term culture of tumours followed by 
producing good quality metaphase spreads. This process is not only time consuming but 
could also induce in-vitro genetic changes (Fox et at., 1995). This presence of 
aneuploidy has also been studied using flow cytometry and static image analysis on both 
fresh and archival material, with conflicting results (Mooy, 1998), which may in part be 
as a result of limitations of the various techniques (Koss et at., 1989; Shankey et at., 
1993). The development of fluorescence in situ hybridisation (FISH) allows the 
interphase cytogenetic analysis of either fresh or archival tumour tissue not only quickly, 
- 93-
but also accurately. It also allows for the examination of multiple genetic changes, by 
the use of probes labelled with spectrally distinct fluorescent dyes (Pinkel et aI., 1988; 
Matsumura et aI., 1992; Kallioniemi et aI., 1996). 
3.1.1 Fluorescence In Situ Hybrjdjsatjon (FISH) 
In situ hybridisation is a method of localising either mRNA within the cytoplasm or 
DNA within the nucleus, by hybridising a strand of nucleotide probe to the 
complimentary target sequence of interest. In situ hybridisation techniques were 
developed in the late 60's based mainly on work undertaken by Gall and Pardue (1969). 
However, it was only in the 1980's that scientists started using the procedure to localise 
single copy base sequences cloned from individual genes (Lichter and Cremer, 1992). 
Formerly radioactive isotopes e2p, 35S or 3H) were used as markers, but the recent 
development of fluorescent dyes (fluorochromes) has not only improved the safety 
aspect, but also the resolution of the procedure (McNeil et aI, 1991). 
FISH not only allows the examination of cells in the interphase stage - so called 
interphase cytogenetics (Cremer et aI., 1986), it also allows for the examination of 
multiple genetic changes, by the use of probes labelled with spectrally distinct 
fluorescent dyes. The resulting examination of the cells can be performed by a charge-
coupled device camera, each image being recorded with a specific filter for each 
fluorochrome (Morrison, 1993). 
In situ hybridisation is based on the site specific annealing of single stranded DNA 
molecules (probes) to denatured complementary DNA sequences (targets) in the cells of 
the tissue under study. Probes can be as small as 20-40 base pairs (bp), and up to 1000 
bp. There are essentially three types of DNA probes used; oligonucleotide probes 
(Lengauer et aI., 1994a; Meyne and Moyzis, 1994), single-stranded DNA probes (Meyne 
and Goodwin, 1994) and double stranded DNA probes (Lengauer et aI., 1994b). The 
DNA probe can consist of base sequences specific for the whole chromosome, 
chromosomal region or specific loci. Chromosome specific repetitive probes target the 
tandemly repeated chromosome specific alpha satellite DNA, which is present at or near 
the centromeres of chromosomes (Hopman et aI., 1997). These probes are useful in 
determining the copy number of various chromosomes and can easily be applied to 
interphase nuclei. The centromeric regions tend to be highly condensed and so a probe 
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hybridised to these regions, appears as a small fluorescent dot. By using a number of 
probes each labelled with a spectrally distinct fluorochrome, it is possible to 
simultaneously detect a number of chromosomal aberrations within each hybridisation. 
However, the use of these alpha satellite centromeric probes is limited to the assessment 
of copy number changes (Fox et aI., 1995). 
Target cells for FISH analysis can be obtained from a number of sources, including 
fine needle aspirates, touch or imprint preparations or histological sections from either 
fresh or paraffin-embedded. Cells may also be disaggregated from either archival fresh 
frozen or formalin-fixed tissue samples (Matsumura et aI., 1992; Schofield and Fletcher, 
1992). The disadvantage of using isolated cells from disaggregated tissues is that it can 
produce a bias in the sample of cells, as examination may only be undertaken of those 
cells that have been easily dislodged. Another disadvantage is the loss of morphological 
correlation from the tissue sample. Morphological correlation can be achieved by using 
tissue sections. However, thin sections (4-6 J.1m) result in the cutting of cells and thus 
producing partial nuclei, which can lead to an underestimation of polysomy (Hopman et 
aI., 1991; Weremowickz et aI., 1994; Brothman et aI., 1994). The use of thick sections 
(40-60 J.1m) overcomes this, however this can lead to difficulties in the interpretation of 
cell superimposition (Southern and Herrington, 1996). A suitable compromise is to use 
thin sections together with the analysis of inflammatory and stromal cells, acting as 
internal controls (Kim et aI., 1993). A recent technique of using laser-scanning confocal 
microscopy on thick (20J.1m) sections may solve this problem. Confocal microscopy 
allows different planes within the section to be observed, thus allowing the presence of 
hybridisation signals to be related to the histological architecture (Kozubek et aI., 2001). 
The use of a control specimen with normal nuclei, preferably from the same tissue of 
origin is essential in order to recognise hybridisation efficiency problems and possible 
signal cross-reactions between different probes (Kallioniemi et aI., 1996). The 
interpretation of FISH relies on the degree to which the apparent hybridisation signals 
accurately correspond to the specific target site for the probes. The number of apparent 
signals will be smaller than the true number of target sites if target DNA is lost during 
preparation or, remains inaccessible to the probe detection reagents or, if signals 
overlap. Extra signals can arise from the fragmentation of target DNA or from the non 
specific binding of the detecting reagents (Devilee et aI., 1988; Matsumura et aI., 1992). 
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There are shortcomings to FISH technology. Firstly, there needs to be the 
development of a specific probe for each genetic defect, by contrast, conventional 
karyotypic analysis looks at the entire genome. Secondly, FISH has a minimum size of 
visualisation, requiring a probe size of around 40-200 kb of genomic DNA, and so can 
miss very small genetic alterations (Kallioniemi et aI., 1996). For aberrations that are 
too small to be detected by conventional FISH (- I 0 kb or less), other techniques may 
be used, such as high-resolution FISH mapping (Raap et aI., 1996), primed in situ 
hybridization (Koch et aI., 1996) and ligase-mediated chain reaction (Landegren et aI., 
1996). 
FISH has already proved useful in clinical practice and is routinely used in the 
diagnosis of trisomy 21 (Klever et aI., 1992; Klinger et aI., I 992; Ward et aI., 1993). 
FISH may also prove useful in the diagnosis of certain constitutional microdeletion 
syndromes (Ledbetter, 1992), the diagnosis of carrier status in X-chromosomal 
recessively inherited diseases associated with deletions, such as Duchenne muscular 
dystrophy (Ried et aI., 1990), and the identification of deleted tumour suppressor genes 
in certain types of cancers (Stilgenbauer et aI., 1993) 
3.1.2 Aims of this Study 
The first part of this study was to perform a retrospective analysis of uveal melanoma 
tumours using centromeric probes for chromosomes 3 and 8 and to correlate the analysis 
with various clinicopathological characteristics and patient survival, in an attempt to 
define any prognostic factors. 
The study was to be repeated using the same centromeric probes to analyse primary 
coiorectal cancers and their corresponding liver metastases, in order to compare the 
findings between colorectal cancers and uveal melanomas, and to assess whether 
abnormalities in the copy numbers of chromosomes 3 and 8 are associated with the 
development of liver metastases, in the case of colorectal cancers. 
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3.2 RESULTS 
A series of 33 tumour samples from 33 patients treated between 1987 and 1995 were 
analysed using FISH. All tumours were categorized histopathologically according to the 
AFIP system of classification for uveal melanomas (Spencer, 1986). Tumour diameter 
was assessed pre-operatively by B scan ultrasonography and subsequent clinical follow-
up was conducted at the Department of Ophthalmology and Orthoptics, University of 
Sheffield. 
Six normal blood controls were analysed using FISH to assess the sensitivity of the 
centromeric probes, 300 cells being counted for each sample. For each uveal melanoma 
tumour sample, again 300 cells were counted (table 3.3). Cells were excluded from 
analysis if they were clumped together or if they appeared to have been cut. 
Patient outcomes were divided into two groups: 1) absence of genetic abnormalities 
(no genetic imbalance) and 2) presence of genetic abnormalities (genetic imbalance). No 
genetic imbalance was defined as a cell having the normal complement of two target 
hybridisation signals for each chromosome (figures 3.4 and 3.5), and the presence of 
genetic imbalance was defined as any combination of target hybridisation signals other 
than two for chromosome 3 and two for chromosome 8 (figures 3.6 and 3.7). Genetic 
imbalance was said to be present if the number of abnormal cells exceeded 70% of the 
total population observed. A value of 70% was taken, following the manufacturers 
recommendations for probe sensitivity, which indicated that approximately 70% of 
normal cells analysed would show constitutional hybridisation signals for either 
centromeric probe. Therefore if the total number of cells analysed showed a normal 
complement in more than 70% of cells analysed, the tumour was said to show no 
genetic imbalance. FISH was performed on six normal blood controls to confirm this 
sensitivity value. 
Statistical Analysis 
Independent samples t-test, chi-square test or Fisher's exact test were used to assess 
any differences in sex, age, tumour cell types, location and mean tumour diameter 
between the two groups. The log-rank test was used to compare survival, which was 
represented by Kaplan-Meier survival curves. Statistical analysis was performed using 
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SPSS statistical software package on a PC computer, with a p value for significance set 
at <0.05. 
3.2.1 Optimising Conditions for FISH on Normal Blood Controls 
A standard FISH protocol was initially used (see Materials and Methods section 2.2.4 
Fluorescent In Situ Hybridisation), and optimum pepsin digestion times were evaluated 
on several normal blood samples. Figure 3.1 show the results of pepsin digestion of a 
normal blood sample (Normal Blood Sample 1), ranging from 0 to 30 minutes. 
Optimum hybridisation for both probes i.e. two constitutional hybridisation signals for 
either probe was with 10 minutes pepsin digestion, where the number of normal cells 
with constitutional hybridisation signals was 82%. Two further blood samples were also 
analysed to confirm this with the duration of pepsin digestion ranging from 5 to 15 
minutes and both samples confirmed optimal hybridisation efficiency at 10 minutes 
pepsin digestion. Normal constitutional hybridisation signals were observed in 91 % and 
90% of cells in normal blood samples 2 and 3 respectively. 
Figure 3.1 FISH results for Normal Blood Sample 1 with pepsin digestion for 
various times. Fifty cells were counted at each pepsin digestion time. 
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A total number of six normal blood sample controls were analysed using FISH with 
chromosomes 3 and 8 centromeric probes. Three hundred cells were counted for each 
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sample with the average number of cells with a normal number of hybridisation signals 
being 96.72% (range 94.33% - 97.67%), and a median of97%. Thus, the sensitivity of 
the two probes in combination concurred with the value supplied by Appligene Oncor, 
which stated that a normal sample of cells would show two hits for each chromosome in 
70% of cells analysed. 
3.2.2 Optimisiog COnditions for FISH 00 Formalin-Fixed Paramo-Embedded 
Tumours 
Preservation of tumour material initially fixed in formalin and then embedded in 
paraffin wax, allows for the convenient storage of tumour tissue over many years. 
Tissue architecture and morphology are both conserved in these paraffin blocks, 
allowing retrospective analysis to be undertaken. This allows a collection of tumour 
specimens to be built up which can be analysed a number of years later. These 
retrospective studies have the advantage of facilitating the correlation of data acquired 
to clinical progression and outcome determined by follow-up undertaken over many 
years. 
Tissue preservation in paraffin wax is not without its problems when attempting to 
use novel techniques to analyse the tissue. A number of protocols exist to allow the 
analysis of paraffin-embedded tissue material. However, difficulties arise when 
chemicals and procedures for tissue fixation are not standardised either between 
Institutions or even within an Institution. 
In this study, dual colour FISH analysis was attempted on eight tissue samples of 
paired primary colorectal cancer and metastatic formalin-fixed paraffin-embedded 
tissue. However, following hybridisation a great deal of auto-fluorescence was 
observed, thus concealing the number of true specific hybridisation signals. A number 
of factors could have been responsible for this: 
1. Operator error. 
2. Problems with the reagents and solutions. 
3. Inefficient removal of paraffin from the tumour sample. 
4. Insufficient permeabilization of tumour cells by pepsin. 
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Operator error and substandard solutions could "be discounted as allhybridisations 
were performed with a normal blood sample to act as a control. Normal blood samples 
consistently showed bright, clear constitutional hybridisation signals for both 
chromosomes 3 and 8. 
To improve the removal of paraffin from the tumour samples, extra washes of xylene 
and ethanol were introduced. However, this had very little effect on reducing auto-
fluorescence and improving hybridisation signals. It was concluded that auto-
fluorescence was an inherent problem with using paraffin-embedded material. An 
attempt was made to improve the intensity of the hybridisation signal by increasing the 
permeablization of the nuclei to the centromeric probes. This was initially performed by 
increasing the duration of pepsin digestion. Care would need to be taken during this 
procedure, as over-digestion by pepsin would destroy cellular and nuclear morphology, 
resulting in a loss of true target hybridisation signals (Kopf et al., 1996). Several slides 
were prepared from two formalin-fixed paraffin-embedded tissue samples of normal 
colon tissue and digested in pepsin for various durations, ranging from 10-60 minutes 
(figures 3.2 and 3.3). 
Figure 3.2 FISH results for Normal Colon Tissue Sample 1 with pepsin digestion 
for various times. Fifty cells were counted at each pepsin digestion time. 
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Figure 3.3 FISH results for Normal Colon Tissue Sample 2 with pepsin digestion 
for various times. Fifty cells were counted at each pepsin digestion time. 
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One would expect to observe two constitutional hybridisation signals for both the 
chromosome 3 and chromosome 8 centromeric probes, however, the number of normal 
hybridisation signals recorded were maximal at 60 minutes for sample 1 (80% of cells 
analysed) but could not be evaluated for sample 2 as there appeared to be poor 
hybridisation of the chromosome 3 centromeric probe, even though optimum 
hybridisation of the chromosome 8 centromeric probe appeared to be at 40 minutes. 
Although not investigated, the better hybridisation efficiency of the chromosome 8 
centromeric probe may have been as a result of its smaller size, thus being able to 
penetrate the permeablised nucleus more readily than its larger counterpart. Another 
interesting finding was the two peaks of optimal hybridisation with the chromosome 8 
centromeric probe. Similar findings are sometimes seen with chromosome banding, 
although the reason for this has never been fully elucidated. Thus, it was concluded that 
different tumour samples would require different durations of pepsin digestion to 
facilitate hybridisation by the probes. 
Two paraffin-embedded colorectal cancer tissue samples were analysed using FISH 
for abnormalities in copy numbers of chromosomes 3 and 8. However, results were 
inconsistent at the various pepsin digestion times, ranging from 30-50 minutes. For 
colorectal cancer sample 1, the majority of cells showed no hybridisation signals for 
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either probe at any duration of pepsin digestion (table 3.1). While for colorectal cancer 
sample 2 the majority of cells at 30 and 40 minutes pepsin digestion showed 3 
hybridisation signal for chromosome 8 and none for chromosome 3, while at 50 minutes 
pepsin digestion the majority of cells showed no hybridisation signal for either probe 
(table 3.2). 
Table 3.1 FISH results for Coloredal Cancer Sample 1. Fifty cells were counted at 
each pepsin digestion time. 
Duration of Pepsin digestion (minutes) 
30 40 50 
Results (Chromosome 3 0:0=49 0:0=31 0:0=25 
hybridisation signals: 0:1=1 2:0=11 1:1=10 
Chromosome 8 1:1=10 2:2=6 
hybridisation signals) 0:1=7 0:2=3 
0:2=3 1:2=2 
1:2=2 0:1=2 
2:2=2 2:1=2 
Table 3.2 FISH results for Colorectal Cancer Sample 2. Fifty cells were counted at 
each pepsin digestion time. 
Duration of Pepsin digestion (minutes) 
30 40 50 
Results (Chromosome 3 0:3=19 0:3=18 0:0=26 
hybridisation signals: 1:3=8 1 :3=15 0:3=7 
Chromosome 8 0:2=8 2:2=5 0:2=7 
hybridisation signals) 2:3=4 1:2=4 1:2=4 
1:2=3 0:2=3 1:3=2 
3:3=2 2:3=2 0:1=2 
0:4=2 1:4=2 1:1 =1 
2:4=2 0:4=1 3:2=1 
2:2=2 
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Therefore, in order to ascertain the true number of hybridisation signals for either 
probe for each paraffin-embedded primary and metastatic tumour analysed, a normal 
tissue control would need to be disaggregated from an adjacent block of paraffin-
embedded tissue, so as to control for tissue fixation and processing differences. 
A further attempt to improve permeablization of the tumour sample was performed 
by increasing the duration of protease digestion in the tumour disaggregation procedure. 
Tumour sample were digested with protease for between 10-60 minutes. The optimal 
duration of digestion was determined by visualising the disaggregated tumour samples 
under a microscope, to ensure that cellular morphology remained intact. However, even 
this procedure failed to improve the intensity of the hybridisation signals. 
It was concluded that, as the duration of digestion with either pepsin or protease 
could not be standardised for all samples and that hybridisation would have to be 
repeated with normal tissue controls for each tumour analysed, the total number of 
hybridisations required for all tumour samples would not be feasible in terms of time or 
reagents. 
3.2.3 Qptimising COnditions (Of FISH On Fresh-Frozen Tumouf Samples 
FISH analysis was successfully completed on 33 fresh-frozen uveal melanoma 
tumour samples that had been embedded in optimal cutting temperature (OCT) 
compound and subsequently stored at -20°C. FISH performed on the original 
disaggregated tissue samples was extremely poor, with very few intact cells and 
abundant cellular debris. This was thought to be attributable to poor disaggregation 
techniques and attempts were employed to rectify this. In these early samples, tissue 
disaggregation employed a combination of coarse tumour mincing using two scalpel 
blades followed by protease digestion. Omitting the protease digestion step and instead 
relying solely on mechanical disaggregation improved disaggregated tumour slide 
preparations. To prevent large clumps of disaggregated tissue from being dropped onto 
slides during slide preparation, tumour samples were freshly fixed using methanol: 
glacial acetic acid fixative and then left to stand for several minutes in order for the 
large clumps of tissue to settle and the upper clearer solution used to prepare slides. 
Thus, with slight adjustments in the tissue disaggregation protocol and in the 
preparation of slides, high quality hybridisations were obtained. 
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3.2.4 FISH Analysis of Fresh-frozen Uveal Melanoma Tumours Using Centromeri~ 
Probes for Chromosomes 3 and 8 
Of the 33 tumours analysed, 16 showed evidence of genetic imbalances. Of these 16 
tumours, 14 patients had died by the end of the study, with 10 having died of liver 
metastases. The cause of death was unknown in two patients, with the rest having died 
of unrelated causes. The median duration of survival for these patients was 37months 
(14-52 months). Of the tumours without evidence of genetic imbalances, 5 patients had 
died by the end of the study, although none had died as a result of either liver metastases 
or from the primary uveal melanoma. The median duration of survival for these patients 
was 114 months (44-204 months), (table 3.5). Two patients were lost to follow up, one 
from each group and were thus excluded from the survival analyses (tables 3.4 and 3.5). 
Of the 16 tumours that showed genetic imbalance, imbalance was due to a loss of 
chromosome 3 in 15 of these cases, with associated additional copies of chromosome 8 
in 5 tumours only. Only one tumour had a gain of chromosome 8 not associated with a 
loss of chromosome 3 (Mel 50) where the patient died due to liver metastases and 
survived only 52 months (table 3.4). In several tumours the results obtained using FISH 
were in accord with previous cytogenetic analysis (Sisley et aI., 1990). 
If only those deaths due to liver metastases are considered, the difference between the 
two groups is statistically significant (p<0.000 1). If it is assumed that all patients who 
died may have had occult metastases, the difference between the two groups is again 
statistically significant (p<O.OOOI). Both scenarios are represented by the Kaplan-Meier 
survival curves (figures 3.8 and 3.9). 
Specific analysis of the predictive value of monosomy 3 with survival showed it to be 
significantly associated with reduced survival in all patients (p<0.000 1) and in those 
with liver metastases (p<0.0001). Both scenarios are represented by the Kaplan-Meier 
survival curves (figures 3.10 and 3.11). However, the gain of chromosome 8 and 
reduced survival did not reach statistical significance (p=0.133), (figure 3.12). 
No significant differences were observed in sex (p=0.732), age (p=0.889), tumour 
cell type (p=0.73), location (p=0.498), or mean tumour diameter (p=O.574) between the 
two groups (table 3.5). 
- 104-
Table 3.3 Results of dual colour FISH analysis. 
Patient Results (Chromosome 3 hybridisation GIINoGI 
signals:Chromosome 8 hybridisation si2nals) 
Mel 1 2:2=285 1:2=82:1=5 1:1=14:4=1 NoGI 
Mel 5 2:2=272 1:3=141:2=93:3=22:1=24:4=1 NoGI 
Mel 7 2:2=282 1:3=4 1:2=33:3=3 1:1=22:1=22:3=2 1:4=1 NoGI 
2:4=1 
Mel 8 2:2=2442:1=271:1=141:2=15 NoGI 
Mel 13 2:2=275 1 :2=25 NoGI 
Mel 14 1:2=1661:3=892:2=42 1:1=22:1=1 GI 
Mel 15 1:3=1641:2=1162:2=14 1:4=6 GI 
Mel 16 1 :2=207 2:2=55 1 :3=29 1: 1 =9 GI 
Mel 21 2:2=2902: 1 =3 1 :3=3 1 :2=3 1: 1 =1 NoGI 
Mel 22 2:2=2832:1=41:2=42:3=33:3=24:2=14:4=1 NoGI 
Mel 24 2:2=236 1 :2=26 No GI (8% GI) 
Mel 26 2:2=200 1 :2=97 1 :3=3 GI 
Mel 28 2:2=2401:2=571:3=1 3:1=14:2=1 No GI (19% GI) 
Mel 31 2:2=289 1 :2= 11 NoGI 
Mel 36 2:2=1801:2=113 1:3=62:1=1 GI 
Mel 37 2:2=1691:2=651:3=602:4=23:3=2 1:4=1 2:1=1 GI 
Mel 40 2:2=128 1:2=871:3=78 1:4=3 1:1=23:3=1 2:3=1 GI 
Mel 44 2:2=1861:2=691:3=12 No GI (27% GI) 
Mel 45 1:2=1672:2=981:3=282:4=2 1:4=1 2:1=1 2:3=1 1:1=2 GI 
Mel 46 1 :2=2402:2=45 1 :3=13 GI 
Mel 47 2:2=261 2:1=191:2=94:4=3 NoGI 
Mel 48 2:2=269 1 :2=202: 1 =6 1 :3=2 1: 1 =3 NoGI 
Mel 50 2:4=1952:2=371:4=282:6=15 1:5=71:3=52:5=3 GI 
1:6=2 
Mel 51 1:2=233 1:3=462:2=13 1:4=4 1:1=32:1=1 GI 
Mel 52 1:2=1292:2=35 1:3=26 1:1=72:4=22:1=1 GI 
Mel 53 1:3=173 1 :2=1162:2=11 GI 
Mel 57 1 :2=213 1 :3=62 2:2=16 1: 1 =8 1 :4=1 GI 
Mel 68 1:2=1122:2=105 1:3=572:4=10 3:3=5 2:1=4 GI 
Mel 69 2:2=203 1 :2=86 1 :3=3 2: 1 =3 1: 1 =5 No GI (29% GI) 
Mel 71 2:2=296 1 :3=24:4=1 3:3=1 NoGI 
Mel 73 2:2=2784:4=12 1:2=32:4=32:1=4 NoGI 
Mel 75 2:2=281 1:2=122:1=7 NoGI 
Mel 94 1:2=2161:3=51 1:1=10 1:4=2 GI 
GI = Genetic imbalance present; No GI = No Genetic imbalance present. 
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Table 3.4 Results of GI status and tumour characteristics. 
Patient Sex Age Cell Location Mean Results Status 
(years) Type tumour (months 
diameter alive since 
jmm) dia~osis) 
Melt M 52 S C 12 NoGI A(153) 
Mel 5 F 48 Mix CB 4.75 NoGI LFU 
Mel 7 M 82 E C 16.5 NoGI DURJ11 11 
Mel 8 M 40 Mix C 12.2 NoGI Al}461 
Mel 13 F 55 Mix CB/C 12.7 NoGI OUR (88) 
Mel 14 M 52 Mix C 15.25 GI DLM(32) 
Mel 15 M 56 Mix C 11.75 GI DUKJ701 
Mel 16 F 61 Mix CB/C 19.75 GI DUR(l~ 
Mel 21 M 54 Mix CB/C 16 NoGI A(134) 
Mel 22 M 79 Mix CB/C 12.7 NoGI DUR1441 
Mel 24 F 69 Mix C 10.05 NoGI A (134) 
Mel 26 M 72 Mix C 8.5 GI DLM (55) 
Mel 28 F 59 E C 25 NoGI DURl1281 
Mel 31 F 38 Unknown C Unknown NoGI A (204) 
Mel 36 M 55 E Conj. 9 GI DLM(40) 
Mel 37 F 70 Mix CB/C 15 GI DLM181 
Mel 40 F 48 Mix C 11 GI Al1201 
Mel 44 F 76 Mix CB/C 15.3 NoGI Al1201 
Mel 45 F 57 Mix C 13.4 GI LFU 
Mel 46 F 64 E CB/C 14.35 GI DLMl6~ 
Mel 47 M 67 Mix C 13.25 NoGI A(IIS) 
Mel 48 M 35 Mix C 15.25 NoGI All 171 
Mel 50 F 48 Mix CB/C 10.35 GI DLM (52) 
Mel 51 F 61 E CB Unknown GI DLM (26) 
Mel 52 F 72 Mix C 17 GI DURi461 
Mel 53 M 46 Mix CB/C 15.6 GI DLM1541 
Mel 57 F 63 Mix CB/C 14.75 GI DLM(38) 
Mel 68 M 71 S Conj. 30 GI DUK(l9) 
Mel 69 F 53 Mix C 9 NoGI A(l021 
Mel 71 M 35 S C 13.45 NoGI Al1001 
Mel 73 M 64 Mix CB/C 20.6 NoGI DUK1631 
Mel 75 F 70 S C 12.3 NoGI A1981 
Mel 94 M 33 Mix C 16.6 GI DLMlrrr 
M = Male; F = Female; E = Epithelioid; Mix = Mixed; S = Spindle; C = Choroid; CB = 
Ciliary Body; Conj. = Conjunctiva; A = Alive; DLM = Died with liver metastases; OUR 
= Died of unrelated causes; DUK = Died of unknown causes; LFU = Lost to follow-up. 
GJ = Genetic imbalance present; No GJ = No Genetic imbalance present. 
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Table 3.5 Results of statistical analysis. 
Genetic Imbalance Genetic Imbalance p value for 
Absent (No GI) Present (GI) difference 
Number of 17 16 
patients 
Sex MIF 9/8 7/9 0.732 
Age (years) 
Mean (SD) 57.41 (15.18) 58.06 (10.96) 0.889 
Median 55 59 
Tumour diameter Incomplete data for Incomplete data for 
(mm) 1 tumour 1 tumour 
Mean (SD) 13.82 (4.60) 14.82 (5.23) 0.574 
Median 12.975 14.75 
Cell type Incomplete data for 
1 tumour 
....., 
Spindle 3 1 
Mixed 11 12 0.730 
Epithelioid 2 3 
Location 
Choroid 7 11 
Ciliary body 1 1 
Ciliary 6 5 0.498 
body/choroid 
Conjunctiva 2 0 
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Figure 3.4 A Captured FISH image of Normal Blood Sample 1. A captured image 
showing the normal complement of two target hybridisation signals for each 
chromosome pair, thus signifying no genetic imbalance. 
Figure 3.5 A Captured FISH image of Normal Blood Sample 5. A captured image 
showing a normal complement of split-target hybridisation signals. The split signals are 
di tributed equally and are of imilar intensity for each chromosome pair. 
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Figure 3.6 A Captured FISH image of Uveal Melanoma Tumour Mel 53. A 
captured image showing cells with monosomy 3 (red hybridisation signals - rhodamine) 
and trisomy 8 (green hybridisation signals - FITC), thus signifying genetic imbalance. 
Figure 3.7 A Captured FISH image of Uveal Melanoma Tumour Mel 50. A 
captured image also showing genetic imbalance with four hits for chromosome 8 (green 
hybridisation signals - FITC) but with a normal complement of two hybridisation signals 
for chromosome 3 (red hybridisation signals - rhodamine). 
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Figure 3.8 Kaplan-Meier survival curves for all deaths due to liver metastases -
Analysis of chromosomes 3 and 8. 
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Figure 3.9 Kaplan-Meier survival curves for all deaths - Analysis of chromosomes 
3 and 8. 
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Figure 3.10 Kaplan-Meier survival curves for all deaths - Monosomy 3. 
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Figure 3.11 Kaplan-Meier survival curves for all deaths due to liver metastases -
Monosomy 3. 
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Figure 3.12 Kaplan-Meier survival curves for all deaths - Gain of Chromosome 8. 
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3.3 DISCUSSION 
3.3.1 Effect of Tissue Fixation on FISH 
FISH is an effective technique for analysing genetic changes in interphase nuclei and 
a number of studies on archival paraffin-embedded tissues have been published 
(Deviliee et aI., 1988; Hopman et aI., 1991; Matsumura et aI., 1992; Qian et ai., 1996). 
However, results are dependent on the method oftumour fixation with a number of 
protocols available for tumour fixation prior to being embedded in paraffin wax (Baker, 
1960). Tumour material may not necessarily be fixed in formalin but a solution of 
various chemicals, some of which will hinder analysis by FISH (Kapranos et al., 1997). 
The purpose of fixation of fresh tissue samples is two-fold. Firstly, the process of 
autolysis and bacterial degradation should be prevented. Secondly, the tissue should be 
preserved in its original state without the loss of small molecules. Ideally, the tissue 
must be left in a condition following fixation, to allow subsequent processing. The aim 
of tissue processing is to progressively dehydrate the tissue of fixative and tissue water 
and then embed the tissue in a solid medium, firm enough to support the tissue, yet soft 
enough to allow a knife to cut sections without damaging the tissue. It is essential that 
the embedding medium thoroughly penetrates the tissue in its liquid form and that it 
solidifies with as little damage to the tissue. At the Royal Hallamshire Hospital, neutral 
buffered formaldehyde is used for fixation, which consists of formalin (which is a 
solution containing 35-40% gas by weight of formaldehyde), sodium dihydrogen 
phosphate monohydrate and disodium hydrogen phosphate anhydrous, with paraffin 
wax being used as the embedding medium. Tissue samples are left in this solution for 
between 4-6 hours generally before being processed. However, if specimens are large, as 
in the case of colon cancer resections, the tissue may be left in the solution overnight to 
allow penetration of the fixative into the tissue. occasionally this time period may 
extend to 48 hours if a cancer is resected over the weekend. 
Fixatives form cross-links between proteins thereby producing a gel in which 
molecules are fixed relative to each other. In the case of formaldehyde these cross-links 
are formed between the lysine residues on the exterior surface of protein molecules, thus 
denaturing the proteins in the process (Baker, 1960). Fixation of tissues also brings 
about changes in the chemical and physical state of RNA and DNA. Although in their 
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native states, RNA and DNA do not react to any extent with formaldehyde at room 
temperature, when the temperature is increased to 45-65°C, as during tissue processing, 
then cross-links begin to form between proteins, namely histones and DNA. The length 
of time in formalin prior to being embedded in paraffin wax not only increases the 
extent of these DNA:protein complexes (Xiao et al., 1995), but can also result in the 
loss of up to 30% of the DNA (Diaz-Cano and Brady, 1997). Gomyo et at., (1995) found 
that with increasing durations of formalin fixation, hybridisation efficiencies when 
performing FISH reduced exponentially with results being unobtainable after 5 days of 
fixation and concluding that FISH analysis could easily be performed on formalin-fixed 
paraffin-embedded material, as long as tissue fixation was kept to as short a time as 
possible. Possible changes to the protocol to improve hybridisation include acid pre-
treatment prior to pepsin digestion; heating the slide to 80°C for 10minutes in 1 M 
sodium thiocyanate which dissociates proteins (notably histones) from DNA, and so 
allowing the DNA probes to access the target DNA more efficiently; suspending the 
disaggregated tumour cells in PBS or glycerol solution at 7S-90°C which is thought to 
induce nuclei swelling and chromatin decondensation (Amoldus et at., 1991; Hopman et 
ai., 1991; Hyytinen et ai., 1994) and microwave heating (Henke and Ayhan, 1994). 
Thus, the effect of variable and prolonged fixation of the colorectal cancer 
specimens meant that FISH analysis was extremely difficult and although various pre-
treatment methods could have been utilised, limitations in time precluded further 
investigation. 
3,3,2 CUnical faome.en and FISH Analysis of Uyeal Melanoma 
Sex and Age 
No significant difference was observed in either sex (p=0.732) or age (p=0.889) 
when using the t-test and Chi-Square test respectively, which is in concordance with 
other published series (McClean et ai., 1982; Coleman et ai., 1993). 
Tumour Cell Type 
No significant difference was observed in tumour cell type (p=0.73) when using 
Fisher's Exact test, which is in contrast to the studies by McClean et ai. (1982) and 
Coleman et al. (1993) who found that tumours with a mixed or epithelioid cell type had 
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a poorer prognosis as compared to those with a spindle cell type. In our study there were 
a total of 4 tumours (12.1 %) with a pure spindle cell type, of which 3 showed no genetic 
imbalance, whilst one tumour (Mel 68) did and in which the majority of the cells were 
observed to have monosomy 3, although the cause of death in this patient was unknown. 
There were a total of23 tumours (69.7%) with a mixed cell type with almost equal 
numbers in each group (11 with no evidence of genetic imbalance and 12 with genetic 
imbalance). Of the tumours with an epithelioid cell type (15.2%), two tumours showed 
no genetic imbalance (Mel 7 and Mel 28) and three tumours showed genetic imbalance 
(Mel 36, Mel 46 and Mel 51), all with monosomy 3 and all of these patients dying as a 
result of liver metastases. There was one tumour in which the histological cell type was 
not recorded in the clinical notes. 
Location 
Uveal melanomas with a ciliary body location appear to be correlated with reduced 
survival (McClean et aI., 1982; Prescher et al., 1996). However, in this study no 
significant association was shown between a specific location and a reduced survival, 
when using Fisher's Exact test (p=0.498), which concurs with other studies (Gordon et 
aI., 1994; Parrella et aI., 1999). Only two tumours (6%), Mel 5 and Mel 51 were situated 
entirely within the ciliary body, where Mel 5 showed no evidence of genetic imbalance, 
whilst Mel 51 showed monosomy 3, with the patient dying as a result of liver 
metastases. Eighteen tumours (54.5%) were situated entirely within the choroid, 11 of 
which showed no evidence of any genetic imbalance. Of the choroid tumours with 
genetic imbalance the majority had monosomy 3 and three tumours (Mel 14, Mel 15 and 
Mel 40) also had additional copies of chromosome 8. In a third group of tumours 
(33.3%), a definite site of origin could not be determined, as the tumours tended to be 
large and were thus classified as ciliary body/choroid. In this group there were near 
equal numbers of tumours with genetic imbalance (n=6) and showing no genetic 
imbalance (n=5). Of the two tumours situated in the conjunctiva (6%), Mel 36 and Mel 
68, both showed evidence of genetic imbalance, both having monosomy 3. The patient, 
Mel 36, died as a result of liver metastases and patient Mel 68, the cause of death was 
unknown. However, patient Mel 68 did have a large tumour (mean tumour diameter of 
30mm) and survived for only 19 months post-operatively. 
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Size 
There was no significant difference shown between mean tumour diameter and the 
presence or absence of genetic imbalance, when using the t-test (p=0.574). The mean 
tumour diameter of those with no genetic imbalance was 13.82rnm and in those with 
evidence of genetic imbalance was 14.82mm. There were two tumours in which the 
mean tumour diameter could not be ascertained from the clinical notes. 
Tumours with and without Genetic Imbalance 
Of the 33 tumours analysed16 tumours showed genetic imbalance, imbalance was 
due to monosomy 3 in 15 of these cases, with concurrent gains of chromosome 8 present 
in 5 tumours only (Mel 14, Mel 15, Mel 37, Mel 40 and Mel 53). Of these tumours, 4 
patients had died by the end of the study, one where the cause was unknown and the rest 
having died as a result of liver metastases. The other patient (Mel 40), with a choroidal 
tumour is still alive 5 years post-operatively. Only one tumour had a gain of 
chromosome 8 (two extra copies) not associated with monosomy 3 (Mel 50). This 
tumour (Mel 50) was of a mixed cell type and located in the ciliary body/choroid with a 
mean tumour diameter of 10.35rnm, with the patient dying as a result of liver 
metastases, surviving only 52 months post-operatively (table 2). 
In several tumours the results obtained using FISH were in accord with previous 
cytogenetic analysis (Sisley et aI., 1990, 1997), thus confirming the reliability of the 
technique in the assessment of abnormalities of chromosomes 3 and 8. 
Survival Analyses 
As stated previously, survival analyses were performed using the log rank test and 
represented by Kaplan-Meier survival curves. Two patients were lost to follow up, one 
from each group, and were excluded from survival analyses. 
If only those deaths due to liver metastases were considered, the difference in 
duration of survival between those tumours with genetic imbalances and those with no 
evidence of genetic imbalance, was statistically significant (p<O.OOOl), suggesting that 
patients with tumours that had genetic imbalances were more likely to die sooner than 
patients in whom the tumours appeared to show no evidence of genetic imbalance 
(figure 3.8). Ifhowever, even ifit was assumed that all patients who died may have had 
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occult liver metastases then the difference between the two groups was still statistically 
significant (p<O.OOOI), (figure 3.9). 
A third analysis considered all tumours with monosomy 3 (irrespective of whether 
there was an associated gain of chromosome 8 and again assuming that all patients who 
died may have had liver metastases), and whether there was any difference in survival 
between tumours with monosomy 3 and those with a nonnal complement of 
chromosome 3 (figure 3.10). This analysis was also statistically significant (p<O.OOOI), 
thus confinning that patients with tumours having monosomy 3 have a worse prognosis 
than those patients in whom the tumours have a nonnal complement of chromosome 3. 
If the analysis is repeated, considering only those patients who died as a result of liver 
metastases again comparing tumours with and without monosomy 3, the difference is 
still statistically significant (p<O.OOOI) (figure 3.11). Note the step in the upper survival 
curve, which represents the patients with tumours having a nonnal complement of 
chromosome 3, this is due to the death of patient Mel 50, who had a tumour with two 
extra copies of chromosome 8 but without monosomy 3. 
The final survival analysis considered all patients with tumours showing additional 
copies of chromosome 8 (irrespective of the presence of mono so my 3) and compared 
them with all those patients with tumours having a nonnal complement of chromosome 
8. There appeared to be no difference in survival between the two groups (p=0.133), 
even though the survival curve for the patients with tumours showing additional copies 
of chromosome 8 is steeper than the survival curve for patients with a nonnal 
complement of chromosome 8 (figure 3.12). A survival analysis comparing tumours 
with additional copies of chromosome 8 and tumours with a nonnal complement of 
chromosome 3 could not be perfonned, as there was only one tumour (Mel 50), which 
would fit this criterion. These findings would at first appear to be in contrast to those of 
Horsman et aI., (1990) and Sisley et aI., (1997), who found a dose related correlation 
between additional copies of 8q and reduced survival. However, as only six tumours 
appeared to have additional copies of chromosome 8 and only one tumour with gains of 
chromosome 8 not associated with monosomy 3, the numbers were too small to reach 
statistical significance. These findings also concur with previous studies, which 
suggested that the gain of chromosome 8 (especially i8q) is a late event and tends to 
occur after either monosomy 3 or alterations of 6p (White et aI., 1998; Parrella et aI., 
1999). 
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3.3.3 Monosomy 3 and Gain of Chromosome 8 as Prognostic Indicators of Liver 
Metastasis and Poor Survival in Uveal Melanoma 
Several retrospective studies relating the presence of monosomy 3 and gains of 8q to 
a reduced survival and hence a poor prognosis have been undertaken previously 
(Prescher et aI., 1996; Sisley et aI., 1997; White et aI., 1998). However, all of these 
studies were performed using the conventional cytogenetic analysis, which requires the 
short-term culture of tumours followed by the production of good quality metaphase 
spreads. The possibility also exists for missing genetic changes due to small number of 
cells studied. The development of fluorescence in situ hybridisation (FISH) allows the 
interphase cytogenetic analysis of a large number of cells accurately. 
Prescher et ai. (1996) examined uveal melanomas from 54 patients, either by 
karyotype analysis or comparative genomic hybridisation, in relation to clinical status, 
having been followed-up for a median of 40 months. Of the 54 tumours examined 30 
had monosomy 3, of which 17 (54%) of these patients had relapsed with metastatic 
disease. In contrast, of the 24 patients in whom the tumours retained both copies of 
chromosome 3, none had developed metastatic disease. Thus concluding that monosomy 
3 was the most significant predictor of poor prognosis, followed by ciliary body 
involvement and a tumour diameter greater than 10mm. Interestingly, histopathological 
subtype and the presence of extra-scleral growth had no additional predictive value in 
their study. 
McNamara et al. (1997) assessed chromosome 3 copy numbers using fluorescent in 
situ hybridisation (FISH) on fresh touch preparations. Of the 17 uveal melanomas that 
they studied (all of which were located in the choroid) only two revealed monosomy 3, 
although the clinical significance of this was not stated. 
Sisley et al. (1997) examined 42 patients using a combination of karyotypic analysis 
and FISH to confirm cytogenetic abnormalities. Twenty-three tumours (54%) had one or 
more additional copies of the long arm of chromosome 8, either as a result of 
translocation or in the form of an isochromosome i(8q) and of these 14 had two or more 
copies. Monosomy of chromosome 3 was found in 21 (50%) of the tumours examined. 
Other abnormalities detected, included deletion of chromosome 1 p in 12 patients (29%), 
deletion of 6q in 13 patients (31 %) and trisomy 6p in 8 patients (19%). FISH was used 
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to confirm cytogenetic abnormalities and was performed using chromosome paints for 
chromosomes 3 and 8 on prepared short-term cultures. Statistical analysis confirmed a 
significant association between chromosome 3 and 8 abnormalities with a ciliary body 
location and a reduced survival. The results also showed a significant correlation 
between increasing copies of chromosome 8q and a reduced survival. 
Interestingly, White et al. (1998), performed cytogenetic analysis on 54 patients who 
underwent enucleation for uveal melanoma and divided the patients into two groups; 
those that had liver metastases (either alive or dead) and those who had no evidence of 
metastatic disease (again, alive or dead). Patients were followed-up for a median of38 
months and they found that abnormalities of chromosomes 3 and 8 (in the form of 
monosomy 3 and additional copies of chromosome 8q) were associated with a poor 
prognosis (presence of metastatic disease) but only when the two abnormalities were 
present together. When a chromosome 3 or 8 abnormality occurred alone, which was 
infrequent, the risk of a poor outcome was the same as if neither abnormality was 
present. However, they also found that additional copies of chromosome 6p correlated 
with a good prognosis even in the presence of chromosome 3 and 8 abnormalities. It 
appeared that gain of chromosome 6p material, either in the form of an isochromosome 
6p or deletion of 6q was protective. And patients with the best outcomes were those 
with a lone abnormality of chromosome 6. Extra-scleral extension was also predictive of 
a poor outcome although there appeared to be no association between tumour location, 
size or histological cell type with clinical outcome. Although they concurred with the 
findings of Sisley et al. (1997), that abnormalities of chromosomes 3 and 8 were 
associated with tumours in a ciliary body location. 
There have been a number of studies utilizing comparative genomic hybridisation 
(CGH) to assess genome wide changes in uveal melanoma (Speicher et aI., 1994; 
Gordon et aI., 1994; Ghazvini et aI., 1996; Becher et aI., 1997; Aalto et aI., 2001; Naus 
et aI., 2001), where the most common genetic changes were loss of chromosome 3, over 
representation of6p, loss of6q and additional copies of8q. CGH allows analysis of the 
entire genome, highlighting regions of chromosomal gains and losses (Kallioniemi et 
aI., 1992). Speicher et al. (1994), repeatedly observed the loss of chromosome arm 9p 
concluding that 9p loss may not entirely be restricted to the development of cutaneous 
melanomas. A similar conclusion was also drawn by Gordon et al. (1994), who also 
observed recurrent abnormalities with gains of chromosomes 7q and 13q. However, 
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both studies conceded small numbers within the study. Naus et at. (2001), used a 
combination of FISH, CGH and spectral karyotyping (SKY), to complement each 
technique to allow a more intensive exploration of chromosomal abnormalities in uveal 
melanomas. Examining two uveal melanoma cell lines and five primary uveal 
melanomas, they revealed a new abnormality using SKY, a der( 17)t(7; 17)(?;q?), that 
had not previously been recognised by conventional cytogenetics. CGH proved 
particularly useful in assigning abnormalities identified by SKY to specific 
chromosomal regions, in particular a small deletion of chromosome region 3q 13-21. 
However, they did not observe monosomy 3 in any of their cases, which is not entirely 
unexpected as the incidence of mono so my 3 in our study was 45% (15/33) and 
clinicopathological data was unavailable for comparison in their study. Aalto et al. 
(2001), examined 14 non-metastasising uveal melanomas with 15 metastasising uveal 
melanomas and 6 of their metastases. They reported significantly more abnormalities in 
the metastases and metastasising uveal melanomas compared to the non-metastasising 
group, commenting that loss of chromosome 1 p was only evident in the metastases and 
metastasising group suggesting a site of a putative tumour suppressor gene. They also 
reported that the frequency of chromosome 6p gains was higher in the non-metastasising 
group, although this was not statistically significant. However, loss of chromosome 6q 
in the metastases and metastasising group was statistically and clinically significant with 
all patients with 6q loss, dying from their disease. 
There are thought to be several putative tumour suppressor genes on chromosome 3 
and oncogenes on chromosome 8, which may be involved in uveal melanoma 
tumourigenesis and metastasis (Kok et aI., 1997; Singh et aI., 1996). A possible 
candidate tumour suppressor gene on chromosome 3 is the fragile histidine triad (FHIT) 
gene lying at 3p 14.2, which is targeted by tobacco smoke carcinogens and where allelic 
deletions has been linked to cancers of the lung, breast, colon, pancreas and head and 
neck (Burke et aI., 1998). The other areas of deletions on chromosome 3p associated 
with cancers is at 3p 21.2-21.3 and at 3p 25-26, which contains the von Hippel-Lindau 
(VHL) syndrome tumour suppressor gene. Von Hippel-Lindau syndrome is a dominantly 
inherited familial cancer syndrome predisposing to a variety of malignant and benign 
neoplasms, most frequently retinal, cerebellar and spinal haemangioblastoma, renal cell 
carcinoma, phaeochromocytoma and pancreatic tumours. The gene is thought to 
function as a cellular gatekeeper, regulating cell cycle exit into the GO phase, with loss 
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of function (as a result of mutation or deletion of both alleles) resulting in cells 
continuing to proliferate (Pause et aI., 1998). Clifford et al. (1998) reported that 
hypermethylation could also lead to the silencing of the VHL tumour suppressor gene in 
renal cell carcinomas from patients with VHL disease. Another putative tumour 
suppressor gene located on chromosome 3p is the thyroid hormone receptor B (THRB) 
gene, which is also found to be deleted in uveal melanomas, predominantly those 
located in the ciliary body, although the significance of this finding is as yet unknown 
(Sisley et aI., 1993). 
In the case of chromosome 8 there not only appears to be a proto-oncogene on 8q but 
also a tumour suppressor gene on 8p. Studies using CGH indicate that a region from 8q 
12 to 8qter are present at an increased relative copy number in a broad range of solid 
tumours (F ejzo et aI., 1998). A region from 8p 22-p21.3 is commonly deleted in 
hepatocellular, colorectal and non-small cell lung cancers (Emi et aI, 1992; Chinen et 
aI., 1996). A region lying between 8p II-p21 is also thought to be a region for one or 
more tumour suppressor genes involved in breast cancer (Adelaide et al., 1998). The c-
myc oncogene (c-myc being the human homologue of an oncogene carried by an acutely 
transforming retrovirus known as Avian myelocytomatosis virus), which has been 
mapped to 8q 24 plays an important role in a variety of malignancies. However, in uveal 
melanomas there is contradictory evidence that over-expression of c-myc may be 
associated with a better prognosis (Chana et aI., 1999). A number of genes also exist on 
chromosome 6p, including WAF J /C1P J, which encodes for a cyclin-dependant kinase 
inhibitor (p21) which is thought to bind to p53 to control cellular progression through 
the cell cycle (EI-Deiry et aI., 1993; Waldman et aI., 1995). The genes encoding MHC 
class 1 molecules are also located on 6p, expressions of which have been found to be 
altered in uveal melanoma using immunohistochemistry (810m et aI., 1997). 
3.3.4 Summary 
The results of this study are in accordance with previously published studies 
analysing uveal melanoma, correlating monosomy 3 with a poor prognosis (Prescher et 
aI., 1992; Sisley et aI., 1997; White et aI., 1998). But this study also shows that 
analysing both chromosome 3 and 8 imbalances is a better prognostic indicator of liver 
metastasis and poor survival than analysing either one alone. Limitations of this study 
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include the small number of tumours analysed and the fact that centromeric probes were 
used, which only allow for the analysis of copy numbers of either chromosome. 
Therefore, subtle sequence changes such as base substitutions; deletions or insertions 
would be missed, as would chromosome translocations (Kallioniemi et aI., 1996). Also 
the significance of chromosome 6 and 1 p changes were not analysed, which in future 
studies could be addressed by the use of a hydroxycoumarin (blue) labelled probes. With 
the emergence of specific oncogenes and tumour suppressor genes in the tumourigenesis 
of uveal melanoma, these genes could also be specifically targeted using FISH. 
This study has shown that FISH analysis for chromosome 3 and 8 is a reliable and 
efficient technique in the analysis of fresh-frozen tumour specimens and is valuable in 
the prediction of prognosis in individuals with uveal melanomas. 
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CHAPTER 4 
4.1 INTRODUCTION 
The progression of colorectal adenoma to carcinoma is accompanied by the 
sequential accumulation of many genetic changes either as a result of chromosomal 
instability or micro satellite instability, with or without the influence of methylation 
(Fearon and Vogelstein, 1990; Frayling, 1999; Robertson and Wolffe, 2000). 
Nanashima et al. (1997) conducted the FISH analysis of 18 paired samples of fresh-
frozen primary colorectal cancers with their liver metastases using alpha satellite DNA 
probes for chromosomes 8, 18, 14/22 (combined) and 20. The authors reported that the 
gain of chromosome 20 was a frequently observed aberration in primary and liver 
metastatic tumours compared to 15 primary tumours which had not known to have 
metastasised. They concluded that the observation of a gain of chromosome 20 in the 
primary tumour could be used to predict liver metastasis. 
One of the limitations of FISH is that it only provides information on one or a few 
loci at a time. This maybe adequate for single genetic abnormality disorders, such as 
Down's syndrome (trisomy 21) or Edward's syndrome (trisomy 13), but many 
malignancies have multiple genetic defects. So a technique that can examine the entire 
genome is more appropriate. One such technique is comparative genomic hybridisation 
(Kallioniemi et al., 1992; du Manoir et al., 1993; Kallioniemi et al., 1994). 
The aim of this study was to look for any gross genomic changes in paired primary 
colorectal cancers and their liver metastases using comparative genomic hybridisation 
(CGH), in an attempt to delineate common regions ofloss or gain, which may be 
prognostic for the development of liver metastases. 
4.1.1 Comparatjye Gepomic Oyhridisatjop (CGO) 
Comparative genomic hybridisation relies on the competitive hybridisation between 
fluorescently labelled tumour DNA and normal reference DNA onto a normal 
chromosome metaphase spread. Regions of gain or loss of DNA sequences, such as 
amplifications or deletions, are seen as changes in the differential ratio between the two 
- 124-
fluorochromes along the chromosomes. The analysis is undertaken using a charge 
coupled device camera and a digital image analysis system. 
The simplest method ofCGH relies on hybridisation of the labelled tumour DNA 
onto a normal metaphase spreads to elucidate areas of amplification, however this is not 
sensitive enough to detect low-level amplification or losses of DNA sequences 
(Kallioniemi et aI., 1992; Joos et aI., 1993). The inclusion of normal reference DNA, 
labelled in a different colour allows for compensation for differences in hybridisation 
efficiency found in one chromosomal region to another (Kallioniemi et aI., 1996). 
It is essential that DNA from tumour specimens contain at least 60% of the malignant 
cells under investigation (Kallioniemi et aI., 1994). DNA extracted from fresh and 
frozen tissue and cell cultures are the most suitable, but recent developments in DNA 
extraction from formalin-fixed archival material have allowed this valuable source of 
DNA to be utilised (Speicher et aI., 1993; Isola et aI., 1994). The incorporation of 
directly labelled nucleotides FITC-dUTP (for tumour DNA) and Texas Red-dUTP (for 
reference DNA) has now replaced the previously used indirect labelling methods 
(Kallioniemi et aI., 1992; Visakorpi et aI., 1995), although directly labelled DNA tend to 
appear dimmer on visualisation, and so the use of digital image analysis is essential if 
low-level amplification and losses are to be detected (Piper et al., 1995), (figure 4.1). 
The red-green ratios from several metaphase spreads are combined to account for any 
hybridisation inefficiencies to produce a mean profile with standard deviations for each 
chromosome (Kallioniemi et al., 1996). The degree of this variation is the best measure 
of the consistency and reliability of the CGH results (Kallioniemi et al., 1996). 
However, caution should be taken when interpreting ratio changes at the centromeres, 
heterochromatic regions and telomeres, and also at chromosome 1 p32-pter and 
chromosomes 19,22 and Y (Kallioniemi et aI., 1994). It should also be noted that the 
differential intensities of the two fluorochromes do not always correlate with the level of 
copy numbers of each area of amplification, with another shortfall being that balanced 
trans locations and ploidy shifts are undetectable (Persson et al., 1999). Small genetic 
changes, such as intragenic rearrangements and point mutations can also be missed and 
genetic changes affecting pericentromeric and heterochromatic regions are inconclusive 
(Kallioniemi et al., 1996). 
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Figure 4.1 A diagrammatic representation of comparative genomic hybridisation 
adapted from Houldsworth and Chaganti, (1994). 
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As CGH analyses the DNA from a population of cells, it cannot provide information 
on genetic changes present in a small subpopulation of cells or individual cells, 
important features of clonal heterogeneity (Kallioniemi et aI., 1996). The development 
of spectral karyotyping and multicolour-FISH, allows the simultaneous visualisation of 
all chromosomes in specific colours (Schrock et aI., 1996; Speicher et aI., 1996). Thus, 
allowing the identification of subtle metaphase chromosomal aberrations, such as 
trans locations and for the identification of small chromosomal structures, such as 
double-minutes, which may reflect oncogene amplification (Sawyer et aI., 1998). 
Comparative genomic hybridisation as a technique has been validated using 
independent methods, such as Southern blotting, loss of heterozygosity (LOH) analyses 
and fluorescence in situ hybridisation (FISH) (Kallioniemi et aI., 1994). The results of 
CGH have also shown good correlation with classical cytogenetic analyses (Speicher et 
aI., 1995). However, CGH tends to pick up more imbalances as compared to karyotype 
analyses, which require the growth of tumour cells in short-term cultures. A possible 
explanation for this could be that tumour cells with simple chromosomal abnormalities 
have a growth advantage over the complex/aneuploid tumour cells in vitro (Persson et 
aI., 1999). 
Conventional CGH analyses use normal metaphase chromosomes as targets for the 
mapping of gains and losses. However, this limits mapping of such imbalances to the 
resolution limit of the metaphase chromosomes (i.e. -5-1 OMb). A further development, 
is replacing the chromosomal target by cloned DNA, immobilised onto glass slides. The 
resolution then being dependant on the size of the immobilised DNA fragments. The 
technique is known as "matrix-CGH" (Solinas-Toldo et aI., 1997; Pinkel et aI., 1998). 
4.1.2 Aims of tbis Study 
The aim of the study was to investigate genomic changes in paired samples of 
primary colorectal cancers and their liver metastases, using CGH, to delineate potential 
chromosomal regions suggestive of putative oncogenes or tumour suppressor genes, 
which may be involved in the metastatic process. 
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4.2 RESULTS 
A series of25 paired tumour samples were obtained for the study. However, as an 
extensive amount of time and reagents had been utilised in optimising the CGH for 
formalin-fixed paraffin-embedded tissue, only two paired samples pCRCS/pLMS and 
pCRC IS/pLM IS were adequately hybridised and processed; although only partial 
results were obtained for these samples. 
For each sample 10 to 15 target metaphase spreads were analysed, chromosomes 
being identified by DAPI banding. 
4.2.1 Optimisation of DNA Extraction and Purification from Formalin-Fixed 
Paraffin-Embedded Tumour Samples 
A number of DNA extraction protocols were attempted in order to obtain the 
optimum quantity and quality of DNA for use in CGH. DNA of poor quality (as a result 
of contamination from RNA or protein) would result in non-specific hybridisation and 
hence increased background fluorescence, whilst a poor yield of DNA would result in 
dim fluorescent signals. 
Tissue for DNA extraction was obtained from microdissected formalin-fixed 
paraffin-embedded tissue material. Several different DNA extraction protocols were 
attempted in order to achieve the most efficient method of DNA extraction which would 
yield DNA of sufficient quantity and quality for use in CGH. 
Tissue samples were de-waxed and digested with proteinase K as outlined in the 
Materials and Methods section 2.2.5.1 DNA Extraction using Phenol:Chloroform for 
Formalin-Fixed Paraffin-Embedded Tissue for use in CGH. DNA purification was 
initially performed using both cold (-20°C) chloroform and ethanol at both room 
temperature and in the cold room (-4°C) to assess whether extraction at 4°C would 
improve the yield of DNA. DNA yield was improved at 4°C, although only slightly 
when assessed quantitatively using the spectrophotometer and qualitatively by 
electrophoresis on an ethidium bromide stained 1 % agarose gel. The DNA was not of 
sufficient quantity or quality for use in CGH, and as the amount of tissue available for 
extraction was limited, a more effective technique was required. A number of organic 
solvents were utilised in combination to improve both the quality and yield of DNA 
- 12S-
cxtracted (table 4.1 ). gain th' ic\d of D was ass 'S'- 'd qualitati ' Ion un cthidium 
bromide stained 1 % agaro. e gel (figure 4.2 ). Meth d B 1 pro ed t) ha e ield 'd th . 
largest quantity of 0 and anal)' is u5ing the . pc trophotometer sho\'. 'd no dincrcn " 
in the quality between mcth ds Bland ' I. Meth d 1 pr du cd the leasl }ield and 
quality of c. tracted 0 A. 
Table 4.1 ombinatioD. of th variou. org ni 01 nl. u, d in D purifi ntion. 
( II procedures wcre performed in pol proP) lene test tub's. with th • ugu' us In 'r 
b 'ing tran ' ferred into fresh test tub's bct\\e 'n wa. h's . \I \vushcs \Ver' pcrf< n11ed t 
room tcmp'rature) . 
Organic olvent Meth d th d 81 thod 
11 wa 'h Phenol Ph 'n 11 : 'hI )rof( ml Ph 'n 11: ' hl( r 1fon11 
2" wa 'h Phenol : 'hlorol(ml1 'hlorol(lml Ph 'nol : 'hIm r1rm 
3r wa h Is prpanol Hhanol 'hi rof1ml 
41 wa h I·than )1 
igure 4.2 ' aptur d imag of 1 % garo. g I . howing th r . ult of th v riou , 
D purification m thod. utili. d. (In Inn' I is a I kb ludd 'r und in lanes R nd 16 I 
sample oro e tra ted from a whole bl( d s mple, ""ith th ' () sl11curs produ . 'd 
using method A I in lane 4, method B 1 in lane 7 and mcth( d ' I in Ian' 11). 
- 129 -
In a further attempt to improve the yield of DNA extracted a variety of methods were 
used to de-wax the tissue more effectively. The various methods used to de-wax the 
paraffin-embedded tissue are outlined in table 4.2. 
Table 4.2 The various organic solvents used in the de-waxing of formalin-fixed 
paraffin-embedded tissue. (In all the methods the microdissected tissue samples were 
transferred to a polypropylene test tube before undergoing de-waxing with the various 
organic solvents. Between each wash, the samples were centrifuged at 15000rpm for 2 
minutes and the supernatant carefully removed). 
Organic solvent MethodA2 Method B2 MethodC2 
Il1t wash 3ml xylene for I Om ins 3ml xylene for 10mins Slides warmed to 60°C 
at room temperature at 70°C (water bath in before microdissection. 
fume cupboard) Then 3ml xylene for 3 
mins at room 
temperature 
2nd wash 3ml xylene for 10 mins 3ml xylene for 30 mins 3ml xylene for I Om ins 
at room temperature at 70°C (water bath in at room temperature 
fume cupboard) 
3rd wash 3ml 100% ethanol for 3ml xylene for 30 mins 3ml 100% ethanol for 3 
10 mins at room at 70°C (water bath in mins at room 
temperature fume cupboard) temperature 
4th wash 3ml 95% ethanol for 10 3ml 100% ethanol for 3ml 100% ethanol for 3 
mins at room 30 mins at room minsat room 
temperature temperature temperature 
5th wash 3ml 70% ethanol for 10 3ml 100% ethanol for 3ml 95% ethanol for 10 
mins at room 30 mins at room mins at room 
temperature temperature temperature 
6th wash 3ml 50% ethanol for to - 3ml 50% ethanol for 3 
mins at room mins at room 
temperature temperature 
7th wash 3ml distilled water for - 3ml distilled water for 
10 mins at room 3 mins at room 
temperature temperature 
Digestion After the final wash the sample, centrifuge at 1000rpm for 10 minutes 
followed by the addition of20J.11 proteinase K and 400J.11 digestion butTer and 
place in rotator at 55°C for 24 hours 
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The de-waxed and digested tissue samples then underwent DNA extraction as per 
method 8 I, outlined previously and extracted DNA was assessed both qualitatively and 
quantitatively (figure 4.3a). 
Figure 4.3 Two captured images of a 1 % agarose gel showing the various DNA 
extraction methods used. Figure 4.3a shows a I kb ladder in lanes 1 and a sample of 
whole blood DNA in lane 8, with the DNA smears produced using method A2 in lane 5, 
method 82 in lane 6 and method C2 in lane 7. Figure 4.3b shows a I kb ladder in lane I 
and DNA smears of two samples of extracted tumour DNA using the Qiagen QIAamp® 
DNA Mini kit in lanes 2 and 5, and the DNA smears of two samples of extracted 
tumour DNA using the method C2 protocol in lanes 3 and 4. 
4.3a 4.3b 
Although method C2 produced the greatest yield of DNA the ratio suggested 
contamination, most probably by protein. A relatively pure DNA sample would be 
essential for CGH, in order to minimise background fluorescence. Our DNA de-waxing 
protocols were compared to a commercially available DNA extraction kit (QIAamp.J(l 
DNA Mini kit purchased from Qiagen Ltd) . Tissue de-waxing and extraction was easier 
and cleaner using the kit, and the extracted DNA was of a slightly greater yield and 
purity. Thus, it was decided to use the QIAamp® DNA Mini kit for subsequent DNA 
extractions (figure 4.3b). 
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4.2.2 Optimisation of CGH Analysis of Formalin-Fixed Paraffin-Embedded 
Tumour Samples 
DNA was extracted from 25 pairs of formalin-fixed paraffin-embedded primary 
colorectal cancers and their corresponding liver metastases, using the Qiagen QIAamp® 
DNA Mini kit. 
CGH was performed as outlined in the Materials and Methods section 2.2.7 
Comparative Genomic Hybridisation. Initially, nick translation was used to label the 
tumour DNA samples with Spectrum Green dUTP. The optimum time required to nick 
translate the DNA was assessed by taking Sill aliquots from the SOIlI reaction mix at I 
hour, 112 hours, 2 hours and 212 hours. The aliquots were run on a 1% agarose gel 
(figure 4.4). On inspection, there appeared to be little difference in the smears seen 
between the various times. However with longer durations of reaction, there appeared to 
be a greater intensity of smaller fragments of DNA visible on the gel, which would 
result in a more granular CGH result. In order to conserve the larger fragments, aliquots 
from the reaction mix were taken after 1 hour and run on a 1 % agarose mini-gel , before 
the reaction was stopped. 
Figure 4.4 Captured image of a 1 % agarose gel showing DNA smears of aliquots of 
a nick translated DNA sample. In lane 1 is a 1 kb ladder and in lane 6 a sample of 
whole blood DNA. A DNA smear of the original extracted DNA sample using the 
QIAamp® DNA Mini kit is seen in lane 2,with aliquots of the nick translated DNA 
samples taken out at 112 hours (lane 3),2 hours (lane 4) and 2Y2 hours (lane 5). 
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CGH results using extracted DNA nick translated with Spectrum Green dUTP, were 
poor, with very low intensities of labelled DNA. The metaphase images also appeared to 
be very granular, in keeping with very small, labelled DNA fragments. In order to 
determine whether tumour labelling with Spectrum Green dUTP was affecting the 
quality of hybridisations, tumour DNA was labelled with Spectrum Red dUTP. 
However, even labelling with Spectrum Red did not improve the intensity of the 
hybridised tumour DNA. 
As both these fluorescent labels fluoresced in ultra-violet light, it was possible to 
visualise the intensity of labelling on a 1 % agarose gel before the gel was stained with 
ethidium bromide to assess the DNA smear. Figure 4.Sa shows that unlabelled Spectrum 
Red runs at a slower rate than Spectrum Green. One can also see that these fluorescent 
labels are associated with a smear of labelled DNA, which is stained more intensely 
with ethidium bromide (figure 4.Sb). 
Figure 4.5 Captured images of Spectrum Red and Spectrum Green labelled DNA 
run on a 1 % agarose gel viewed under UV light without (figure 4.5a) and with 
(figure 4.5b) ethidium bromide staining. In lane 1 is a lkb ladder and in lane 4a 
sample of whole blood DNA. Nick translated DNA smears using Spectrum Red 
labelling and Spectrum Green labelling are seen in lanes 2 and 3 respectively. 
4.5a 4.5b 
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At this stage a different method of labelling the extracted DNA was utilised. As the 
process of nick translation digests DNA into smaller fragments, a labelling system that 
avoids degradation would have a distinct advantage. The Ulysis ULS (Universal 
Linkage System) method labels DNA directly with a fluorescent label and thus does not 
degrade DNA. Both the Ulysis and nick translation techniques were compared side-by-
side. Again images were taken of a 1 % agarose gel before and after staining with 
ethidium bromide. Both showed similar levels of intensity, however as expected the 
DNA smear of DNA labelled using the Ulysis system was longer than using the nick 
translation method, as the larger fragments of DNA were not digested. Interestingly, a 
sample nick translated first and then having undergone the Ulysis method of labelling 
produced the greatest intensity of labelling (figure 4.6a). 
Figure 4.6 Captured images of the various DNA labelling techniques used, run on 
the same 1 % agarose gel viewed under UV light without (figure 4.6a) and with 
(figure 4.6b) ethidium bromide staining. In lane 1 is a 1 kb ladder, with a sample of 
whole blood DNA in lane 7 and an aliquot of extracted DNA sample which has been 
used for all experiments in lane 6. Together with nick translated labelled DNA smears 
using Spectrum Green (lane 2 and 4), a dGreen Ulysis labelled DNA smear (lane 5) and 
a combined nick translated Spectrum Green and Ulysis dGreen labelled DNA (lane 3). 
4.6a 4.6b 
CGH was initially attempted using extracted DNA labelled with dGreen using the 
Ulysis system and hybridised against normal female nick translated DNA labelled with 
Spectrum Red. Images taken using the Ulysis dGreen labelling system, showed a 'halo-
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effect' around each of the metaphase spreads (figure 4.7a). Although the software could 
analyse these images, it was possible that this 'halo-effect' could affect analysis. 
CGH was repeated using extracted tumour DNA labelled with rhodamine using the 
Ulysis system, together with normal female nick translated DNA labelled with 
Spectrum Green. A 'halo-effect' around each metaphase was again observed. Therefore, 
CGH experiments were repeated using normal total genomic female blood DNA, which 
was digested with DNAse to produce fragmented DNA. The DNA was then labelled 
with rhodamine using the Ulysis system and hybridised against normal female nick 
translated DNA labelled with Spectrum Green. On this occasion, no 'halo-effect' could 
be seen, suggesting that this effect may be as a result of formalin-fixation or paraffin-
embedding (figure 4.7b). 
Figure 4.7 Captured images showing the green 'halo-effect' around a metaphase 
spread when CGH was performed using Ulysis dGreen labelled tumour DNA 
(figure 4.7a) and no 'halo-effect' when CGH was performed using Ulysis 
rhodamine labelled fragmented normal female blood DNA (figure 4.7b). 
4.7a 4.7b 
The hybridised metaphases were analysed to test the validity of this labelling method 
and all CGH profiles were found to be within the normal range, as would be expected 
for a normal sample. To test the hypothesis that formalin-fixation or paraffin-embedding 
produced this 'halo-effect', a sample of normal formalin-fixed paraffin-embedded colon 
tissue was taken and its DNA extracted and labelled using Ulysis dGreen and hybridised 
against a normal female nick translated DNA labelled with Spectrum Red. The CGH 
image confirmed that the ' halo-effect' was most likely due to the effects of formalin-
fixation or paraffin-embedding. The CGH results also showed that this ' halo-effect' did 
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not influence the analysis performed by the computer software, as the results showed 
normal CGH profiles (figures 4.8a-d). 
Figure 4.8. A typical captured image of a Ulysis dGreen labelled DNA from 
formalin-fIxed paraffIn-embedded normal colon tissue (fIgure 4.8a), with its DAPI 
stained image (fIgure 4.8b). Figure 4.8c shows the Ulysis dGreen fIltered image 
whilst fIgure 4.8d shows the Ulysis rhodamine fIltered image. 
4.8b 
The' halo-effect' may also have resulted from non-specific hybridisation of very 
small, labelled fragments of DNA to the edges of chromosomes. We contacted 
Kreatech, who suggested we use Qiagen Clean-Up columns, to remove the very small 
fragments of labelled DNA and any unincorporated fluorochromes. Two kits are 
available from Qiagen for this task, a nucleotide removal kit (which removes 
nucleotides and oligonucleotides less than 40 bp long), and a PCR clean-up kit (which 
removes 01 igonucleotides less than 100 bp long). Initially the nucleotide removal kit was 
used as Qiagen recommended this kit. However, there still appeared to be the 'halo-
effect'. Secondly, the PCR clean-up kit was used. The CGH images were better, with no 
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evidence of the 'halo-effect'. However, the intensity of the images was too low for 
analysis by the computer. 
The amount ofUlysis labelled DNA (which had been 'cleaned' using the PCR clean-
up kit) was increased in each hybridisation, proving to be extremely successful. CGH 
was repeated using DNA extracted from normal paraffin-embedded colonic tissue and 
labelled with the Ulysis system and cleaned using the PCR clean-up kit. This also 
proved to be successful and was used as a control in subsequent CGH hybridisations to 
set the image intensity level for correct analysis. MPE600 fragmented with DNAse was 
also labelled with the Ulysis system and used as a positive control in subsequent CGH 
hybridisations. Results confirmed that the method was suitable for detecting the known 
aberrations of the MPE600 DNA. However, due to the limited resources, Ulysis labelled 
MPE600 was not available for the final set of CGH experiments. 
Consultation with Kreatech confirmed that similar problems had also been 
experienced by other researchers. They confirmed that the 'halo-effect' was as a result 
of very small, labelled fragments of DNA hybridising non-specifically to any RNA or 
cytoplasmic debris on the slides and suggested that the DNA be cleaned twice using the 
Qiagen columns and titrating the amount of Ulysis labelled DNA used in CGH 
hybridisations. 
CGH was also performed using extracted DNA labelled with a combination of nick 
translation and Ulysis labelling. However, there appeared to be a lot of background 
signals as a result of non-specific hybridisations between the very small, labelled 
fragments of DNA and residual cytoplasm/debris on the slides. It was felt that this 
avenue of labelling would not be cost effective in either time or reagents. Therefore, it 
was decided that the Ulysis labelling system offered the best possibility of a successful 
hybridisation for analysis. 
A further setback was encountered, with extensive background fluorescence as a 
result of non-specific hybridisation to cytoplasmic debris on the normal metaphase 
target slides, which had been purchased from Vysis. This became a consistent problem 
with variability in the quality of slides not only existing between differing batches but 
also within individual batches. This problem had also been encountered by other 
researchers, both within the department and other institutes. Therefore, in an attempt to 
reduce the background debris (which was most likely to be cytoplasmic remnants), 
Vysis slides were pre-treated with pepsin digestion using the same protocol as for FISH 
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(see Methods and Materials section 2.2.4 Fluorescent In Situ Hybridisation - pepsin 
digestion steps 1-3, with the exclusion of the final PBS-MgCh wash). The slides were 
then dehydrated through an ethanol series and allowed to air-dry at room temperature. 
Pepsin digestion was performed for 5, 10 and 15 minutes, with CGH being performed as 
per protocol thereafter, together with a control slide, which had not been pre-treated. 
Nick translation labelled 46XX and Ulysis labelled colorectal cancer were used for all 
slides. The results of pre-treatment are shown in table 4.3. 
Table 4.3 The results of pepsin digestion pre-treatment for various durations. 
Duration of Pepsin Digestion Pre-treatment 
Slide 1 Slide 2 Slide 3 Slide 4 
Omins 5mins 10 mins 15 mins 
(control) 
Level of 
Background ++++ +++ +++ + 
fluorescence 
Appearance of Normal Metaphases Increasing over Very pale 
target appearance over-digested digestion metaphases. 
metaphases with good appeanng Unable to 
DAPI staining 'moth eaten' distinguish 
chromosomes 
Intensity and Good coverage Poor coverage Poor coverage Extremely poor 
quality of but unable to for both red for both coverage for 
hybridisations analyse because and green fluorochromes. both 
of high fluorochromes. Computer able fluorochromes. 
background No analysis to analyse No analysis 
fluorescence. possible. hybridisations, possible. 
but reliability 
of results 
questionable. 
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As each batch ofVysis slides would be produced slightly differently as a result of 
variances in humidity and temperature during the manufacturing process, pre-treatment 
with pepsin digestion would have to be standardised for each batch, thus resulting in the 
expenditure of more time, reagents and tumour material. 
As a final attempt to obtain usable target metaphase slides, target slides were 
manufactured in-house using PHA stimulated lymphocytes from healthy male 
volunteers. Lymphocytes were cultured and harvested by the Department of Genetics, 
Children's Hospital, Sheffield. The target metaphase slides were prepared as outlined in 
Materials and Methods section 2.2.1.5 Preparation of Metaphase Chromosome Spreads -
steps 12 and 13. The slides underwent pre-treatment with pepsin digestion and fixation 
as outlined in Materials and Methods section 2.2.4 Fluorescent In Situ Hybridisation. 
The resulting slides were then used to perform CGH using formalin-fixed paraffin-
embedded paired tumour samples pCRCI8/pLM18 and pCRC8/pLM8 and also fresh-
frozen paired tumour samples fCRCI and fLMI (see chapter 6.3). CGH was performed 
in all cases with nick translation labelled 46XX controls. CGH was finally partially 
successful for these paired tumour samples, although further experiments to refine the 
technique could not be performed due to time restriction. 
4.2.3 Results of CGH Analysis of Tumour Samples pCRC18. pLM18. pCRC8 and 
pLM8 
No chromosomal abnormality was found for the primary colorectal cancer pCRC 18, 
and was thus deemed not to have been successful. Whilst for its paired liver metastasis 
(pLM 18), the abnormalities detected included gains of chromosomes 2 and 3 and 
chromosome arms 8q and 13q and loss of chromosome arms 8p and 9q. 
For tumour sample pCRC8 again no significant chromosomal abnormality was 
detected, whilst for pLM8, analysis of the hybridisation was not possible due to high 
background fluorescence. 
Figure 4.9 shows a typical two-colour image of CGH for pLM 18 with figure 4.10 
showing the DAPI stained image of the same metaphase spread. ULS red was used to 
label the test tumour DNA and Spectrum Green the normal 46XX reference DNA. The 
ratio of ULS red and spectrum green fluorescence was plotted along each chromosome 
ideogram, where chromosomal imbalances were detected on the basis of deviation of the 
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ratio profile from the balance value CULS red:Spectrum Green = 1: 1). Values of 1.25 
and 0.75 were used as respective diagnostic cut-offlevels to represent amplification and 
deletion respectively. Figure 4.11 shows the average ratio profile for pLM18. Figure 
4.12 shows the average profile from the analysis of several chromosome spreads, where 
vertical lines to the left of the chromosome ideogram indicates deletion whilst to the 
right indicates amplification. 
Figure 4.9 A typical two-colour image of pLM18 (tumour DNA labelled Ulysis 
rhodamine and normal reference DNA labelled Spectrum Green). 
Figure 4.10 The DAPI stained image of the target metaphase spread as seen in 
figure 4.9, for pLMI8. 
• 
• 
• 
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Figure 4.11 The average ratio profile of several metaphase spreads for pLMI8. 
n- IO 14 18 n-5 
~~~ 
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Figure 4.12 The average ratio profile ideogram for pLM18, where vertical lines to 
the left of the chromosome ideogram indicate deletion whilst to the right indicate 
amplification. 
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4.3 DISCUSSION 
4.3.1 Optimisation of DNA Extraction and Purification from Formalin-Fixed 
Paraffin-Embedded Tumour Samples for use in CGH 
The foremost problem with extracting DNA from paraffin-embedded tissue material, 
is that the DNA is rarely well preserved and is usually degraded, resulting in the loss of 
long fragment DNA (1000-2000 bp) which is essential for COHo if a uniform 
hybridisation is to be achieved (Ohazvini et aI., 1996). In this study several protocols 
were utilised with modifications in an attempt to obtain high quality DNA suitable for 
COHo Attempts to improve extraction and purification were greeted with limited 
success, with the optimal protocol utilising the Qiagen QIAamp DNA Mini Kit, which 
proved to be the most efficient method of DNA extraction and purification. 
Improvements to the original standard DNA extraction protocol could have included the 
use of microwave irradiation in order to de-wax the paraffin-embedded tissue material, 
thus obviating the need for organic solvents and potentially reducing the loss of DNA, 
although protein contamination would still have been a problem (Banerjee et aI., 1995; 
Diaz-Cano and Brady, 1997; Sato et aI., 2001). 
4.3.2 Optimisation of CGH on Formalin-Fixed Paraffin-Embedded Tumour 
Samples 
There are several reasons for why more gains or losses were not observed in the 
tumour specimens, when compare to other studies (Kom et aI., 1999; AI-Mullah et aI., 
1999; Aragane et aI., 2001; Nakao et aI., 2001). These include: 
1. Operator error. 
2. Poor image analysis as a result of computer hardware or software deficiencies. 
3. Excessive contamination of the extracted tumour DNA samples by normal tissue 
DNA. 
4. Specific gains or losses were so small that the resolution of COH was unable to 
visualise such differences. 
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5. Extremely heterogeneous tumour samples which resulted in any large gains or losses 
cancelling out. 
6. Prolonged tissue fixation resulting in excessively degraded tumour DNA. 
Operator error could be discounted because normal 46XX control samples hybridised 
well and showed normal profiles when analysed. Although, a positive control such as 
MPE600 was not available for the latter experiments, in the earlier experiments the 
expected imbalances were observed. With the latter experiments the intensity of the 
Ulysis rhodamine labelled tumour DNA was not as bright as that of the Spectrum Green 
labelled normal reference DNA and so initially the captured images were un-analysable 
by the computer. In an attempt to rectify this, the duration of exposure using each filter 
during the image capturing process was determined empirically, until an image was 
obtained which the computer could analyse. This could mean that hybridisation intensity 
levels along the chromosomes could have been artificially compromised, thus masking 
regions of gains or losses, the result being an apparently normal tumour DNA analysis. 
The incorrect pairing of chromosomes due to inadequate DAPI staining could have 
accounted for the low observance of imbalances, as any significant differences may have 
been negated when several chromosome ideograms are combined to produce an average 
profile. Although this was not thought to be a major problem as chromosome pairing 
was verified by an experienced cytogeneticist (Dr K. Sisley). 
Excessive contamination by normal tissue DNA could largely be excluded as tumour 
tissue was microdissected from slides which were confirmed to contain viable tumour 
tissue as oppose to necrotic tissue by two independent histopathologists (Dr M. 
Muzaffer and Dr S. Cross). 
An extremely heterogeneous tumour sample could have resulted in non-significant 
net gain or loss of chromosome material, although this is unlikely as other studies all 
showed extensive gains and losses of chromosome material (Korn et aI., 1999; AI-
Mullah et aI., 1999; Aragane et aI., 2001; Nakao et aI., 2001). Conversely, the 
microdissected tumour sample may have contained material from a specific subclone of 
cells which only showed minor abnormalities, again this is thought to be unlikely as 
tumour material was microdissected from several slides from a single paraffin-
embedded tissue block. Another possibility, is that the structural changes were so small 
« 1 Omb) that the resolution of CGH was unable to visualise such differences. 
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A final possibility, is that prolonged tissue fixation in an unknown fixative lead to 
excessive degradation during tumour DNA extraction, resulting in a propensity of short 
length fragments of DNA (-300-600 bp) which hybridised non-specifically to the target 
metaphase spread in preference to the longer fragments of DNA (-1000-2000 bp), 
which in turn would have prevented any significant changes from being visualised 
(Ghazvini et aI., 1996). Long length DNA fragments were confirmed to have been 
produced as all extracted tumour DNA samples showed a 'smear' when electrophoresed 
on ethidium bromide stained agarose gels and the use of the Ulysis labelling technique 
would have prevented DNA fragmentation which is a consequence of the nick 
translation labelling technique. The use of fresh tumour material would have hopefully 
eliminated many of these problems. 
Thus, a variety of problems could have been responsible for the low numbers of 
chromosomal aberrations detected, not least the problem with the quality of target 
metaphase slides, which was in part rectified by the manufacture of in-house target 
metaphase slides. With additional study successful analysis could have been performed, 
should time have permitted. 
4.3.3 CGH Analysis of Paired Primary and Liver Metastatic Coloredal Cancer 
The progression from colorectal adenoma to cancer has been associated with specific 
chromosomal changes with gains in chromosome arms 13q, 8q and 20q and losses in 
chromosome arm 18q occurring more frequently in cancers than in adenomas (Meijer et 
aI., 1998). With nearly 90% of all colorectal cancers showing chromosomal 
abnormalities only a minority exhibit a normal karyotype (Muleris et aI., 1990; Bardi et 
aI., 1995). The most common numerical abnormalities are loss of chromosome 18 
(26%) and gain of chromosome 7 (25%). Other common abnormalities include losses of 
chromosomes Y (15%), 17 (13%), 14 (12%) and 22 (12%), and common gains include 
those of chromosomes 20 (14%) and 13 (12%). Less frequent findings include loss of Ip 
and gain of 1 q, loss of 8p and gain of 8q, loss of 13p and gain of 13q and loss of 17p 
and gain of 17q (Bardi et aI., 1997). More recently, allelic imbalance with loss of 
chromosome arms 8p (Halling et aI., 1999) and 18q (Martinez-Lopez et aI., 1998) have 
been reported to be significantly associated with reduced survival in patients with Dukes 
B and C staged cancers. 
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Due to the problems encountered using the COH technique, significant results were 
only obtained for pLM 18, showing gain of chromosomes 2 and 3, and chromosome 
arms 8q and 13q, and loss of chromosome arms 8p and 9q. These findings are similar to 
the results obtained by Kom et al. (1999), who found significant gains of chromosome 
arms Sq and 13q and loss of Sp amongst others, on examining 26 paired tumour samples 
using COHo AI-Mullah et al. (1999), on examining 7 paired samples with COH, also 
found gains of chromosome arms 8q and 13q with loss of chromosome Sp. Similarly, 
Aragane et al. (2001) also found a gain of 8q, in particular Sq23-24, and also associated 
gain of 8q with a significantly reduced disease-free survival period. Nakao et at., (2001) 
examined 35 primary tumours, 16 of which had liver metastases and assessed whether 
there were specific genetic changes associated with either the presence or absence of 
liver metastases. Although they did not specifically examine the liver metastases for 
chromosomal abnonnalities, they found significant gains in chromosome arms 8q and 
13q in primary tumours with liver metastases, whereas they found no changes in 6q or 
7q in those primary tumours without evidence of liver metastases. Although only one 
tumour sample appeared to have successfully hybridised in our study, the results did 
concur with these other studies. 
Of the other abnonnalities found by Kom et al. (1999), gain of chromosome arm 20q 
and loss of chromosome 18 and chromosome 1 p were also significant; suggesting that 
chromosome arm 20q may harbour a candidate oncogene responsible for metastasis. AI-
Mullah et al. (1999) also came to a similar conclusion, associating gains of 20q with 
advanced colorectal cancers and liver metastasis. They also found a significant 
association between loss of 17p and gains of6p and 17q with liver metastasis, and 
postulated that these regions may also harbour genes involved in liver metastasis. 
Aragane et al. (2001) also found frequent gains of7p, 7q13-36, 15q21-26, 19p and 20q 
and loss of ISq 1-23 and 5q21. As well as gains of 8q, they associated gains of 20q and 
loss of ISq with a significantly reduced disease free period. Nakao et al. (2001) found a 
significant difference in the frequency of chromosomal abnormalities in 6q, 7 q, 8q, 13q 
and 20q, when comparing primary colorectal cancers with and without liver metastases, 
stating that loss of 17p and 18q and gain of 7q, 8q, 13q and in particular 20q, may 
influence the occurrence of liver metastases. 
Of the studies already mentioned investigating chromosomal abnormalities in 
primary and liver metastatic colorectal cancer (Kom et aI., 1999; AI-Mullah et aI., 1999; 
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Aragane et aI., 2001), only AI-Mullah et ai. (1999), used formalin-fixed paraffin-
embedded tissue, analysing seven paired samples, whereas the other studies were able to 
analyse fresh-frozen tumour specimens. AI-Mullah et aI. (1999) used a phenol-
chloroform DNA extraction technique and a random-primed labelling technique with 
indirect detection when performing COH. This would have enabled repeat detection 
washes to enhance the intensity of any hybridisation signals. Although, COH has been 
successfully performed on a variety of formalin-fixed paraffin-embedded tumour tissues 
such as breast (Nishizaki et aI., 1997), oesophageal cancer (Van Dekken et aI., 1999), 
uveal melanoma (Aalto et aI., 2001) and malignant gliomas (Paunu et aI., 2000) to name 
a few, using a variety of DNA labelling techniques; nick translation (Nishizaki et aI., 
1997; Aalto et aI., 2001; Paunu et aI., 2000), and ULS (Alers et aI., 1999; Van Dekken 
et aI., 1999; Naus et aI., 2001), COH is still dependant on good quality extracted DNA 
and target metaphase slides. A technique which may have improved analysis of paraffin-
embedded material is DOP-PCR (degenerated oligonucleotide primer-PCR), which 
universally amplifies extracted DNA. The amplified DNA can then subsequently be 
labelled using either nick translation or ULS methods (Zitselsberger et aI., 2001). 
However, meticulous laboratory technique and negative controls are essential to ensure 
that DNA contamination has not taken place (Lichter et aI., 1995), and the fluorescent 
ratios along the chromosomes can be more variable (Speicher et aI., 1993). Time and 
resources permitting, the DOP-PCR (universal DNA amplification) method would have 
been the next avenue to be explored in amplifying the extracted DNA from the paired 
tumour specimens followed by labelling by either technique. Again however, COH 
would only be successful if good quality target metaphase slides were available. 
4.3.4 Summary 
The technique of COH was developed to analyse the genomic changes in primary 
colorectal cancers and their liver metastases. Several hurdles were overcome in the 
development of this technique, including the poor quality of DNA obtained from the 
formalin-fixed paraffin-embedded tissue samples and the highly variable quality of the 
purchased target metaphase slides. Time permitting a more extensive analysis of the 
paired samples would have been undertaken. Though, from the limited data obtained, 
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which was comparable with other reports, gain of chromosome arms 8q and 13q may be 
involved in the development of liver metastases. 
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CHAPTER 5 
5.1 INTRODUCTION 
As mentioned previously, there appears to be two major mechanisms involved in the 
tumourigenesis of colorectal cancer, chromosomal instability and microsatellite 
instability (Vogel stein et al., 1988; Fearon and Vogel stein, 1990; Aaltonen et aI., 1993; 
Peltomrud et aI., 1993; Ionov et aI., 1993; Thibodeau et aI., 1993). Although 
microsatellite instability was initially described in association with hereditary non-
polyposis colorectal cancer, up to 20% of sporadic colorectal cancers are also thOUght to 
exhibit MSI (Thibodeau et aI., 1993; Aaltonen et aI., 1993; Kim et aI., 1994; Riischoff et 
aI., 1995). Colorectal cancers with MSI express a distinct phenotype characterised by 
mucinous growth, location to the right side of the colon, poor histological differentiation 
and paradoxically a more favourable prognosis (Kim et aI., 1994). The presence ofMSI 
has been further categorised to MSI-H (MSI at >30% of micro satellites examined) and 
MSI-L «30% of microsatellites examined) (Boland et aI., 1998). Whereas MSI-H 
tumours tend to be associated with inactivation of DNA mismatch repair genes, MSI-L 
tumours appear to behave similarly to tumours with CIN, with some reports suggesting 
that most colorectal cancers will exhibit some degree of MSI depending on the selection 
and number of loci examined (Halford et al., 2002; Laiho et aI., 2002). There is also 
continuing debate as to whether MSI-L tumours really represent a distinct 
clinicopathological entity (Gonzalez-Garcia et al., 2000; Tomlinson et aI., 2002). 
Several studies have associated the presence of MSI colorectal tumours in patients 
with a more favourable prognosis compared to patients with microsatellite stable (MSS) 
tumours (Thibodeau et aI., 1993; Lothe et al., 1993; Gafa et aI., 2000; Gryfe et aI., 2000; 
Hemminki et aI., 2000). While other studies have stated that any survival advantage is 
not independent from the stage of the disease i.e. the TNM classification remained the 
best indicator for prognosis (Messerini et aI., 1999; Salahshor et aI., 1999; Johannsdottir 
et aI., 1999; Feeley et aI., 1999; Curran et aI., 2000; Gervaz et aI., 2002). Recently, a 
number of studies have also implicated that individuals with MSI-H tumours are at 
greater risk of developing metachronous tumours (Sengupta et aI., 1997; Masubuchi et 
aI., 1999; Shitoh et aI., 2002). Moreover, some studies only selected certain categories 
of patients «50 years of age), and few studies assessed the prognostic significance of 
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MSI in the presence of LOH of 17p and 18q, which are thought to adversely affect 
prognosis (Jen et aI., 1994; Choi et aI., 2002). The incidence of MSI in sporadic 
colorectal cancer has also been found to be related to disease staging, with the incidence 
increasing proportionately with stage, the incidence having been reported to be 12% for 
Dukes A cancers and between 20-34% for Dukes Band C cancers (Aaltonen et aI., 
1994; Bubb et aI., 1996; Chen et aI., 1997). 
The relevance of staging classifications is not limited to prognosis, such systems 
also detennine the administration of any adjuvant therapy. Currently, adjuvant 
chemotherapy with 5-fluorouracil and levimasole has been limited to patients with 
Dukes C (TNM stage III) cancers as no survival benefit has been proven for patients 
with Dukes B (TNM stage II) cancers (Moertel et aI., 1990; NIH Consensus Conference, 
1990). However, Dukes B staged cancers represent approximately 50% of all colorectal 
cancers and have a 5-year survival rate of 60-75% with surgery alone, which would 
suggest that 15-20% of all patients with colorectal cancer, will eventually die of 
metastatic disease without even being considered for adjuvant therapy (Moertensen et 
aI., 1992). However, identifying this subgroup of patients with genetic techniques has 
proven to be extremely difficult (Chung, 1998; Rosty et aI., 2001). 
Liver metastases when present at the time of diagnosis are associated with 
significant morbidity and mortality, with the median survival time being about 10-15 
months (Ballantyne and Quin, 1993). Although surgical resection of the liver metastases 
improves overall survival, surgery is only indicated in localised metastases which 
account for only 20-25% of all cases, thus chemotherapy plays an important role in these 
patients (Geoghegan and Scheele, 1999). Previous studies have indicated that p53 
mutations alter the response to chemotherapeutic agents, conferring resistance to certain 
agents (Weller, 1998). The presence ofMSI has also been implicated in resistance to 
chemotherapeutic agents (Kinzler and Vogel stein, 1996; Wright et aI., 2000). 
5.1.1 Aim of this Study 
The aim of the study was to assess the presence or absence of MSI in primary 
colorectal cancer and it's paired liver metastasis (whether present synchronously or 
metachronously) and compare it to overall survival, specifically to assess whether the 
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presence of MSI in either the primary or metastatic tumour is associated with a better 
prognosIs. 
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5.2 RESULTS 
A series of 31 paired tumour samples (of both the primary colorectal cancer and its 
liver metastasis) from 31 patients undergoing liver resection for liver metastases, 
between January 1997 and December 1999 were analysed for MSI using the PCR 
technique. Of the 31 patients, 18 were male and 13 were female, the median age was 63 
years with an age range Of 41-82 years. Of the primary tumours analysed, 29 showed 
moderate histological differentiation, the other two being well differentiated. Five 
primary tumours were situated in the right colon, 3 in the left colon, 12 in the sigmoid 
colon and 11 in the rectum. Eighteen had synchronous liver metastases and were thus 
staged Dukes 0 (TNM stage IV). Of those which had metachronous liver metastases, 
the median time between diagnosis of the primary tumour and diagnosis of the liver 
metastasis was 16.9 months (range 6.3-102.9 months), all being diagnosed by routine 
ultrasound surveillance. Of the primary tumours with metachronous metastases, 7 were 
initially staged as Dukes B (TNM stage II) and 7 as Dukes Cl (TNM stage III). Ten 
patients with tumours staged as either Dukes C or Dukes D received adjuvant 
chemotherapy and lor radiotherapy, one patient with a Dukes B staged tumour received 
adjuvant chemotherapy. None of the patients had received neo-adjuvant 
chemo/radiotherapy. There were no mortalities within 30 days of the liver resection 
surgery. The median duration of follow-up after resection of the primary tumour was 92 
months (range 13 -186 months), with 17 patients having died by the end of the study as a 
result of recurrent disease and one from a myocardial infarction (table 5.1). 
The presence of a family history of colorectal cancer could not be assessed as 
this data was incomplete. 
A reference panel of microsatellite primers recommended for the detection of MSI 
in colorectal cancer were used (Dietmaier et aI., 1997; Boland et aI., 1998). These 
included three mononucleotide repeats (BAT25, BAT26 and BAT40) and five 
dinucleotide repeats (D2S 123, APC (D5S346), Mfd 15 (D 17S250), D lOS 197, D 18S58 
and 0 18S69) and one tetranucleotide repeat (MYCL 1) located to loci on chromosome 
2p, 4q12, Ip13.1, 2p16, 5q21122, 17ql1.2-qI2, 10qter, 18q22.3, 18q21 and Ip32 
respectively. (Unfortunately, primers BAT26, D2S123 and MYCLI failed to amplify, 
this will be discussed in section 5.3.1 Optimising Conditions for PCR for use on 
Formalin-Fixed Paraffin-Embedded Tumour Specimens). 
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MSI-H was defined as instability at 2 or more loci. 
Statistical Analysis 
Independent samples t-test, Fisher's exact test and the Wilcoxon Mann Whitney U 
test were performed to determine any significant differences in clinicopathological 
variables between tumours (primary and/or metastatic) with MSI-H and those without 
MSI (microsatellite instability stable - MSS). The log-rank test was performed to 
compare survival, which was represented by Kaplan-Meier survival curves. Logistic 
regression analysis was performed to predict whether MSI-H tumours (either primary or 
metastases) were significantly associated with specific clinicopathological variables 
(age, sex, primary tumour location, stage of the primary tumour, the presence of solitary 
or multiple metastases, the presence of synchronous or metachronous metastases, the 
administration of adjuvant chemotherapy or radiotherapy and pre-operative (liver 
resection) CEA levels). Statistical analysis was performed using SPSS statistical 
software package on a PC computer, with a p value for significance set at <0.05, but for 
logistic regression analysis a p value for significance was set at <0.008 using the 
Bonferroni correction, due to the small sample size. 
5.2.1 Optimising Conditions for peR for use on Formalin-Fixed Paramn-
Embedded Tumour Specimens 
Initially 1 % agarose gels were used in order to detect any microsatellite instability, 
however, the resolution obtained was extremely poor (figure 5.1). In order to improve 
the resolution and to produce tightly defined bands, a 2% agarose gel was used, however 
even this failed to improve the resolution. As a shift of 1 base pair was needed to be 
detected in order to define microsatellite instability, it was felt that agarose gels would 
not provide the necessary resolution. It was therefore decided to run the PCR products 
on polyacrylamide gels and then to use silver staining to detect the products. These gels 
did provide a vast improvement on agarose gels, however even using a variety of gels at 
various concentrations (6%,8% and 10%) failed to provide the resolution of 1 base pair 
required (figure 5.2). 
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Figure 5.1 PCR products electrophoresis on a 1 % agarose gel, using primers 
D18S58, BAT40, APC, BAT25 and D2S123 on samples from case pCRC14. 
T=primary tumour; N= normal colonic tissue; M= liver metastasis. A 1 kb marker has 
been run in the far left hand lane. 
Figure 5.2 PCR products electrophoresis on 8% polyacrylamide gel using the 
MYCL1 primer on samples from cases pCRC2, pCRC12, pCRC14 and pCRC15. 
T=primary tumour; N= normal colonic tissue; M= liver metastasis. A 1 kb marker has 
been run in the far left hand lane. 
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At this point the department purchased a LiCor 4200 LongReadIR automated 
sequencer which used primers labelled with either IRD 700 or IRD 800 with 
electrophoresis performed on 25cm LongRanger gels. The resolution produced was to a 
single base, sufficient to detect any microsatellite instability. Seven paired samples, 
consisting of the primary colorectal cancer and its paired liver metastases and a normal 
tissue control microdissected from either normal colonic mucosa or liver parenchyma, 
were used as test samples (figure 5.3). 
Figure 5.3 PCR products electrophoresis on a 25cm LongRanger gel using primers 
MYCLl and APC with samples pCRC2, pCRCl2, pCRCl4, pCRC15, pCRC17, 
pCRCl8 and pCRC25. T=primary turnour; N= normal colonic tissue; M= liver 
metastasis. 
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,r '1 po(' 11 RC l4 
T "r T T 1 
A C 
pi: '1 pCR< 11 ",' It( l4 pc: (' l~ pell t 1 pC ] ' I pCR< ~ 
MT MT MT . :\I 
Once the PCR reactions had been optimised for use on the LiCor automated 
sequencer, the rest of the tissue samples were microdissected and digested according to 
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the protocol. However, these samples failed to amplify even after increasing the number 
of cycles to 35. Subsequently, the volume of DNA added to the peR reaction was 
increased from 1 III to 21l1, this produced a very slight improvement with the number of 
cycles set at 30. So the volume of DNA was increased further to Sill, however this had 
the opposite effect and no amplified products were visualised at all. As a final measure, 
the ph of the original and the recently digested tumour samples were assessed using ph 
strips. The original samples had a ph of 8.5 whereas the recently digested samples had a 
ph of 11, which was confirmed using a new ph meter. The ph of the digested samples 
were corrected, and the peR reactions repeated. These samples were divided into three 
groups, one without correcting the ph, a second group using I III of the corrected ph and 
a third group of samples using 21ll of the corrected ph. These were then assessed against 
the original test samples acting as positive controls. All samples amplified except for the 
fist group of samples, which had not been ph corrected, thus confirming that the high ph 
was the reason for the peR reactions failing to amplify. Both the 1 III and 21-11 DNA 
volumes produced amplified products however, the use of the larger volume of DNA 
produced an increase in non-specific products, thus 11-11 was sufficient for most reactions 
(figure 5.4). 
Figure 5.4 Results of the pH correction experiment performed on the second batch 
of microdissected formalin-fixed paraffin-embedded tumour samples. peR reaction 
performed using the APe primer with electrophoresis on 25cm LongRanger gels, with 
the original samples as controls in the far left hand lanes. 
Original samples - 1111 of 
DNA used for each reaction 
Second batch samples 
without pH correction 
Second batch samples + 
22111 3M Tris HCI - 1111 
of DNA used for each 
reaction 
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Second batch samples + 
22111 3 M Tris IICI - 2111 of 
DNA used for each 
reaction 
Having successfully produced amplified products using the IRD labelled primers 
with LongRanger gel electrophoresis, three of the primers subsequently failed to amplify 
these were BAT26, D2S123 and MYCLI. The other primers continued to amplify 
suggesting that the problem possibly existed with primers. Since they had previously 
amplified a possible explanation was that continual freeze-thawing of the primers 
(during retrieval from storage at -20°C), had somehow cleaved the fluorescent IRD label 
off the primers, another explanation being gradual degradation of the tumour DNA 
samples, as they had been stored at 4°C. A further batch of labelled BAT26 was 
purchased as some studies have suggested that BA T26 is the perhaps the most sensitive 
marker for MSI assessment in colorectal cancers (Dietmaier et aI., 1997; Cravo et aI., 
1999), however, even this new batch failed to amplify with our DNA, suggesting indeed 
that the DNA had started to degrade. Due to limited resources and time, further tumour 
samples could not be microdissected or labelled primers be purchased. Thus, only seven 
micro satellite markers were successfully analysed (BAT25, BAT40, APC (D5S346), 
Mfd15 (D17S250), DIOS197, D18S58 and D18S69). 
5.2.2 Results of Microsatellite Analysis of Primary Colorectal Cancers and their 
Liver Metastases 
Of the 31 primary tumours analysed 3 tumours (9.7%) exhibited microsatellite 
instability at two or more loci, thus were considered as MSI-H, six tumours (19.4%) 
exhibited MSI at one locus and were considered to be MSI-L (table 5.2). When 
considering MSI-H and MSS primary colorectal cancers, there was no significant 
statistical difference in age (p=O.72 1), sex (p=>O.95), pre-operative CEA levels 
(p=O.749), Dukes stage (p=O.349), TNM stage (p=O.598), histological differentiation 
(p=O.875), the site of the primary tumour (p=O.122), the presence of either synchronous 
(p=>O.95) or metachronous liver metastases (p=>O.95), presence or absence of 
recurrence (p=O.IOI) or in survival (p=O.3702). However, there was a significant 
difference in the presence of either solitary or multiple liver metastases and MSI-H 
tumours, where the presence of MSI-H in primary tumours was significantly associated 
with solitary liver metastasis (p=O.049), (table 5.3). 
Of the 31 liver metastases analysed 4 tumours (12.9%) were considered as MSI-H, 
whereas 11 tumours (35.5%) were considered as MSI-L (table 5.2). When considering 
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MSI-H and MSS colorectal cancer liver metastases, there was no significant difference 
in age (p=O.523), sex (p=>O.95), pre-operative CEA levels (p=O.635), the presence or 
absence of recurrence (p=O.333) or in survival (p=O.3972). However, there was also a 
significant difference in the presence of either solitary or multiple liver metastases and 
MSI-H tumours, where again the presence of MSI-H in liver metastases was 
significantly associated with solitary liver metastasis (p=O.016), (table 5.3). 
Three primary tumours exhibited MSI-H (CRCI7, CRC89 and CRC94) of these the 
paired liver metastases of CRC 17 and CRC89 also exhibited MSI-H with MSI present at 
the same loci in both the primary and metastasis, whilst the paired liver metastasis of 
CRC94 exhibited MSI-L with MSI present at one locus similar to that of the primary 
tumour (figure 5.5). CRC17 was a Dukes D staged tumour located in the left colon with 
a solitary liver metastasis. The patient did not receive any adjuvant therapy and survived 
for 96 months after the original colonic surgery before succumbing to recurrent liver 
disease. CRC89 was a Dukes C 1 staged caecal tumour with a solitary metachronous 
liver metastasis diagnosed 41.2 months after the primary tumour had been resected. The 
patient did receive adjuvant chemotherapy after the original surgery and is currently 
alive and well. While CRC94 was staged as a Dukes D sigmoid tumour with a solitary 
liver metastasis, the patient did not receive any adjuvant therapy and is currently alive 
and well. The liver metastases from CRC15 and CRC34 also exhibited MSI-H, where 
the primary tumours were staged as Dukes C 1 and Dukes B, and situated in the left 
colon and rectum respectively. Primary tumour CRC15 exhibited MSI-L, whereas 
CRC34 was MSS. Both liver metastases were solitary, diagnosed 2.5 months and 22.9 
months after the original colorectal surgery, with patient CRC34 receiving adjuvant 
chemotherapy after the original rectal surgery and is currently alive and well. However, 
patient CRCl5 died 67 months after the original colonic surgery, succumbing to 
peritoneal recurrence. 
There appeared to be a trend for improved survival in patients with primary tumours 
exhibiting MSI-H compared to those without MSI (MSS), although this was not 
statistically significant (p=O.3702), (figure 5.6), nor was there any significant difference 
in survival between metastatic tumours exhibiting MSI-H and those without MSI 
(MSS), (p=O.3972), (figure 5.7). When considering the initial stage of the disease for all 
the primary colorectal cancers, there also appeared to be a trend for improved survival in 
patients with Dukes B staged primary tumours, although as expected, since all patients 
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at some point developed metastases, this was not statistically significant (p=O.3454), 
(figure 5.8). 
Logistic regression analysis of the relationship between the presence of MSI-H in 
either the primary or metastatic tumour and possible risk factors such as age, sex, 
primary tumour location, stage of the primary tumour, the presence of solitary or 
multiple metastases, the presence of synchronous or metachronous metastases, the 
administration of adjuvant chemotherapy or radiotherapy and pre-operative CEA levels 
showed that MSI-H tumours were significantly associated with the presence of solitary 
metastases (p=O.007), (table 5.4). 
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Table 5.1 Results of MS} status and dinicopathological characteristics. 
Case Su Age Primary Dukes TNM stage Pre-op Differentia Adjuvant Adjuvant Syncbronous! Time to Number of Recurrence - Status Duration Primary Metastasis (pCRC) site stage CEA -tion cbemo- radio- metacbronou5 metacbronous metastases: site (Deadl of (MSSI (MSSI 
levels therapy Therapy liver metastases solitaryl Alive) survival MSI-LI MSI-LI (mglml) metastases (months) multiple (montbs) MSI-H) MSI-H) (number of 
tumoun) 
2 F 53 Siwnoid D T3NOMI 0.9 Moderate No No Synchronous N/A Multiple (2) Yes -lung Dead 119 MSS MSS 
9 F 62 Rectum B T3NOMO 25.0 Moderate No No Metachronous 16.9 Solitary Yes - liver Dead 170 MSS MSS 
11 M 74 Rectum C T4N2MO 2350.0 Moderate Yes Yes Metachronous 15.1 Multiple (3) Yes - liver Dead 66 MSS MSS 
Il M 70 Sigmoid D T3NIMI 7.7 Well Yes Yes Synchronous N/A Multiple (4) Yes - abdo Dead 49 MSS MSS 
14 M 54 Rectum D T3N2MI 500.0 Moderate Yes No Synchronous N/A Multiple (5) Yes - pelvis Dead 44 MSS MSS 
15 F 79 Left C T4NIMO 17.4 Moderate No No Metachronous 2.5 Solitary Yes - abdo Dead 67 MSI-L MSI-H 
17 F 74 Left D T3NIMO 742.0 Moderate No No Synchronous N/A Solitary No Dead 96 MSI-H MSI-H 
18 M 57 Rectum D T3NIMI 31.0 Moderate No Yes Synchronous N/A Solitary No Alive 140 MSS MSS 
19 M 82 Rectum D T3NOMI 385.0 Moderate No No Synchronous N/A Multiple (3) Yes - abdo Dead 46 MSS MSS 
25 M 66 Rectum B T3NOMO 6140.0 Moderate No No Metachronous 15.7 Multiple (2) Yes -lung Dead 150 MSS MSI-L 
27 F 69 Sigmoid C T4NIMO 6.0 Moderate Yes No Metachronous 5.3 Multiple (3) No Dead 36 MSS MSS 
30 F 61 Sigmoid D T3N2MI 20.0 Moderate No No Synchronous N/A Multiple (2) Yes - liver Dead 52 MSS MSS 
32 M 67 Siwnoid D T3NIMI 6.0 Moderate Yes No Synchronous N/A Multiple (2) Yes -liver Dead 88 MSS MSS 
34 M 65 Rectum B T2NOMO 4.0 Well Yes No Metachronous 22.9 Solitary No Alive 181 MSS MSI-H 
35 M 49 Rectum D T2NIMI 47.8 Moderate Yes No S}1lchronous N/A Solitary No Alive 170 MSS MSS 
38 F 68 Sigmoid D T3NOMI 6.9 Moderate No No Synchronous N/A Multiple (3) No Dead 13 MSS MSI-L 
43 M 55 Rectum D T4N2MI 60.2 Moderate No No Synchronous N/A Multiple (5) Yes -Iun~ Dead 71 MSI-L MSI-L 
46 F 76 Ri~t D T3NOMI 2.9 Moderate No No Synchronous N/A Solitary No Alive 129 MSS MSI-L 
47 F 47 Rectum C T4NIMO 2842.0 Moderate No Yes Metachronous 3.7 Multiple (3) Yes -liver Dead 66 MSI-L MSI-L 
48 F 51 Rectum B T2NOMO 7.6 Moderate No Yes Metachronous 21.5 Multiple (2) No Alive 158 MSS MSI-L 
49 M 72 Right D T3NIMI 87.9 Moderate No No futnchronous N/A Multiple (3) Yes -liver Dead 57 MSS MSI-L 
58 F 47 Sigmoid D T3NIMI 3.2 Moderate No No Synchronous N/A Multiple (2) Yes -liver Dead 38 MSS MSS 
59 M 52 Ri~t D T3NOMI 54.0 Moderate No No Synchronous N/A Solitary Yes -liver Alive 89 MSS MSS 
62 F 63 Sigmoid B T3NOMO 16.1 Moderate No No Metachronous 14.4 Multiple (2) Yes-lung Dead 115 MSS MSS 
70 M 70 Sigmoid C T3NIMO 82.3 Moderate Yes No Metachronous 18.7 Multiple (2) No Alive 103 MSS MSS 
74 M 64 Sigmoid D T2NOMI 1.0 Moderate No No Synchronous N/A Multiple (2) No Alive 97 MSS MSS 
i 77 M 45 Sigmoid D T3NOMI 1.9 Moderate No No Synchronous N/A Multiple (2) No Alive 92 MSI-L MSI-L 
89 M 41 Ri~ht C T2NlMO 0.8 Moderate Yes No Metachronous 41.2 Solitary No Alive 186 MSI-H MSI-H 
94 M 63 Sigmoid D T3NlMI 5.6 Moderate No No ~chronous N/A Solitary No Alive 80 MSI-H MSI-L 
95 M 58 Left C T3NlMO 276.0 Moderate Yes Yes Metachronous 35.4 Solitary No Alive 171 MSI-L MSI-L 
96 F 52 Right B T3NOMO 929.1 Moderate No No Metachronous 25.0 Solitary No Alive 142 MSI-L MSI-L 
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Table 5.2 Results of the microsatellite marker analysis showing the number and loci affected for each case (+ = MSI; - = MSS). 
Case Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis Primary Metastasis Primary Primary Metastasis Metastasis 
(pCRC) BATl5 BAT 25 BAT40 BAT 40 APC APC Mfdl5 Mfd15 010S197 010S197 018S58 018S58 018869 D18869 MSI-L MSI-H MSI-L MSI-H (no. loci) (no. loci) (no. loci) (no. loci) 
2 - - - - - - - - - - - - - - - - - -
9 - - - - - - - - - - - - - - - - - -
11 - - - - - - - - - - - - - - - - - -
12 - - - - - - - - - - - - - - - - - -
14 - - - - - - - - - - - - - - - - - -
15 - - - - - - - + - - + + - - +(117) - - +(2/7) 
17 - - - - - - + + - - + + - - - +(2/7) - +(217) 
18 - - - - - - - - - - - - - - - - - -
19 - - - - - - - - - - - - - - - - - -
25 - - - - - - - - - - - + - - - - +(117) -
27 - - - - - - - - - - - - - - - - - -
30 - - - - - - - - - - - - - - - - - -
32 - - - - - - - - - - - - - - - - - -
34 - + - + - - - - - - - - - - - - - +(2/7) 
35 - - - - - - - - - - - - - - - - - -
38 - - - + - - - - - - - - - - - - +(117) -
43 - - - - + + - - - - - - - - +(117) - +(117) -
46 - - - - - + - - - - - - - - - - +(1/7) -
47 - - - - - + - - - - - - + - +(117) - +(117) -
48 - - - - - - - + - - - - - - - - +(1/7) -
49 - - - - - + - - - - - - - - - - + -
58 - - - - - - - - - - - - - - - - - -
59 - - - - - - - - - - - - - - - - - -
62 - - - - - - - - - - - - - - - - - -
70 - - - - - - - - - - - - - - - - - -
74 - - - - - - - - - - - - - - - - - -
77 - - + + - - - - - - - - - - +(117) - +(1/7) -
89 + + + + + + - - - - + + - - - +(4m - +(2/7) 
94 - - - - + - - - + + - - - - - +(4/7) +(117) -
95 - - - - + + - - - - - - - - +(117) - +(1/7) -
96 - - - - + + - - - - - - - - +(1/7) - +(117) -
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Figure 5.5 PCR products electrophoresis for cases pCRCI5, pCRCI7, pCRC34, pCRC89 and 
pCRC94 on a 25cm LongRanger gel. Shifts in bands suggesting MS! are exhibited in the 
metastasis at locus Mfd 15 and in both the primary and metastasis at locus D 18S58 in case pCRC 15, 
whilst case pCRC 17 exhibits MSI in both the primary and metastasis. Case pCRC34 exhibits MSI 
in the metastasis only at loci BA T25 and BAT40, whilst pCRC89 exhibits MSI in both the primary 
and metastasis at loci BAT25, BAT40, APC and D18S58. Case pCRC94 exhibits MSI in the 
primary only at locus APC but in both the primary and metastasis at locus D lOS 197. T=primary 
tumour; N= normal colonic tissue; M= liver metastasis. 
pCRC15 
Mfd15 D18S58 
TNM TNM 
pCRC89 
BAT25 BAT40 APC 
TNM TNM TNM 
pCRC17 
Mfd15 D18S58 
TNM TNM 
D18S58 
TNM 
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pCRC34 
BAT25 BAT40 
TNM TNM 
pCRC94 
APC DI0S197 
TNM TNM 
Table 5.3 Results of univariate statistical analysis. 
All Primary tumour Liver metastasis 
cases MSS MSI- MSI- P value for MSS MSI- MSI- P value for 
L H significance L H significance 
Total No. 31 22 6 3 16 11 4 
(71%) (19%) (10%) (52%) (35%) (13%) 
Mean age (SD) 61.5 63.3 56 59.3 0.721 62.1 59.4 64.8 0.523 
(l0.7) (9.4) (12.3) (16.8) (9.7) (10.4) (16.9) 
Gender 
Male 18 13 3 2 >0.95 10 6 2 >0.95 
Female 13 9 3 1 6 5 2 
Primary site 
} 0.122 
Right 5 3 1 1 
Left 3 0 2 1 
Sigmoid 12 10 1 1 N/A N/A N/A N/A 
Rectum 11 9 2 0 
ProximallDistal l 5/26 3/19 115 1/2 0.422 
Dukes Stage 
B 6 5 1 0 
} 0.349 C 7 3 3 1 N/A N/A N/A N/A 
D 18 14 2 2 
Mean Pre-op 
472.9 444.8 687.7 249.5 221.0 941.8 191.1 CEA levels 0.749 0.635 
(mg/ml), (SO) (1242) (1367) (1112) (426.6) (586.2) 
(1922) (367.4) 
Differentiation 
Well 2 2 0 0 0.875 N/A N/A N/A N/A 
Moderate 29 20 6 3 
Synchronous 
metastases 18 14 2 2 } Metachronous >0.95 N/A N/A N/A N/A 
Metastases 13 8 4 1 
Solitary 
} 0.049 } 0.016 
metastases 12 6 3 3 4 4 4 
Multiple 
metastases 19 16 3 0 12 7 0 
Recurrence 
Absent 15 9 3 3 0.101 13 8 4 0.333 
Present 16 13 3 0 3 3 0 
Status 
Alive 13 8 3 2 0.558 5 6 2 >0.95 
Dead 18 14 3 1 11 5 2 
I Proximal colon is defined as sites proximal to the splenic flexure. 
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Table 5.4. Results of logistic regression analysis of the clinicopathological 
variables. 
MSI-H Primary tumour MSI-H Liver metastasis 
Variable Roa's pvalue for Roa's p value for 
score significance score significance 
statistic statistic 
Age 0.138 0.710 0.442 0.506 
Sex 0.101 0.751 0.123 0.726 
Primary site (right sided 0.727 0.394 0.267 0.605 
tumours) 
Dukes'Stage 0.839 0.360 N/A N/A 
TNM Stage 0.416 0.519 N/A N/A 
Pre-operative CEA levels 0.111 0.739 0.244 0.621 
Histological differentiation 0.229 0.632 N/A N/A 
SynchronouslMetachronous 0.101 0.751 2.062 0.151 
metastases 
SolitarylMultiple metastases 5.259 0.022 7.272 0.007 
Figure 5.6 Kaplan-Meier survival curves for all deaths in patients with primary 
colorectal cancers exhibiting MSI-H and primary colorectal cancers classified as 
MSS or MSI-L. 
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Figure 5.7 Kaplan-Meier survival curves for all deaths in patients with primary 
coloredal cancers exhibiting MSI-H and primary coloredal cancers classified as 
MSS or MSI-L. 
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Figure 5.8 Kaplan-Meier survival curves for all deaths in patients with originally 
staged Dukes B, C and D primary colorectal cancers. 
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p=O.3454 
5.3 DISCUSSION 
The incidence of MSI-H in this study was 9.7% (3/31) for primary tumours and 
12.9% (4/31) for liver metastases. The only significant association in this study being 
the presence of MSI-H in the primary tumour and the development of solitary liver 
metastasis; however, this did not translate into an improved prognosis. 
Several studies have already been undertaken exploring the presence of 
microsatellite instability in primary and metastatic colorectal cancer (Ishimaru et aI., 
1995; Chen et aI., 1997; Kochhar et al., 1997; Schneider et aI., 2000). 
Ishimaru et ai. (1995), examined 80 primary fresh-frozen primary tumours and 36 
fresh-frozen liver metastases, in 14 cases the primary tumour and liver metastases were 
obtained from the same patient. The incidence of MSI was examined using 8 
radio labelled microsatellite markers; one mononucleotide repeat (RB intron 21), five 
dinucleotide repeats (03S1284, 014S65, 014S78, LPL and 08S167), one 
tetranucleotide repeat (RB intron 20) and one pentanucleotide repeat (p53 intron 1). MSI 
was detected in 20.1 % (17/80) primary tumours including five which showed MSI at 
two or more loci, while the incidence in liver metastases was 22.2% (8/36), however, 
there was only one case where MSI was present at more than one locus in the liver 
metastases group. Of the 14 paired primary and metastatic tumours, three pairs showed 
evidence ofMSI in both the primary and metastatic tumour, but only at one locus, where 
MSI was present at the same locus in both the primary and metastasis. There were no 
cases where MSI was present in the metastasis but not in the primary tumour. The 
authors concluded that MSI occurred early in colorectal cancer tumourigenesis and that 
clones of cells with instability at different loci metastasized and grew preferentially at 
different sites, whether this is in the colon or liver. They found no significant 
relationship between the presence or absence of MSI and clinicopathological variables. 
Although when comparing the MSI-L (12 primary and 1 metastasis) and MSI-H (5 
primary and 1 metastasis) groups, significant associations were found between MSI-H 
and right sided tumour location and allelic retention (Le. no LOH) on chromosomes 17p 
and 18q. However, they concede that the number of tumours in these subgroups were 
small. 
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Chen et al. (1997), examined 30 patients with Dukes D staged primary tumours and 
their paired liver metastases, extracting DNA from paraffin-embedded tissue and 
examining MSI at 4 loci; Mfd-27, Mfd-26, TPS3 and D2S123 representing sites on the 
APe, Dee and p53 genes and on chromosome 2 respectively. They detected MSI in 
30% (9/30) primary tumours and in 43.3% (13/30) of the liver metastases. Although 
there appeared to be a trend for better survival in Dukes D staged patients with MSI 
compared to those without MSI, this was not statistically significant. In 8 patients, MSI 
was found at the same loci in both the primary and metastatic tumour, but more 
interestingly they also found MSI present only in the liver metastasis in four cases. They 
noted that MSI was detected at the TPS3 and D2S123 loci in these four cases, which 
tend to be involved in the later stages of colorectal cancer tumour progression. At first 
glance the results of Chen et al. (1997) are contradictory to those of Ishimaru et al. 
(199S), where Chen et al. (1997) found a higher incidence ofMSI in the metastatic 
tumours (a similar finding in our study), but this may partly be attributed to sample size 
or the number and selection of micro satellite loci. Chen et al. (1997) concluded that MSI 
was associated with progression in disease staging and in the metastatic process in 
sporadic colorectal cancer as a consequence of either increased genetic instability with 
tumour progression, or clonal selection by the metastatic process, which has been 
demonstrated in gastric cancer (Chong et al., 1994) and small cell lung cancer (Merlo et 
aI., 1994). 
The incidence of MSI in liver metastases was reported to be 2.S% in a study by 
Kochhar et al. (1997), after examining 141 liver metastases and examining MSI with 
markers located to chromosomes Sq, 8p, 10q, lSq, 17p, 18p and 18q. Concluding that 
this extremely low frequency may have been as a result of selection of patients with 
Dukes D primary tumours who had potentially curative resection for metastatic 
colorectal cancer and who represent a small fraction (20-2S%) of all patients with 
metastatic disease. However, one would assume that in the studies by Ishimaru et al. 
(199S) and Chen et al. (1997) those patients had also undergone potentially curative 
liver resection. They also reported that allelic imbalance (LOH) was present with at least 
one marker in 87% of all tumours analysed and that allelic imbalance on 17p was 
significantly associated with extra-hepatic disease an extra-hepatic lymph node 
involvement, thus resulting in reduced survival. Allelic imbalance in primary colorectal 
cancer and liver metastases has also been investigated by Thorstensen et aI. (1996), who 
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examined the presence of allelic imbalance in 12 primary tumours, 15 local recurrences 
and 22 distant metastases (20 liver metastases and 2 lung metastases), assessing 
allelotypes at 43 microsatellite loci throughout the genome. Two of the twelve primary 
tumours (16.7%) showed evidence of allelic imbalance, whereas more than 20% of the 
distant metastases exhibited allelic imbalance, with the greatest incidence of allelic 
imbalance in these metastases being on chromosome arms 14q, 17p, 18p and 18q. 
However, the authors stated that the frequency of allelic imbalance was influenced by 
the percentage of normal cells present in the biopsy from which the DNA had been 
extracted, where the proportions of normal cells was indirectly related to the frequency 
of allelic imbalance seen, which may have accounted for the low frequency seen in 
primary tumours, where the percentage of tumour cells was less than fifty percent. 
Allelic imbalance could not be reliably assessed in our study as the concentration of 
DNA in each sample of primary tumour, normal colonic and metastatic tumour tissue 
was variable. 
A more recent study by Schneider et al. (2000), found the incidence of MS! in 
primary tumours to be 15% (6/39). However, no MSI was detected in 29 liver 
metastases examined, when using a panel of 25 micro satellite markers. However, the 
authors stated that a major shortcoming of the study was that primary and metastatic 
tumours were not from the same patient and tumours had been resected in different 
centres in different countries. 
It is not immediately apparent why patients with tumours exhibiting microsatellite 
instability should develop fewer metastases, as compared to patients with MSS tumours, 
a possible reason is statistical error due to the small number of tumours analysed. 
Interestingly, Boeker et al. (1996), reported a significantly lower proliferative capacity 
in microsatellite unstable sporadic colorectal cancers as oppose to MSS tumours, 
speCUlating that the genetic instability initiated by defective DNA mismatch repair, leads 
not only to tumour formation but also affects genes involved in tumour progression and 
possibly leads to early cell death as a result of lethal mutations. Defective mismatch 
repair could result in the production of dysfunctional cell-cycle proteins or novel cell-
associated neoantigens, thus activating an immune response (Nicholl and Dunlop, 
1999). Concordant with this suggestion is the marked lymphocytic infiltration seen in 
colorectal cancers exhibiting MSI. which has been indicated as a positive prognostic 
indicator, similarly gastric cancers with MSI are also associated with lymphocytic 
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infiltration and also appear to be associated with an improved prognosis (Seruca et aI.. 
1995). Thus. a possible explanation for the significant association between the presence 
of MSI and solitary liver metastases is that MSI not only acts to contribute to tumour 
initiation it also paradoxically restraints tumour progression and if it is assumed that 
liver metastases can themselves metastasize (Fidler, 1990). the presence ofMSI in 
tumours could possibly diminish the occurrence of metastases from the initial liver 
metastasis. thus accounting for solitary metastatic tumours. 
5.3.1 Summary 
The incidence of MSI-H in primary tumours (9.7%) and liver metastases (12.9%) in 
this study were slightly less than those reported in other studies (lshimaru et aI.. 1995; 
Chen et aI.. 1997), however. this may have been reflected in the number and selection of 
markers used. The finding that the incidence of MSI in metastases being higher than in 
primary tumours is in agreement with Chen et ai. (1997). This study also found a 
significant association between MSI-H status and the likelihood of solitary metastases. 
although this did not translate into a statistically significant survival advantage. Of the 
five patients with MSI-H tumours (one primary tumour MSI-H, three primary and liver 
metastases MSI-H and one liver metastasis MSI-H) two patients had died, both from 
recurrent disease. Shortcomings of this study include the small sample size, which may 
have concealed a clinically important difference. and possibly the small number of 
microsatellite markers used. Ideally, the amplification of all ten primers, especially 
BA T26, would have assured that no tumour had been classified as MSS when instability 
was in fact present (Cravo et aI., 1999). The administration of adjuvant chemotherapy to 
patients CRC34 and CRC89 may have selected for clones with MSI-H, thus tending to 
corroborate the conclusions drawn by Fink et al. (1996) and Carethers et al. (1999). both 
observing that the presence of defective DNA mismatch repair in both in vitro and 
animal studies was associated with 5-fluorouracil and platinum chemotherapeutic drug 
resistance. However. both these patients continue to be alive and well and so it is 
unclear whether this possibility of drug resistance. really does have any clinically 
detrimental affect. Whether, MSI-H liver metastases behave differently to MSS tumours 
and lead to differing prognoses, will only be borne out by larger prospective studies. 
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CHAPTER 6 
During the course of the study ethical approval was sought and obtained to 
commence the prospective collection, storage and analysis of fresh tumour samples of 
primary colorectal cancers with synchronous liver metastases. But as a consequence of a 
subsequent change in policy within the North Trent region, surgeons were advised not to 
sample liver metastases as the possibility for curative resection of liver metastases could 
be compromised. Thus, only one fresh-frozen sample of a primary colorectal cancer 
with its liver metastasis was available for analysis. Nevertheless, analysis of this one 
paired sample allowed us to assess the full potential of the various techniques already 
discussed for any future prospective studies. The following is a discussion of the results 
obtained for fresh-frozen tumour sample fCRC 1 and tLM 1. 
The tumour specimens were obtained intra-operatively and stored at -80°C. 
Clinicopathological data 
The patient was a male aged 51 years old with a rectal carcinoma associated with 
synchronous multiple (> 10) liver metastases localised to the right lobe of the liver. The 
patient underwent a palliative anterior resection, the primary tumour being staged as T4, 
N2, Ml (Dukes D) with moderate histological differentiation. The patient had not 
received any neo-adjuvant therapy but did receive adjuvant chemotherapy (S-FU/folinic 
acid). The patient survived 8 months before succumbing to metastatic disease. 
6.1 CELL CULTURE AND KARYOTYPIC ANALYSIS OF rcRCI AND fl..Ml 
Both the primary colorectal cancer and its synchronous liver metastasis were 
amenable to cell culture as outlined in Materials and Methods section 2.2.1.1-2.2.1.6. 
However, obtaining analysable metaphase spreads from short-term cultures proved to be 
a more difficult problem to solve. Initially, using a protocol which had been previously 
established for uveal melanomas within the Department of Ophthalmology and 
Orthoptics, University of Sheffield, very few metaphase spreads were obtained, and if 
any spreads were visualised, the chromosomes were extremely condensed. precluding 
any practical analysis. A number of changes were made to the protocol including 
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changes to the concentration of colcemid and the time of harvesting. The most 
efficacious solution was to add 101lg/ml colcemid to a T25 cell culture flask and leave 
for 24hr before harvesting. Even with these changes only fCRC 1 produced metaphase 
spreads which were amenable to analysis. The result of one typical analysis is shown in 
figure 6.1, namely loss at chromosome 13, a 13p translocation t(13; 17)(Pll;q 11) and a 
loss of chromosome 15 and a derivative chromosome 20 add(20q). These findings will 
be discussed later in this chapter. 
Figure 6.1 A typical karyotype for fCRCI, showing a loss at chromosome 13q, a 
ISp:17p translocation and a gain at chromosome 20q (~=abnonnality). 
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6.2 FLUORESCENT IN SITU HYBRIDISATION OF (CRCI AND fLMt 
Using the protocol standardised for the FISH analysis of fresh-frozen uveal 
melanoma samples, FISH analysis of fCRC 1 and fLM I proceeded without 
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complications. In order to assess the effect of cell culture on tumour samples, FISH 
analysis was perfonned on both fresh-frozen and cell cultured samples at passage seven. 
For each sample, 300 cells were counted. Cells were excluded if they were clumped 
together or if they appeared to have been cut. The results of the FISH analysis are shown 
in table 6.1. 
Table 6.1 Results of the FISH analysis. 
fCRCl fCRClwlp7 fl....Ml fl....Mlwlp7 
Results 2:2=175 58.3% 2:2=239 79.6% 2:2=162 54% 2:2=263 87.7% 
(Chromosome 3 1:3=40 13.3% 1:2=19 6.3% 2:3=46 15.3% 1:2=10 3.3% 
hybridisation 1:2=38 12.6% 4:4=13 4.3% 1:3=44 14.6% 2:4=10 3.3% 
signals: 2:3=22 7.3% 2:3=8 2.6% 1:2=24 8% 2:1=4 1.3% 
Chromosome 8 3:3=12 4% 3:3=6 2% 2:4=10 3.3% 2:3=4 1.3% 
hybridisation 2:4=6 2% 1:3=5 1.6% 3:3=9 3% 4:4=4 1.3% 
signals) 3:2=4 1.3% 2:1=5 1.6% 2:1=2 0.6% 
1:4=3 1% 3:2=1 0.3% 3:2=2 0.6% 
4:3=1 0.3% 1:4=1 0.3% 
Analysing the FISH results of fCRC 1 and tLM 1, the majority of cells show nonnal 
constitutional target hybridisation signals for both chromosomes 3 and 8 (58.3% and 
54% respectively) and at first glance there appears to be no similarity to uveal 
melanomas (where gross abnonnalities of chromosomes 3 and 8 are associated with 
metastasis to the liver). However, both fCRCI and tLMI show a variety of other 
abnonnalities in the number of hybridisation signals for chromosomes 3 and 8, where 
gains of chromosome 8 appear to be the second commonest finding when all the 
abnonnalities are grouped together. Monosomy 3 is also a frequent finding within both 
fCRC 1 and tLM I. This would all tend to support the original hypothesis that an 
abnonnality of chromosomes 3 and 8 are related to liver metastasis. 
Comparing the FISH analysis results between the fresh-frozen tumour samples 
(fCRei and tLMI) to the cell cultured sample fCRClwlp7 and tLMlwlp7 (which 
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represented a single wash of the original tumour sample at passage 7), there appears to 
be a larger proportion of cells with normal constitutional number of hybridisation 
signals in the cell cultured sample as compared to the fresh-frozen sample. This is not 
entirely surprising as cell culture characteristically leads to the selection of clones suited 
to an in vitro environment and thus not necessarily representing the clones present in 
vivo, where a number of clones will co-exist together. This clearly demonstrates one of 
the limitations of genetic studies using cultured cells. 
6.3 COMPARATIVE GENOMIC HYBRIDISATION OF fCRCl AND ft..Ml 
DNA was extracted from each tumour sample using the Qiagen QiaAmp protocol for 
fresh-frozen tissue as outlined in Materials and Methods section 2.2.5.3. The DNA was 
labelled using the nick translation technique as outlined in Materials and Methods 
section 2.2.6.1. Tumour DNA was labelled red and was co-hybridised with Spectrum 
Green labelled reference 46XX DNA onto metaphase target slides which had either been 
purchased from Vysis or produced in-house. 
No results were obtained for either tumour sample when using the Vysis slides, 
whereas using slides made in-house, CGH was partially successful with results being 
obtained for fCRCI (figures 6.2 and 6.3). The hybridisation for fLMI could not be 
analysed as a result of high background fluorescence, most likely due to non-specific 
hybridisation to cytoplasmic remnants on the slide. However, the analysis of fCRC 1 
showed gains of chromosome arms 20q with loss of chromosome arms 13q (figure 6.4). 
Although not present in all the metaphases analysed there were also potential gains of 
chromosome arms 4p and 17p and loss of chromosome arms 4q and 2q. The results 
using CGH were comparable to the karyotype analysis, where there was evidence of loss 
of chromosome arm 13q and gains at 20q. Interestingly, changes in chromosome arms 
4p and 4q were not evident using conventional cytogenetic analysis, but not entirely 
surprising as CGH analysis not only allows a greater degree of resolution but also 
amalgamates variations from a population of tumour cells. However, a shortfall of CGH 
is that trans locations cannot be observed, as is evident by the 13p: 17q translocation seen 
with karyotypic analysis but missed by CGH. This translocation could possibly have 
resulted in either the inactivation of a tumour suppressor gene or the activation of an 
oncogene (Sheer, 1997). 
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Figure 6.2 A typical two-colour image of feRel (tumour DNA labelled Ulysis 
rhodamine and normal reference DNA labelled Spectrum Green). 
Figure 6.3 A DAPI stained image of the target metaphase spread as seen in figure 
2, for feRel. 
I 
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Figure 6.4 An average ratio profile of several metaphase spreads for fCRCl. 
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Several studies have implicated the possibility of a tumour suppressor gene on 
chromosome 4q, although as yet none has been identified (Niketeghad et aI., 2001; 
Zitselsberger et al., 2001). The gain of chromosome arm 20q has previously been 
reported to be associated with the development of liver metastases (Korn et ai., 1999; 
AI-Mullah et al., 1999; Hidaka et al., 2000; Aragane et ai., 2001), with a region 
localised to 20q 13.2 as a possible site of an oncogene involved in metastasis (Korn et 
aI., 1999; Hidaka et al., 2000). Nanashima et al (1997) performed cytogenetic analyses 
using FISH on primary colorectal cancers and their hepatic metastases. The study found 
gains of chromosome 20 as a frequent aberration in both the primary and metastatic 
regions in patients with liver metastases from colorectal cancers. Several genes are 
known to exist on chromosome 20 and which include E2F, BCLX (Stokke et ai., 1995), 
SRC (Asimakopoulos et at., 1994), and proliferating cell nuclear antigen (PCNA) (Ku et 
aI., 1989). Of the genes mentioned only an increased expression of SRC and PCNA has 
been associated with liver metastases of colorectal cancer (Teixeira et aI., 1994, 
Nakamura et al., 1996; Irby et aI., 1999). Analysis of breast cancers using CGH, 
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suggests that chromosome 20q 13 was the locus for another as yet unknown gene 
associated with metastases in these cancers (Tanner et aI., 1995). 
It is reassuring that there is a concordance of results between karyotypic analysis and 
CGH analysis of fCRC 1, although unfortunately results could not be obtained for the 
paired liver metastasis tLMI. The comparison between CGH and karyotypic analysis 
demonstrates the advantages and shortfalls of CGH. 
6.4 MICROSATELLITE ANALYSIS OF {CRCl AND fl...Ml 
Using the protocol described in Materials and Methods section 2.2.8.2 PCR using the 
Abgene Thermo-Fast 96 low profile plate and the Primus 96 Plus thermo cycler for use 
on LongRanger sequencing gels microsatellite analysis offCRCI and tLMI was 
performed using IRD labelled primers with electrophoresis on a LongRanger gel, using 
the LiCor 4200 ONA sequencer with analysis using the LiCor Base ImagIR software. 
All PCR reactions were performed with positive and negative controls and were 
successful. All ten primers were used; BAT26, BAT40, Mfdl5, 02S123, APC, Bat25, 
0108197,018858,018869 and MYCLI. No micro satellite instability was detected 
with any of the primers for either fCRCl or tLM1, using DNA extracted from normal 
colon mucosa as the normal control. This is not entirely surprising as the incidence of 
MSI in sporadic colorectal cancers is up to 20% (Thibodeau et aI., 1993; Aaltonen et aI., 
1993) and in our study (Chapter 5) the incidence of MSI-H was 9.7% in primary 
colorectal cancers and 12.9% in the liver metastases. The primary colorectal cancer in 
this study was a rectal cancer, and as stated in other studies MSI tends to be associated 
with right sided colonic tumours (Thibodeau et aI., 1993; Lothe et aI., 1993; Kim et aI., 
1994). 
6.5 SUMMARY 
All the fore mentioned techniques were successfully applied to the analysis of a 
single paired sample of fresh-frozen primary colorectal cancer and its liver metastasis, 
albeit partial success using CGH analysis. 
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CHAPTER 7 
7.1 GNERAL DISCUSSION 
The majority of patients with cancer die as a consequence of metastatic disease rather 
than the effect of the primary tumour, more so in the cases of colorectal cancer and 
uveal melanoma. Thus, metastases pose a significant cause of morbidity and mortality in 
these patients (Ballantyne and Quin, 1993). 
A number of genetic changes will take place in the development and metastasis of the 
primary tumour to a distant site (Schirmacher, 1985; Klein and Klein, 1985), with only 
those cells with the necessary genetic or phenotypic adaptations being able to survive 
and progress at this distant site (Fidler and Kripke, 1977; Fidler, 1990; Gregoire et aI., 
1993; Radinsky, 1995; Singh et aI., 1997; Nicolson and Moustafa, 1998). 
The aim of the research was to elucidate novel genetic abnormalities, which would 
be predictive for the development of liver metastases in patients with colorectal cancer. 
The information could then be used to institute adjuvant therapies or, enhance the 
surveillance for liver metastases, with the view to offer potentially curative liver 
resection. 
Patients with uveal melanoma are also known to develop a high frequency of liver 
metastases and thus the study was designed to compare the two malignancies, and to 
establish whether colorectal cancers capable of metastasising to the liver shared 
common genetic abnormalities with posterior uveal melanoma. It has already been 
established by cytogenetic analysis that monosomy 3 and gain of chromosome 8q has 
been particularly associated with reduced survival and the development of liver 
metastases in patients with uveal melanoma (Prescher et al., 1996; Sisley et aI., 1997; 
White et aI., 1998). Thus, the analysis of uveal melanoma tumour specimens provided a 
starting point from which to conduct this study. The prospective collection of uveal 
melanoma tumours had already been established in the Department of Ophthalmology 
and Orthoptics, University of Sheffield, while no protocol existed for the collection, 
storage and analysis of colorectal cancers and their liver metastases and so initial 
investigations were dependant on the analysis of formalin-fixed paraffin-embedded 
tumour specimens, while ethical approval was sought. 
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The initial part of this investigation involved the fluorescent in situ hybridisation 
examination of uveal melanoma specimens using alpha centromeric probes for 
chromosomes 3 and 8, where long term follow-up data was available. FISH examination 
using the same probes were also used to investigate paired samples of colorectal cancers 
and their liver metastases, but due to the variability in length of formalin-fixation of 
both the primary and secondary colorectal cancer specimens, FISH analysis of the 
archival paraffin-embedded tissue samples was unsuccessful. In contrast, FISH 
examination of the fresh-frozen uveal melanoma tissue samples proved more successful 
with results showing a statistically significant association between the presence of 
abnormalities in copy numbers of chromosomes 3 and 8, with reduced survival and the 
development of liver metastases. The results concurred with previous studies, 
suggesting the possibility of a putative oncogene on chromosome 8 and a tumour 
suppressor gene on chromosome 3 (Prescher et al., 1996; Sisley et al., 1997; White et 
aI., 1998). The unavailability of liver metastatic tissue from patients with uveal 
melanoma meant that FISH analysis for genetic imbalance could not be assessed. 
FISH analysis for chromosomes 3 and 8, proved to be a reliable and efficient 
technique in the analysis of fresh-frozen tumour specimens and valuable in the 
prediction of prognosis in patients with uveal melanoma. Further large scale prospective 
studies will be required to define the sensitivity and specificity of this technique in 
clinical practice. 
In an attempt to examine the archival primary colorectal and liver metastatic tissue 
specimens, comparative genomic hybridisation was utilised, to allow a genome-wide 
search for regions of amplification and deletion. The technique was optimised for the 
analysis of formalin-fixed paraffin-embedded tissue samples, by improving DNA 
extraction methodology as well as labelling techniques. Problems in the variable quality 
of target metaphase slides were overcome by the production of target metaphase slides 
in-house. Unfortunately, only partial results were obtained from the analysis of a single 
liver metastatic tissue sample, showing gain of chromosomes 2,3, 7 and of chromosome 
arms 8q and 13q, with loss of chromosome arm 8p. These findings concurred with other 
studies Kom et aI., 1999; AI-Mullah et aI., 1999; Aragane et al., 2001; Nakao et al., 
2001). Further refinements and development of the technique could have allowed the 
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complete analysis of all the samples, but limitations in time prevented this and until 
more extensive studies have been undertaken, only limited conclusions can be drawn. 
Microsatellite instability in primary colorectal cancers has been linked to improved 
patient survival (Thibodeau et aI., 1993; Lothe et aI., 1993; Gafa et aI., 2000; Gryfe et 
aI., 2000; Hemminki et al., 2000), although not all studies have confirmed this 
(Messerini et aI., 1999; Salahshor et aI., 1999; 10hannsdottir et aI., 1999; Feeley et aI., 
1999; Curran et aI., 2000; Gervaz et aI., 2002). The presence of micro satellite instability 
in the paired samples of primary and liver metastatic colorectal cancer tissue was 
assessed using polymerase chain reactions, using a reference panel of micro satellite 
markers. The analysis of 31 paired samples showed an incidence of high level MSI 
(MSI-H), in 9.7% of primary tumours and 12.9% ofliver metastases, which is in 
accordance with other reports (Ishimaru et al., 1995; Chen et aI., 1997). A significant 
association was found with the presence of MSI in either primary or secondary tumours 
with the likelihood of solitary liver metastases, although this did not translate into a 
significantly improved prognosis. 
In an analogous study by a colleague (Mr Neil Cross), MSI was essentially found to 
be absent in the primary uveal melanomas studied (unpublished data), and as no liver 
metastases from uveal melanoma patients was available to study, it was not possible to 
assess whether MSI existed in the liver metastases, as was found in colorectal cancer 
liver metastases. Certainly, the primary uveal melanomas examined did not exhibit MSI 
and in this respect appear to differ from colorectal cancers. 
In the final part of the study a fresh paired sample of a primary colorectal cancer and 
its synchronous liver metastasis was obtained. FISH analysis was particularly 
interesting, where both the primary and liver metastasis showed evidence of genetic 
imbalance for chromosomes 3 and 8, in a manner consistent with the findings for uveal 
melanomas. Although, more variability was seen compared with most uveal melanomas, 
abnormalities of chromosomes 3 and 8 were present, in particular gain of chromosome 8 
and monOsomy 3 being a frequent finding. If confirmed, this finding would suggest that 
colorectal cancers metastasising to the liver do share some common genetic changes 
with uveal melanomas, possible implying the involvement of similar genes, however, it 
is too early to draw such conclusions on the basis of one paired sample. CGH analysis of 
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the primary colorectal cancer corroborated karyotype findings with evidence of gain of 
20q and loss of 13q, which were in agreement with other studies (Nanashima et aI., 
1997; Kom et aI., 1999; AI-Mullah et aI., 1999; Hidaka et aI., 2000; Aragane et aI., 
2001). Further paired samples were not available for study, due to a change in policy in 
the Trent Region, where sampling liver metastases was discouraged, as future liver 
resection surgery could be compromised. Nonetheless, the analysis of this single paired 
sample demonstrated that the techniques could be applied successfully in the genetic 
analysis of cancer specimens. 
7.2 FUTURE RESEARCH 
Recent developments in the fields of genomics and molecular biology have unleashed 
an array of new techniques to explore the development and treatment of cancer. The 
human genome will shortly be sequenced, with the promise of increasing the 
understanding of how genes and the environment interact to give rise to the cellular 
mechanisms that underlie the biological process and the genetic variations between 
individuals, providing scope for new therapeutic developments such as 
pharmacogenomics and gene therapy, with the potential to eventually provide 
opportunities for disease prevention. 
Genetic screening for familial diseases, may allow for the identification of 
susceptible individuals, thus allowing diagnostic interventions or removal of the target 
organ to be offered. Stratification with reference to pharmacogenetic consideration will 
allow more appropriate, effective and safer drug treatments to be offered (Sadee, 1999). 
Choi et al. (2002) and Rosty et aI. (2001) have already tried to stratify patients into 
groups according to LOH and MSI status and relate this to response to chemotherapeutic 
agents. The development of cDNA microarray technology allows for the assessment of 
numerous polymorphisms on a single glass plate or 'gene chip'. Thus, genome-wide 
screening for polymorphisms could identify important polymorphisms associated with a 
particular clinical response or adverse reaction, thus enabling chemotherapy to be either 
directed to a specific group of patients, who would positively respond or be avoided in 
those in whom severe toxicity could result. Microarray analysis could also be used to 
predict survival in those patients with particular polymorphisms, in response to 
chemotherapy (Wei et aI., 2002). Further large scale studies will expand on these 
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preliminary results and incorporate novel colorectal cancer pathway molecules. 
However, within the genome little is known of the non-coding DNA sequences, of the 
mechanisms responsible for replication, RNA splicing, the control of cell cycle and gene 
expression or of the roles of centro meres and telomeres. The complexity of genetic 
analysis is compounded further because of ethnic and racial variations. Moreover, 
variable expressivity and incomplete penetrance are already seen in relatively simple 
monogenic disorders such as retinoblastoma and furthermore, the expression of similar 
phenotypes can arise from genetic heterogeneity, whether in the form of allelic 
heterogeneity (different mutations at the same allele) or locus heterogeneity (different 
mutations at the same locus). Similarly, different mutations in the same gene can result 
in differing clinical manifestations, such as in the RET oncogene, where activating 
mutations can result in multiple endocrine neoplasia type II (identified by familial 
phaeochromocytomas, parathyroid and medullary thyroid cancers), whilst inactivating 
mutations are associated with Hirschsprung's disease (Mulligan et aI., 1993; Romeo et 
aI., 1994; Edery et aI., 1994). Thus, the identification of mutations is not necessarily the 
be all and end all. 
The initial speculation that gene therapy would revolutionise medicine has been over-
optimistic. A number of problems still need to be overcome before gene therapy can be 
widely used in routine clinical practise. Despite these difficulties a number of trials are 
already underway assessing the use of gene therapy in treating cancer (Harris and 
Sikora, 1996). Another expanding field has been in stem cell technology. 
Haematopoietic stem cells have already been used in the treatment of various 
haematological conditions. The difficulty with using solid tissue stem cells has been in 
reproducing the three-dimensional arrangements and cell-cell and cell-extracellular 
matrix that exists in solid tissues. The existence of hepatic stem cells could 
revolutionise liver resection surgery for the treatment of both primary liver and 
metastatic cancers, allowing more extensive resections to be performed followed by 
tissue regeneration (Allain et aI., 2002; Danet et al., 2002). 
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7.3 CONCLUSION 
The research undertaken in this study has utilised a number of techniques in the 
investigation of the genetic changes involved in liver metastasis. Fluorescent in situ 
hybridisation allowed for the targeting of specific DNA sequences, while CGH allowed 
for a genome-wide search of regions of chromosomal amplification or loss. Possible 
chromosomal rearrangements were visualised with karyotypic analysis, whereas, PCR 
allowed for the analysis of micro satellite instability. It has been shown that all the 
techniques used have had their advantages and disadvantages, but by using several 
techniques complementing each other genetic analysis could be successfully performed. 
The prospective collection of fresh-frozen tissue will allow for genetic analysis to be 
correlated to clinical outcome and other clinicopathological variables. The short-term 
culture of primary colorectal cancers and liver metastases will allow for the correlation 
of genetic analysis to phenotypic expression, from assessing the production and function 
of proteins to cell-cell or cell-extracellular matrix interactions. The development of new 
techniques such as the DNA microarray technology could be applied to assess the 
relevance of genetic polymorphisms and the effects of various chemotherapeutic agents 
to cultured cells, with the aim of providing each patient with a tailor-made therapeutic 
regimen, thus maximising efficacy and minimising side-effects. The development of 
gene-therapy to either halt the progression of cancer cells or augment their response to 
therapeutic agents is also an area that could be developed from the genotype-phenotype 
analysis. 
This study has shown the ways in which emerging technologies can be applied to the 
investigation of both uveal melanomas and colorectal cancers. Continued investigations 
may subsequently lead to the identification of specific genetic changes related to the 
development of liver metastases, the aim of which would be to allow clinicians to 
determine prognosis for their patients, augment current surveillance protocols for 
recurrence or metastasis, instigate adjuvant treatment, or to specifically target these 
genetic abnormalities with novel therapies. 
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Appendix I: Summary of treatment options for colorectal cancer. 
Stage Treatment Options 
0 1. Local excision of polyps or colon resection for larger tumours 
I (Dukes A) 1. Wide surgical resection and anastomosis 
II (Dukes B) 1. Wide surgical resection and anastomosis 
2. ? Adjuvant chemotherapy 
III (Dukes C) 1. Wide surgical resection and anastomosis with adjuvant 
chemotherapy of either 
5-FU/levamisole for 12 months or 
5-FU/leucovorin for 6 months 
2. ? Adjuvant radiotherapy 
IV (Dukes D) 1. Surgical resection and anastomosis or by-pass surgery for selected 
patients with obstructing cancers 
2. Surgical resection of isolated metastases (liver/lung) 
3. Chemotherapy 
4. Radiotherapy 
5. Clinical trials evaluating new drugs and biologic therapy 
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Appendix II: The various staging classifications used for coloredal cancer. 
Dukes Staging 
A - Tumour confined to the bowel wall 
B-
C-
(0-
Aster-Coller 
A-
Rt-
R2-
Ct-
C2-
0-
Tumour grows beyond the bowel wall 
Lymph node metastases present 
Distant metastases present - added by Turnbull) 
Tumour limited to mucosa - carcinoma in situ 
Tumour extends through the muscularis mucosae but not beyond 
the muscularis propria 
Tumour extends beyond muscularis propria 
B I with regional lymph node metastases 
B2 with regional lymph node metastases 
Distant metastases 
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TNM Classification 
T assesses the tumour stage 
TX - Primary tumour cannot be assessed 
TO - No evidence of primary tumour 
Tis - Carcinoma in situ - limited to mucosa 
Tt - Tumour invades submucosa but does not extend beyond 
muscularis propria 
T2 -
T3 -
T4-
Tumour invades muscularis propria but not beyond 
Tumour extends beyond muscularis propria but not T4 
Tumour perforates visceral peritoneum or invades adjacent organs or 
structures (including loops of bowel) 
N assesses regional lymph node stage 
NO - No regional lymph node metastases 
Nt - 1-3 regional lymph node metastases 
N2 - 4 or more regional lymph node metastases 
N3 - Regional lymph node metastases along named vascular trunks 
M assesses distant metastases 
MX - Distant metastases cannot be assessed 
MO - No distant metastases 
Ml - Distant metastases present 
Appendix III: Primer sequences, annealing temperatures and chromosomal location. 
DNA Primer Primer Sequence 5'--3' Repeat Motif Annealing Temp. Size (bp) Chromosomal location 
BAT-25 TCG CCT CCA AGA ATG T AA GT mononucleotide 58°C -90 4q12 
TCT GCA TIT T AA CTA TGG CTC TTTT .TTTT.(T),.A(Tb 
BAT-26 TGA CTA CIT ITG ACT TCA GCC mononucleotide 58°C -80-100 2p 
AAC CAT TCA ACA TIT ITA ACC C (T)s. .... (Ah6 
BAT-40 A IT AAC ITC CTA CAC CAC AAC mononucleotide 58°C -80-100 1p13.1 
GT A GAG CAA GAC CAC CIT G TTTT.TT .. (Th .............. TTTT.(T)40 
APC ACT CAC TCT AGT GAT AAA TCG CA dinucleotide 55°C 96-122 5q21/22 
AGC AGA T AA GAC AGT A IT ACT AGT T (CA)26 
Mfd15CA GGA AGA ATC AAA TAG ACA AT CA dinucleotide 52°C -150 17ql1.2-12 
GCT GGe CAT ATA TAT ATf TAA ACC (TAlL... .. .......(CA)24 
DlOSl97 ACC ACT GCA CIT CAG GTG AC CA dinucleotide 65°C 161-173 10qter 
GTG AT A eTG TCC TCA GGT CTC C CACCAGA(CA)7.A.A(CA)uCAGAAA)2 
Dl8S69 CTC TIT CTC TGA eTC TGA CC CA dinucleotide 60°C -110 18q21 
GAC ITT CTA AGT TCT TGC CAG (CA)~(CA)14(T)6 
D2Sl23 AAA CAG GAT GeC TGC CIT TA eA dinucleotide 60°C 197-227 2p16 
GGA CIT TCC ACC TAT GGG AC (CA)I3TA(CAhs(T/G Ah 
Dl8S58 GeT CCC GGC TGG TIT T eA dinucleotide 53°C 144-160 18q22.3 
GCA GGA AA T CGC AGG AAC IT (GC)sGA(CA)17 
MYeLl TGG CGA GAC TeC ATC AAA G tetranucleotide 53°C 140-209 Ip32 
CIT ITT AAG CTG CAA CAA GAAAA(GAAAA)2 T AAAA(AlG) lOGAAAGA(GAAA)14 
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Appendix IV: Publications and Abstracts. 
Publications: 
Prediction of prognosis in patients with uveal melanoma using fluorescence in situ 
hybridisation. 
Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K. 
British Journal of Ophthalmology. 85: 1440-1444,2001. 
Abstracts: 
Prediction of liver metastases in patients with uveal melanoma using FISH. 
Patel KA, Edmondson N, Talbot F, Sisley K, Parsons A, Rennie IG. 
Clinical and Experimental Metastasis. 17(9): 753, 2000. 
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